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Background: Atherosclerosis is a chronic vascular inflammatory disease 
characterised by disturbed blood flow due to an atheromatous plaque build-
up within arterial layers. These plaques contain various forms of modified 
cholesterol, such as oxidised low-density lipoprotein (OxLDL). OxLDL enters 
vascular cells, contributing towards foam cell formation and initiating over 
exuberant repair processes, leading to arterial occlusion and life threatening 
myocardial infarction or stroke. Endothelial cells, by producing pro-
inflammatory cytokines, such as interleukin-1 beta (IL-1β), are also strongly 
involved in the pathogenesis of atherosclerosis. However, little is known of 
the link between OxLDL and endothelial cell actions. Hypothesis: I 
hypothesised that OxLDL enters the arterial endothelium and induces IL-1β 
secretion, potentially via a caspase-1/NLRP3 mechanism. Methods: Human 
coronary artery endothelial cells (HCAEC), isolated from different donors, 
were cultured and stimulated with pro-inflammatory cytokines TNFα and IL-
1α (10 ng/ml each, for 48 hours), followed by incubation with native human 
OxLDL cholesterol at multiple concentrations (10-200 ug/ml) for 6 hours. 
Inhibitors of Caspase-1 (YVAD), NLRP3 (MCC950) and P2X7 receptor 
(A438079 HCl) were also used. Cell lysates and culture supernatants were 
collected and analysed for IL-1β using ELISA and Western Blot. Cell viability 
and caspase-1 activity were also measured. Results: Brightfield microscopy 
imaging showed OxLDL enters HCAECs, and forms particles. However, 
17 
 
uptake of OxLDL was not seen following inhibition of the P2X7 receptor. 
OxLDL induced the release of IL-1β from stimulated HCAECs with maximum 
release at concentration of 50 ug/ml compared to control. This release was 
not caused by toxicity of the OxLDL: cell viability was confirmed by lactate 
dehydrogenase cell viability assay. Inhibition of either NLRP3 or Caspase-1 
significantly reduced the release of extracellular IL-1β (4-fold, p<0.0001; 14-
fold, p<0.0001, respectively). Release of IL-1β was associated with 
expression of active GSDMD, suggesting the release via a pyroptosis 
mechanism. Conclusion: HCAEC uptake of OxLDL occurs via the P2X7 
receptor. OxLDL elicits IL-1β release in activated HCAECs by a Caspase-
1/NLRP3 mechanism, without causing toxicity. The released IL-1β probably 
exits the cells via a GSDMD-induced membrane pore. These data show that 
the study of modified lipids linked to the release of inflammatory cytokines 
such as IL-1 from endothelial cells could lead to the discovery and 










1.1 What is Atherosclerosis and Why Study it?  
In 1755, the Latin term “atheroma” was used, for the first time, to describe 
deposited plaque on the innermost layer of arterial walls by Albrecht von 
Halles (Li and Fang, 2004, DUFF, 1951). However, since the development of 
atheroma was reported to be accompanied with abnormal arterial wall 
hardening “sclerosis”, in 1940, Félix Marchand devised the term 
“atherosclerosis”  (Benditt, 1977). 
Atherosclerosis is a chronic inflammatory lipoprotein-driven disease, that 
develops in the inner layer of arteries as a result of the pathological 
production of a lipid heavy plaque contained within a fibrous cap known as 
an “atheroma” (Adams et al., 2000). The pathological development of 
atherosclerosis takes decades to occur (stages shown in Figure 1.1), and is 
diagnosed clinically as a life-threatening condition underlying the cause of 
many acute coronary syndromes (ACS) including myocardial infarction (MI), 
ischemic heart disease (IHD), ischemic stroke and coronary heart disease 
(CHD) (Libby, 2013, Nabel and Braunwald, 2012). CHD is considered the 
leading cause of death worldwide, with reduced coronary blood flow at 
atherosclerotic lesion sites being the causative agent in 90% of CHD cases 
(Herrington et al., 2016, Lung et al., 2014).  
Risk factors for developing atherosclerosis include ageing and smoking, in 
addition to a medical history of diabetes mellitus, hypertension and 
hyperlipidaemia, all of which play a role in causing inflammation and 
vascular injury to the endothelial layer of the arterial wall (Messner and 





 (Figure 1.1) Development of an Atherosclerotic Plaque and Progression 
into a Lesion: (A) Healthy artery, free from any plaque accumulation or 
development on its endothelial cell layer, compared to a developed 
atheroma surrounded by a fibrous cap (B). This necrotic core is composed of 
apoptotic smooth muscle cells (SMC) and is rich in lipids which contain foam 
cells and cholesterol crystals. The collagen released from smooth muscle 
cells forms the fibrous cap. In the late stage of an atheroma, more 
atheromatous plaque has been deposited (C), surrounding the majority of 
the vessel lumen, allowing a limited amount of blood to pass through i.e. 
decreased blood flow. The plaque protrudes through the surrounding 
fibrous cap, causing a plaque rupture. Plaque rupture can be seen in cardiac 
patients of MI and ACS and is composed of necrotic tissue that in many cases 






Studies have concluded that hyperlipidaemia causes both inflammation and 
endothelial dysfunction, which are the major events in developing 
atherosclerosis (Ross, 1999b, Shimokawa, 1999, Morton et al., 2015). 
Investigating the disease pathways and the inflammatory markers involved, 
as well as identifying the molecules and mechanisms that cause vascular 
injury relevant to atherosclerosis development, will help enhance and 
improve the current therapeutic agents and drugs used to treat the disease. 
However, despite the advances and the clinical effectiveness of 
hypolipidemic agents as treatment and prevention agents for CVDs [statins 
(simvastatin and lovastatin) (Yebyo et al., 2019), cholesterol absorption 
inhibitors (Ezetimibe) (Bach et al., 2019), PCSK9 inhibitors (Evolocumab and 
Alirocomab) (Tomkin and Owens, 2017), nicotinic acid (Romani et al., 2019), 
fibric acids (Gemfibrozil and Bezafibrate) (Millan et al., 2018) and omega-3 
fatty acids (Abdelhamid et al., 2018)], CVDs are still the global leading cause 
of death with an uncontrolled, increasing, prevalence in the developing 
world (Thirunavukkarasu and Khader, 2019, Mc Namara et al., 2019).  
This continued, increasing, prevalence has triggered a renewed interest in 
studying and investigating the inflammatory processes associated with the 
early development of atherosclerosis and CVD. Recently, a growing number 
of studies were dedicated to investigating the major inflammatory markers, 
in particular, interleukin-1 (IL-1) and its production and release from vascular 





1.2 Pathophysiology of Atherosclerosis 
The process of atheroma development, referred to as “atherogenesis”, is a 
complicated process involving the interaction and signalling between 
different molecules and often takes years to develop (Steffen et al., 2015). 
Clinically, it has always been a challenge to investigate and diagnose patients 
at an early stage before the appearance of symptoms (Wierzbicki, 2013). 
Initially, it is thought that the innermost endothelial layer of the artery wall 
becomes injured due to contact with blood circulation with a stream of 
laminar and turbulent physical force applied to the surface (Ross and Agius, 
1992). However, some regions along the vascular tree, called sites of 
predilection, are known to be more prone to atherosclerosis development 
than others (Gu et al., 1998). These regions are exposed to different 
haemodynamic stress conditions which experience alterations in shear 
stress with a reverse cyclical direction of flow known as oscillatory flow 
(Malek et al., 1999).  
There is a well-established understanding that oscillatory flow promotes 
endothelial dysfunction, inflammation, and leukocyte adhesion and 
migration, primarily  by increasing the expression of adhesion molecules 
such as intracellular adhesion molecule-1 (ICAM-1) and vascular adhesion 
molecule-1 (VCAM-1), which contribute towards leukocyte recruitment, 
creating an atherogenic inflammatory environment (Chappell et al., 1998).  
Additionally, areas with high shear stress that can be found in major curves, 
such as the aortic arch and areas near branch points, are more prone to 




Celentano, 2013). However, in the presence of hyperlipidaemia, the 
disturbed blood flow in these regions causes endothelial dysfunction (Xu, 
2000, Foteinos et al., 2008). This injury of the endothelial cell layer, together 
with the subendothelial precipitation of low-density lipoprotein cholesterol 
(LDL-C), are considered the first alterations of the vasculature (shown in 
Figure 1.2A) (Palinski et al., 1989). A complex process then starts as 
lymphocytes and monocytes adhere to the endothelial surface of the artery 
wall (Figure 1.2B), involving adhesion molecules and their receptors 
(predominantly ICAM-1 and VCAM-1), which further enable leukocytes to 






 (Figure 1.2) Transverse 3D Illustration of the Pathophysiology of 
Atherosclerosis within an Artery During Different Stages of Lesion 
Development: (A) Molecules of LDL-C start to precipitate along the 
dysfunctional endothelial layer of the vessel. (B) Monocytes adhere together 
along the endothelial layer, and start migrating through the endothelial layer 
into the subendothelial layer and differentiate into macrophages (C). Due to 
the dysfunctional endothelium more circulating cholesterol molecules and 
lipoproteins can enter the subendothelial space where they can be digested 
by the newly differentiated macrophages. As a result of this digestion they 
are transformed into foam cells (D), which become fatty streaks along the 
vessel wall (E) that start to build up together and form an immature 
atheroma. Continuous precipitation of lipoprotein molecules and its 
digestion by macrophages increases the amount of plaque built up which 
increases the size of the atheroma (F). When a mature atheroma is formed 
(G) it is more vulnerable to rupture. Plaque rupture (H) allows the plaque to 
forcefully exit the fibrous cap and diffuse into the blood stream, where 




The role of ICAM-1 is evidenced by the fact that low concentrations are 
found in endothelial cells and leukocyte membranes, with increased 
concentrations upon cytokine stimulation. Interleukin-1 (IL-1) and tumour 
necrosis factor alpha (TNF-α), expressed by macrophages, lymphocytes and 
vascular endothelium, both induce ICAM-1 expression (Kim et al., 2008). 
VCAM-1 is known to mediate adhesion of monocytes and lymphocytes to 
the vascular endothelium. In addition, its upregulation by cytokines is 
induced by IL-1 and TNF-α, and regulation of both pro-inflammatory 
cytokines is via the transcription factor known as nuclear factor kappa-light-
chain-enhancer of activated B cells (NF-κB) (Kim et al., 2001). NF-κB, a pivotal 
mediator for adaptive and innate immunity, is known to induce the 
expression of many genes that encode inflammatory molecules, which play 
key roles in the pathological development and maintenance of an 
atherosclerotic lesion.  These inflammatory molecules include: cytokines (IL-
1, IL-2, IL-6, IL-8 and TNF-α)(Sun et al., 2013, Hayden and Ghosh, 2011), 
chemokines (MCP-1 and IL-18)(Liu et al., 2017), adhesion molecules (ICAM-
1, VCAM-1 and matrix metalloproteinases (MMPs)) (Kim et al., 2008, Tak and 
Firestein, 2001), and participate in inflammasome regulation including the 
NLRP3 inflammasome (Bauernfeind et al., 2009). 
Furthermore, monocytes are known to migrate into the subendothelial 
intimal space, with the aid of chemoattractant molecules such as monocyte 
chemoattractant protein-1 (MCP-1) (Gu et al., 1998), which attracts both 




their migration, monocytes differentiate into macrophages (Ross, 1993) 
(Figure 1.2C). This differentiation is associated with increased expression of 
the antigen CD68 (which is mainly found on lysosomes of macrophages), 
with the main regulator of this process being macrophage colony stimulating 
factor (M-CSF) ((Clinton et al., 1992, Smith et al., 1995)).  
Additionally, the dysfunctional endothelium allows the continued entry of 
an excess of circulating lipoprotein and cholesterol molecules (Davignon and 
Ganz, 2004), including  cholesterol crystals that have crystalized from a liquid 
form, which pierce the intimal layer and the plaque, making it more 
vulnerable to plaque rupture (Abela, 2010). Some of the LDL-C molecules 
undergo oxidized modification and become inflammatory molecules due to 
oxidation enzymes and free radicals such as reactive nitrogen species (RNS) 
and reactive oxygen species (ROS) (Singh et al., 2015).  
Studies report that these radicals are generated in vivo, mainly in vascular 
cells, by different endogenous systems secondary to the human body’s 
exposure to pathological conditions (such as diabetes mellitus  (Giacco and 
Brownlee, 2010) and hyperlipidaemia (Onody et al., 2003)) and 
physiochemical conditions (such as smoking (Dikalov et al., 2019) and 
exposure to ionizing radiation (Bucci et al., 2006, Baselet et al., 2019)). ROS-
induced oxidative stress occurs when the equilibrium between generation 
of ROS and the ability to initiate antioxidant responses (mainly 
mitochondrial antioxidants, specifically mitochondrial targeted vitamin E) is 




2015). ROS-induced oxidative stress exerted on modified LDL-C molecules in 
the intima, results in the formation of oxidized LDL (OxLDL) (Leonarduzzi et 
al., 2012) a major contributor to atherosclerosis development and key player 
in my study. Furthermore, oscillatory shear stress induces an increased 
production of ROS in endothelial cells, and LDL molecules are generally only 
oxidised in cells containing excess ROS (Cunningham and Gotlieb, 2005, 
Hwang et al., 2003).  
These modified LDLs are prone to be ingested by macrophages, as their 
scavenger receptors are expressed by macrophages, e.g. the LOX-1 
scavenger receptor (Qiao et al., 1997, Dai et al., 2013) allowing their 
transformation to foam cells (Figure 1.2D), which eventually contribute to 
fatty streaks in the arterial wall (Figure 1.2E) with the aid of T lymphocytes 
(Abela, 2010, Bobryshev, 2006). The continued insult to smooth muscle cells 
and the endothelium of artery walls triggers intense fibro-proliferative 
inflammatory responses that act together to develop an atheroma, through 
continued build-up of fatty streaks, lipoprotein molecules and cholesterol 
crystals (Figure 1.2F). Continued build-up and increased expression of 
regulatory molecules enhances the destabilisation of the plaque and 
increases the size of the atheroma making it vulnerable to rupture (Figure 
1.2G).  
1.2.1 Plaque rupture, erosion and the role of cholesterol crystals 
There a is well-established understanding that plaque rupture is a life 
threatening clinical event (Shah and Lecis, 2019, Friedman, 1975). It exposes 




rich in necrotic core material (Figure 1.2H), leading to coronary thrombosis 
(Miller, 2016). There are two contrasting mechanisms allowing the release 
of this thrombogenic material. Often, a thin cap fibroatheroma (TCFA) is 
formed, allowing direct rupture of the cap and subsequent release of the 
plaque constituents (Vengrenyuk et al., 2006). Alternatively, plaque erosion 
can occur, permitting thrombi formation on lesion surfaces without 
complete plaque rupture (Spagnoli et al., 2007).  Both plaque rupture and 
erosion are considered to be the two leading causes for ACS (Abela and Aziz, 
2005) (Thondapu et al., 2020). Furthermore, sudden coronary death, the 
most abrupt clinical form of reported ACS, has been shown by coronary 
computed tomography angiography (CCTA) to have the presence of luminal 
thrombosis in the form of plaque rupture or plaque erosion which is a 
hallmark of sudden coronary death cases (van den Hoogen et al., 2019). 
 There is distinct fundamental difference between rupture and erosion of 
plaque (Farb et al., 1996). Plaque rupture takes place in a “vulnerable 
plaque”. A classical rupture-vulnerable plaque is composed of a large lipid 
core, which is filled with macrophages that engulf modified LDL particles and 
became foam cells, or dead macrophages that result in debris accumulation 
(Ouweneel et al., 2019, Virmani et al., 2006). The surrounding extracellular 
matrix molecules (mainly interstitial collagen) creates the TCFA, which 
encapsulates this lipid core and its contents (Libby and Aikawa, 2002).  
Conversely, plaque erosion classically occurs in a plaque that is lipid-poor 




(Libby, 2015, Libby et al., 2019, Pasterkamp et al., 2017). Furthermore, 
fibrinous clots, which complicate plaque rupture, have fewer platelets when 
compared with the platelet-rich thrombi that complicate erosion (Libby et 
al., 2019, Quillard et al., 2017, Badimon et al., 2012). 
Although many molecular mechanisms of plaque rupture have been 
described (Bentzon et al., 2014), a few recent studies have highlighted the 
potential role of cholesterol crystals in causing physical plaque rupture as 
the crystalized shape can make it easy for these to pierce through the intima 
and the fibrous cap, causing a plaque explosion (Abela, 2010). Abela 
demonstrated that atherosclerotic plaques of patients who died from ACS, 
have cholesterol crystals perforating the cap and the surface of the intima. 
This supports previous work that showed that the process of cholesterol 
crystallization from liquid forms (which are also present within the arterial 
walls (Lundberg, 1985)), to solid crystals, increases cholesterol volume in the 
vessel wall and that this crystallization process is the trigger for 
atherosclerotic lesion core expansion (Abela and Aziz, 2006). This results in 
more pressure directed towards the fibrous cap, which can lead to overlying 
intima and plaque cap disruption leading to a thrombosis that blocks the 
artery (Dai et al., 2016). 
Several lipid-lowering agents (such as aspirin, ethanol and statins) have also 
been shown to have an effect on dissolving cholesterol crystals, suggesting 




however the exact mechanism is not fully understood (Bentzon et al., 2014, 
Dai et al., 2016, Abela, 2010).   
1.3 The role of Inflammation in Atherosclerosis 
Until relatively recently (1990s), there was a long-established understanding 
that the occurrence of atherosclerosis was primarily due to a metabolic 
disorder rather than an inflammatory condition, and many studies 
hypothesised it as no more than a monotonous lipid storage disorder and 
accumulation of lipid debris (Libby et al., 2002). However, investigation of 
the link between inflammation, lipoprotein metabolism and atherosclerosis 
began in the 1950’s and continues to the present day. Early studies reported 
inflammatory changes such as elevated levels of pro-inflammatory 
mediators, including C-reactive protein (CRP), a representative marker for 
the pro-inflammatory cytokine IL-1 and other cytokines, which play a key 
inflammatory role in atherosclerosis (Enos et al., 1953, Kushner et al., 1978).  
Clinical studies on ACS patients have shown that levels of the acute phase 
reactant serum CRP are elevated in association with disease progression and 
development of cardiovascular complications (Ridker et al., 2005). That high 
sensitivity CRP measurement is an indicator of ACS severity and plays a role 
in risk stratification and patient prognosis prediction, has also been shown 
recently, in a study conducted on more than 10,000 ACS patients (Liu et al., 
2020). The importance of inflammation in atherosclerotic progression is also 
indicated by studies using therapies that aim to lower serum lipid levels 
through changes in diet and lifestyle alone. These were not effective, with 




of the disease has not been altered (Pearson et al., 2003, Grundy et al., 2004, 
Ridker, 2018). The drug class of statins, which are now routinely prescribed 
(and have been used effectively for LDL cholesterol lowering, for more than 
30 years), are known to have pleiotropic effects especially upon 
inflammation (Oesterle et al., 2017). These are cardiovascular protective 
effects that are independent of LDL cholesterol lowering (further explained 
in section 1.4). 
1.3.1 The Role of the Pro-Inflammatory Cytokine IL-1 in Atherosclerosis 
IL-1 is an inflammatory cytokine that is mainly released from macrophages 
and monocytes during the innate response to inflammation, transducing 
signals through activation of a complement pattern recognition receptor and 
TNF alpha (Dinarello et al., 2012). In atherosclerosis, IL-1 is crucially involved 
in the inflammatory process of vessel walls and is recognised as a potential 
target presenting a manageable therapeutic system, as it is highly expressed 
in arteries of patients with atherosclerosis and CHDs (Satterthwaite et al., 
2005). 
The production of the cytokine interleukin 6 (IL-6) is promoted by IL-1 via 
NF-kB (Yi et al., 2014), and together these play a role in stimulating the liver 
to produce CRP (Schindler et al., 1990). High serum levels of IL-6 are 
observed in ACS patients (Nijm et al., 2005), and high levels of CRP alone are 
considered a major clinical sign of increased mortality in ACS patients 
(Biasucci et al., 1999, Liu et al., 2020). Furthermore, in vivo experimental 
studies have reported a reduction in the formation of neointima in mouse 




study, IL-1β−/− mice experienced a fourfold increased lumen area and a 
fourfold reduction in neointima/media, compared to wild-type mice. 
Studies on the genetically modified Apolipoprotein E (ApoE) deficient mice, 
which are more vulnerable to developing atherosclerotic lesions (Kolovou et 
al., 2008), have shown that interleukin-1 receptor antagonist (IL-1ra), which 
blocks the interleukin-1 receptor 1 (IL-1R1) has an inhibitory effect on the 
intimal development of fatty streaks (Elhage et al., 1998), while complete 
genetic deletion of IL-1R1 reduces the development of atherosclerosis as a 
result of a fatty diet (Chamberlain et al., 2009). Clinical trials on ACS patients 
have also shown that treatment with recombinant human (IL-1ra) had an 
effective role in reducing markers of inflammation e.g. CRP over the 
treatment period (Morton et al., 2015). The CANTOS (Anti-inflammatory 
Thrombosis Outcome Study) trial, which used cankinumab, a monoclonal 
therapeutic antibody that targets IL-1β, investigated the clinical 
effectiveness of IL-1β inhibiting agents. The study was conducted on 10,061 
patients with previous MI and high hs-CRP level (2 mg or more per litre), and 
showed that inhibition of IL-1β resulted in better patient prognosis with 
significant reduction in rates of adverse clinical events (Ridker et al., 2017).   
All these previous studies emphasise the key role of IL-1 as a target to reduce 
the development of atherosclerosis and thus reduce clinical cardiovascular 
manifestations.  
Interleukin 1 beta (IL-1β) and interleukin 1 alpha (IL-1α), both have been 




(Satterthwaite et al., 2005). Both cytokinescomplexc are synthesised as 
precursor proteins and their signalling effects are exerted by activation of IL-
1R1 as well as inhibited by IL-1ra (Dinarello, 2005). IL-1β is initially produced 
as pro-IL-1β, an inactive form that can be activated into a mature IL-1β by 
cleaving enzymes such caspase-1 (Burns et al., 2003) (section 1.5). IL-1α 
stays bound to the plasma membrane and associated with local 
inflammation, and is released from necrotic cells (such as necrotic human 
aortic vascular smooth muscle cells (Clarke et al., 2010)) while IL-1β is 
secreted completely, making it a circulatory isoform (Dinarello, 2009, 
Dinarello, 1991). This attributes to IL-1β having both paracrine and 
endocrine effects, and it is, therefore, a potentially better target of study 
than IL-1α (Rader, 2012). Furthermore, it has been reported in vivo and in 
vitro that IL-1β has important roles in different stages of atherogenesis (Van 
Tassell et al., 2013). 
1.3.2 IL-1β is an Important Target for Atherosclerosis Development and 
Progression 
IL-1β plays a major role in endothelial activation by promoting adhesion 
molecule expression and eliciting the production of chemokines, causing 
infiltration and recruitment of inflammatory cells into the sub-intimal space 
during atherogenesis (Szmitko et al., 2003). IL-1β also enhances vascular 
endothelial growth factor (VEGF) expression, which then promotes 
endothelial cell reactivity, through increasing vascular leakiness which 
further aggravates inflammation and infiltration of immune cells (Lange et 




The level of plaque inflammation is directly related to the extent of plaque 
formation (Van Tassell et al., 2013). Expression of IL-1β correlates with the 
progress of the atherosclerotic lesion, where very high levels of IL-1β 
expression were seen in complicated lesions and less expression in stable 
lesions. Low expression was reported in coronary arteries of healthy 
individuals (Dewberry et al., 2000). Furthermore, levels of plasma IL-1β are 
elevated in patients with more severe atherosclerotic complications 
(Ikonomidis et al., 2005) and this elevation was a precursor for less 
favourable ACS prognosis (Orn et al., 2012).  
In addition, IL-1β has a crucial role in plaque destabilisation as it up-regulates 
MMPs’ expression and over production in macrophages, endothelial cells 
and SMCs, all of which are components that build up to form the plaque 
during atherogenesis. This elevated expression leads to degradation of the 
subendothelial collagen matrix and exposure of the contents of the vessel 
wall to flowing blood, increases the chance of plaque rupture, leading to 
acute coronary syndrome  (Newby, 2016).   
This central role of IL-1β is supported in experimental models where ApoE 
deficient mice also lacking IL-1β exhibit smaller atherosclerotic lesions, in 
response to reduced VCAM-1 and MCP-1 expression in blood vessels (Kirii et 
al., 2003, Libby, 2008).Given the central and proven role of IL-1β, it is clear 
that release of IL-1β has to be carefully controlled within the body, and there 
are several levels of regulation possible (Brough et al., 2011, Folco et al., 




but this is not the case for vascular wall cells like endothelium. One recently 
discovered mechanism is that vessel wall proteases e.g. neutrophil elastase 
lead to IL-1β release inside lysosomally derived extracellular vesicles (Alfaidi 
et al., 2015). There are also suggestions that cholesterol crystals may 
promote processing and release of IL-1β from macrophages (Rajamaki et al., 
2010). In monocytes, the mechanism to enable this is via the NLRP3 
(nucleotide-binding domain leucine-rich repeat containing (NLR) family, 
pyrin domain containing 3) inflammasome (Duewell et al., 2010), but no data 
are available from vessel wall cells such as endothelium and this, therefore, 
is the main aim of my study.  
1.4 The Role of Cholesterol and Cholesterol Crystals 
Cholesterol is an organic lipid molecule, biosynthesized by all human and 
animal cells (80% synthesised in the liver) and is a vital cellular component 
that maintains cellular fluidity and provides structural integrity for 
membranes (Chang et al., 2006). Owing to its chemical and physical 
characteristics as a low aqueous soluble molecule, it cannot be transported 
in blood without lipoprotein carriers, such as LDL (Phillips, 2014). The main 
route for cholesterol settlement into cellular membranes is through LDL 
receptor mediated endocytosis (Le May et al., 2013). 
In the cell, excess free cholesterol undergoes esterification by acetyl 
coenzyme A (acyl-CoA) cholesterol acyltransferase (ACAT) (see Figure 1.3), 
which turns it into cholesterol esters that are deposited as droplets of lipid 






 (Figure 1.3) Cellular Cholesterol Biosynthesis: Cholesterol synthesis is 
initiated by the transportation of Acetyl-CoA from mitochondria to 
cytoplasm. Acetyl-CoA is converted into HMG-CoA by HMG-CoA synthase 
which is encoded by the HMGCS1 gene. The conversion into mevalonate is 
by the action of HMG-CoA reductase (HMGR) which is an endoplasmic 
reticulum bound enzyme. Mevalonate is activated by phosphorylation into 
mevalonate 5-diphosphate which undergoes an ATP-dependent 
decarboxylation. As a result, an activated isoprenoid molecule known as 
isopentenylpyrophosphate (IPP) is synthesized. Squalene is then synthesised 
from IPP with the action of the squalene synthase enzyme. Cyclisation of 
squalene yields lanosterol, which is converted into cholesterol through a 





It has long been known that the accumulation of cholesterol in both ester 
and crystal forms are widely present in atherosclerotic plaques (Katz et al., 
1976, Katz and Small, 1980). Recently, however, cholesterol has been 
implicated in other areas. A complicated clinical syndrome, with a 
challenging management approach and poor prognosis, called CCE 
(Cholesterol crystal embolic) syndrome, was described in 2017 (Ghanem et 
al., 2017). This syndrome occurs as the result of plaque rupture accompanied 
by cholesterol crystal release into the circulation, embolizing into multiple 
tissue organs, initiating systemic and local inflammation, which eventually 
leads to vascular obstruction, and fibrosis, causing symptoms mimicking 
vasculitic conditions.  
In cultured human macrophages, it has been reported that the collection of 
non-esterified cellular excess free cholesterol (Figure 1.3) is transformed 
eventually to cholesterol crystals (Geng et al., 2003). Macrophages undergo 
an adaptive mechanism, which promotes sterol crystallization, in response 
to the oxidative products of cholesterol. However, crystallization and 
nucleation of free cholesterol only takes place during the onset of plaque 
formation, when cholesterol esterification is diminished and membrane 
cholesterol is supersaturated.  
Studies using SMCs showed that the accumulation of free cholesterol itself 
in SMC is not inflammatory, as it did not alter MCP-1 or VCAM-1 (Rong et al., 
2003). However, cellular free cholesterol did promote smooth muscle cell 




pathophysiology of atheroma development (Feil et al., 2014, Giannotti et al., 
2019). In addition, SMC showed elevated production of ROS in addition to 
mitochondrial dysfunction when overloaded with free cholesterol (Kedi et 
al., 2009). 
Surprisingly, however, there are no definitive studies on the effects of 
cholesterol crystals in cultured endothelial cells, despite that these cells 
express receptors for oxidized lipoproteins, and have the biochemical 
pathways for sterol synthesis and receptor-mediated endocytosis of 
lipoproteins (Hassan et al., 2006). 
Pathology studies on coronary arteries of ACS patients showed that, at the 
sites of plaque rupture, there were usually dense clusters of cholesterol 
crystals (Abela et al., 2009). Electron microscopy, used to visualise 
cholesterol within tissue prepared without the use of solvents also showed 
that in vitro statins and aspirin could dissolve cholesterol crystals, due to 
their lipophilic properties and their anti-inflammatory and pleiotropic 
effects (Abela, 2010). This observation may well be connected to the success 
of clinical trials that have used statins to prevent and reduce the occurrence 
of cardiovascular events (Ridker et al., 2008). Statins could act as solvents of 
cholesterol crystals thereby preventing the volume expansion that leads to 
plaque rupture and development of clinical coronary symptoms (Ioannou et 





1.4.1 Modified LDL cholesterol in atherosclerosis 
There is well established understanding that the process of atherosclerosis 
development is mainly caused by LDL modification (in particular oxidative 
changes) in the arterial wall by ROS (Aviram, 1993, Lepedda and Formato, 
2020). There is also a suggestion that smoking, a common risk factor of 
atherosclerosis, exerts its effects, by increasing ROS production from cells, 
in particular endothelial cells, and therefore increasing the chances of LDL 
alterations (Miao et al., 2019). Studies reported that circulating modified LDL 
has a direct effect on inducing damage to the endothelium and cause 
endothelial dysfunction (Paoletti et al., 2004), while extensive modification 
of LDL causes oxidative stress and accelerates endothelial cell senescence, 
two key atherosclerosis leading events (Yang et al., 2019, Ehara et al., 2001).  
Several modified LDL forms have been identified since the 1970s, these 
include: Oxidised LDL (OxLDL) (Schuh et al., 1978), Acetylated LDL (AcLDL) 
(Goldstein et al., 1979) and Aggregated LDL (AgLDL) (Dyerberg et al., 1978).  
1.4.1.1 OxLDL 
The oxidative modification of proteins and lipids is commonly seen in several 
pathophysiological processes in vivo, such as inflammation-related gut 
diseases, diabetes and CVD (Sottero et al., 2018, Randle et al., 1994).  
Lipid molecules containing native LDL are easily oxidized under oxidative 
stress, such as hydroperoxides, lipooxigneases and free radicals (Itabe, 1998, 
Di Pietro et al., 2016).  
In addition to being the most studied form of modified LDL in context to 




inflammatory and proatherogenic form of modified LDL. The 
prothatherogenic properties of OxLDL are mainly driven by oxidised 
phospholipids, which are also the principal epitopes and the major structural 
feature making OxLDL recognisable by scavenger receptors as a ligand 
(Leitinger, 2005). Macrophages are known to take up OxLDL by scavenger 
receptors, which leads to their formation into lipid-laden foam cells, which 
is the hallmark of an early atherosclerotic lesion. Although there is almost 
no size difference between unmodified native LDL molecules (22-27.5 nm in 
diameter (Campos et al., 1992)) and OxLDL molecules (25-30 nm in diameter 
(Han and Pak, 1999)), OxLDL at only 50 μg/ml can induce foam cell 
formation, while the concentration needed in native LDL is at 2 mg/ml (40-
fold greater)(Kruth et al., 2005). 
1.4.1.2 AcLDL 
Unlike OxLDL, AcLDL is an artificial model ligand that is used in variety of 
modified lipid studies and was never reported to be found in vivo (Steinberg, 
2009). There are several methods of preparation of AcLDL, the most 
common is acetylation with excess acetic anhydride, which has been 
previously used been used as a targeted drug delivery mechanism reported 
to be taken up by cells via scavenger receptors (Limmon et al., 2008). AcLDL 
and OxLDL behave similarly as they are both degraded inside lysosomes and 
are taken up by macrophages via scavenger receptors at similar 
concentrations (Liu et al., 2015, Brown et al., 2000). Furthermore, the size of 
AcLDL in diameter is almost identical to that of OxLDL as measured by atomic 





Although the molecular mechanisms of lipid droplet formation and retention 
of LDL in the subendothelial arterial space are not entirely understood, there 
is growing evidence supporting the fact that modified LDLs undergo fusion 
and aggregation, which limits their exit from the arterial wall and contributes 
to atherogenesis (Hurt-Camejo et al., 2000, Camejo et al., 1998, Zhao et al., 
2004), thus forming AgLDL molecules.  
AgLDL has been reported to be found in vivo in arterial walls of CVD patients 
as well as ApoE deficient mice (Zhao et al., 2004, Aviram et al., 1995, Hoff 
and Morton, 1985, Maor et al., 2000). The exact mechanisms leading to 
AgLDL formation are also poorly understood, however, in contrast to native 
LDL, it has been reported that native LDL does not normally aggregate nor 
fuse under normal physiological conditions, highlighting the importance of 
LDL modification prior to aggregation (Goldstein et al., 1979, Lu and Gursky, 
2013).  
AgLDL is also taken up by macrophages (Haberland et al., 2001) and HVSMCs 
incubation with AgLDL in vitro induces foam cell formation (Costales et al., 
2015). 
Since AgLDL is formed via the fusion and aggregation of modified LDLs, it has 
been reported with variety of sizes. A study reported the formation of AgLDL 
molecules which ranged 40-200 nm in diameter (Zhang et al., 2000) while 





1.4.2 Cholesterol Crystals Promote Endothelial Cell Activation  
Although the role of cholesterol crystals in different stages of atherosclerosis 
development, including promoting inflammation and plaque rupture, is well 
established (Sections 1.2-1.4), questions arise as to if/how cholesterol 
crystals play a role in endothelial cell activation. Cholesterol crystals (at 
concentration of 2 mg/ml, prepared by dissolving and mixing free 
cholesterol with 1-propanol in vitro (Samstad et al., 2014)) can activate 
HUVECs only when co-incubated with whole blood (Nymo et al., 2014). 
These data could be explained by the presence of many activating factors in 
whole blood such as TNF and IL-1β or, perhaps, cellular vesicles arising from 
other cells such as neutrophils or monocytes. TNF has a key role in activating 
the endothelium following incubation with cholesterol crystals, 
demonstrated by use of an IL-1β specific inhibitor canakinumab which did 
not affect expression levels of adhesion molecules ICAM-1 or E selectin, 
while inhibition with the TNF inhibitor infliximab resulted in complete 
attenuation of their responses (Nymo et al., 2014). In addition, cholesterol 
crystals promoted the release of IL-1ra from the whole blood and inhibited 
signalling of IL-1β explaining the insufficient effect of IL-1β alone (Nymo et 
al., 2014).   
1.4.3 The Link Between Cholesterol Crystals and IL-1β 
The potential mechanistic link between the effects of cholesterol crystals 
and release of IL-1β is the NLRP3 inflammasome (Duewell et al., 2010), which 




and PYD domains-containing protein 3), a gene that is mainly expressed in 
macrophages (Kunnas et al., 2015) (further details in section 1.5).  
Macrophage uptake of oxidised LDL (OxLDL) via the CD36 scavenger 
receptor, leads to formation of intracellular cholesterol crystals that activate 
NLRP3 through lysosomal destabilisation (Moore et al., 2013, Oury, 2014). 
NLRP3 plays a major role in the cleavage of pro-IL-1β into a mature form via 
caspase-1 activation (Shenderov et al., 2014), and can be activated with 
cholesterol crystals in peripheral blood mononuclear cells (PBMCs) following 
lipopolysaccharide (LPS) priming as well as cytokine cell priming (Duewell et 
al., 2010). 
There are little data on endothelial cells, but HUVECs primed with TNF-α 
have increased expression of adhesion molecule ICAM-1 and E-selectin, in 
addition to increased release of IL-1β, when also activated by cholesterol 
crystals (Samstad et al., 2014). However, human coronary artery endothelial 
cells (HCAECs) primed with TNF-α and LPS did not show increased IL-1β 
release upon incubating with cholesterol crystals (same concentration used 
by (Samstad et al., 2014) and (Nymo et al., 2014), 2 mg/ml) (Champaiboon 
et al., 2014).  This was explained by the presence of hydrocortisone in the 
media of HCAECs, which is known to inhibit the release of IL-1.  
1.5 The Caspase-1/NLRP3 inflammasome activation pathway of IL-
1β secretion 
1.5.1 Understanding the Caspase-1/NLRP3 mechanism 
It is well established that the NLRP3 inflammasome is formed in the 




pathogen associated molecular patterns (PAMPs), and after its cytoplasmic 
formation, the NLRP3 inflammasome serves as the molecular platform for 
the activation of Caspase-1 and for the processing of proIL-1β (Martinon et 
al., 2002, Karasawa and Takahashi, 2017a).  What distinguishes the NLRP3 
inflammasome from others, is that the NLRP3 inflammasome can be 
activated by both endogenous or exogenous DAMPs which makes them 
involved in pathophysiological mechanisms of sterile inflammatory diseases 
(Lamkanfi and Dixit, 2014).  
The protein structure of the NLRP3 inflammasome complex is composed 
mainly of three parts: 1) NOD-like receptor protein number 3 (NLRP3 
protein); 2) an apoptosis associated speck-like protein containing a caspase-
1 recruitment domain (ASC), which is occasionally referred to as the adaptor 
protein; 3) the cysteine protease caspase-1 (Martinon et al., 2002, Burns et 
al., 2003, Strowig et al., 2012). The NLRP3 protein is also composed of three 
domains: 1) NACHT, which is a central nucleotide domain; 2) C-terminal 
leucine-rich repeats (known as LRRs); 3) pyrin domain (PYD) which is an N-
terminal effector domain. ASC also contains an N-terminal PYD and contains 
a caspase recruitment domain (CARD) C-terminal. Caspase-1, (which was 
previously known as IL-1 converting enzyme (ICE) (Black et al., 1989)), 
contains a CARD as well as two catalytic domains known as p10 and p20 
(Duewell et al., 2010, Jiang et al., 2017).  
When a cell is stimulated by DAMPs, the stimulation triggers the NLRP3 to 




which provides a scaffold for the oligomerization of ASC by the interacting 
PYDs. Due to the structure of NLRP3 protein, and because it lacks CARD, 
NLRP3 therefore cannot choose to recruit caspase-1, unless in the presence 
of ASC. After oligomerization of ASC, it interacts with caspase-1 via the 
homophilic interaction with CARD, which induces the auto-activation of 
caspase-1 allowing it to exercise its pro-inflammatory effects (Karasawa and 
Takahashi, 2017a, Karasawa and Takahashi, 2017b).  
Studies have shown that cholesterol crystals and OxLDL are considered 
danger signals that can activate the NLRP3 inflammasome in macrophages 
(Rajamaki et al., 2010, Duewell et al., 2010, Abdul-Muneer et al., 2017), 
although the exact mechanisms of recognition and activation of NLRP3 by 
cholesterol crystals or LDL molecules are not understood. However, multiple 
upstream pathways have been reported to be essential for the activation of 
the NLRP3 inflammasome: 1) lysosomal destabilisation; 2) potassium ion 
(K+) efflux, which is mainly induced by the P2X7 receptor in macrophages; 3) 
production of mitochondrial ROS (Guo et al., 2015). It is well-established that 
among those three upstream pathways, lysosomal destabilisation, 
accompanied with a subsequent release of cathepsin B, is the most 
important pathway (Lima et al., 2013, Niemi et al., 2011, Karasawa and 
Takahashi, 2017a).    
The most accepted understanding of IL-1β production and release is known 
as the “two-step process”(Wang et al., 2013), or the “two-signal process” 




1β, which is known as the priming step or first signal. This process is 
regulated by the NF-kB-mediated mRNA induction of NLRP3 and pro-IL-1β  
synthesis, and is mediated by cytokine receptors (such as the IL-1 receptor) 
or PRRs (such as TLRs). At this stage, both the cytosol accumulated pro-IL-1β 
and the NLRP3 are inactive and in standby mode, until a second signal is 
given.  This second signal, known as the activation signal or oligomerization 
signal (Satoh et al., 2013), which could be the exposure and uptake of 
cholesterol crystals or OxLDL (as DAMPs) by the cell, results in activation of 
the NLRP3 and release of active caspase-1 (Zheng et al., 2013, Abdul-Muneer 
et al., 2017, Rajamaki et al., 2010). The NLRP3 inflammasome mediated 
activation of caspase-1 initiates the rapid processing of pro-IL-1β 31 kD (the 
precursor of IL-1β), cleaves the pro-IL-1β into a mature IL-1β (17 kD), causing 
the release of mature bioactive IL-1β outside the cell. Thus, to regulate and 
maintain inflammatory homeostasis of the potent inflammatory cytokine IL-
1β, this two-signal process is crucial.  
1.5.2 Activation of the Caspase-1/NLRP3 mechanism by cholesterol and 
release of IL-1β from macrophages 
The first group to show the direct involvement of the NLRP3 inflammasome 
in atherosclerosis development and the importance of cholesterol in the 
process of the underlying NLRP3 activation mechanism were Duewell et al. 
2010. Their study used IL-1α/β-/-, NLRP3-/-, or ASC-/- bone marrow cells 
transplanted into atherosclerosis-prone, LDL receptor-deficient mice (LDLR-
/-) and showed that absence of these inflammatory molecules dramatically 




cholesterol crystals as an important candidate for NLRP3 activation, the 
study also reported the successful activation of NLRP3 inflammasome and 
release of IL-1β from macrophages. The release of IL-1β from LPS-primed 
macrophages, secondary to cholesterol crystal treatment was more than 60 
fold greater than untreated LPS-primed only macrophages. This release was 
completely inhibited when a Caspase-1 inhibitor was used (YVAD).  
Interestingly, this study was also among the first to highlight the presence of 
OxLDL, which possesses highly inflammatory and atherogenic properties, 
leading to cholesterol crystallization and activation of the NLRP3 
inflammasome mediated activation of caspase-1. Macrophages internalised 
OxLDL molecules, resulting in the formation of peri-nuclear crystals as early 
as one hour post incubation, with OxLDL treatment (200 μg/ml for 24 hours) 
inducing the release of almost 10-fold more IL-1β compared to untreated 
macrophages which did not release IL-1β (Duewell et al., 2010).  
1.5.3 The pyroptosis theory of IL-1β exit from the cells 
The mechanism by which IL-1β is released from cells is not fully elucidated. 
One possible mechanism is that IL-1β and other non-signal sequence 
protiens might exit cells via membrane pores. This is supported by the 
observation that activated caspase-1 is also capable of cleaving gasdermin D 
(GSDMD), which is known as the pore forming protein or the pyroptosis 
inducing protein (Evavold et al., 2018).  
Pyroptosis is a form of highly inflammatory programmed cell death, which is 
accompanied by membrane pore formation, and increased permeability of 




danger molecules (Kayagaki et al., 2015, Shi et al., 2015). The association of 
GSDMD cleavage and caspase-1 activation in the pathway of mature IL-1β 
release from macrophages during atherosclerosis development, is 
evidenced by the fact that the pore formed after release of active GSDMD is 
the exit gate for active IL-1β (Evavold et al., 2018). However, the role of 
GSDMD and its association with the release of IL-1β from vascular 
endothelial cells has not been investigated.   
Thus, because the mechanism of release of IL-1β is still unknown and the 
exocytosis of IL-1β has no signal sequence (Martín-Sánchez et al., 2016), 
understanding pyroptosis-mediated membrane pore formation and 
permeabilization in endothelial cells will add further understanding to the 
mechanism of IL-1β release.  
1.6 Summary and Knowledge Gap 
Cholesterol, cholesterol esters and cholesterol crystals are present in 
atherosclerotic plaques, including in endothelial cells. These are not usually 
seen histologically, because pathological processing of samples removes all 
these entities. However, cholesterol crystals have been shown to elicit IL-1β 
release from macrophages, and this is well known. However, the release of 
IL-1β from other cell types in the vessel wall, especially endothelial cells in 





1.7 Hypothesis, Aims and Relevance of the Study 
I hypothesise that cholesterol enters the endothelium and induces IL-1β 
secretion via a caspase-1/NLRP-3 mechanism. Secondly, I hypothesise that 
cholesterol esters (lipid droplets) and cholesterol crystals stored in cells 
induce IL-1β secretion following priming of the cells with an inflammatory 
stimulus. Finally, that IL-1β secretion in response to the above stimuli can be 
inhibited by treatment with inhibitors of the NLRP3 inflammasome or 
inhibition of any of its up-/downstream factors.  
The first aim of this project was to investigate whether cholesterol, in both 
the forms of free native cholesterol and modified cholesterol, induces the 
release of IL-1β from human coronary artery endothelial cells (HCAECs), and 
whether the release of IL-1β was secondary to uptake by vascular 
endothelial cells. A further aim was to investigate the mechanism of 
cholesterol uptake and IL-1β release by HCAECs using inhibitors of Caspase 
1 and NLRP3. 
Cholesterol crystals are common in atherosclerosis, and their point of entry 
to the vascular wall is the endothelium. Thus, identifying a cellular 
mechanism to prevent cholesterol-primed pro-inflammatory IL-1β release 
from endothelial cells could eventually lead to a new targeted therapeutic 
agent which may have a promising influence on the future of cardiovascular 
treatment regimes, and aid in reducing mortality rates.





2.1.1 Reagents & Solutions: 
Stock concentrations, working doses, sources of solutions and reagents used 
are listed in appendices (I & II). 
2.2 Methods: 
2.2.1 Cell culture: 
All cell culture experiments were carried out under a Class II sterile laminar 
flow hood and all cells were incubated at 37ᵒC with 95% air and 5% CO2. 
Strict sterile procedures were used at all times to prevent the development 
of infections which might alter the interpretation of the results and interfere 
with the quantification methods used. 
2.2.1.1 Human umbilical venous endothelial cells (HUVECs): 
HUVECs were used as an initial model to test the effect of cholesterol, due 
to their cost effectiveness compared to HCAECs and their easy availability as 
a fresh endothelial cell line, in addition to being responsive to cytokine 
stimulation as previously reported (Alfaidi et al., 2015). HUVECs were 
isolated from the fresh umbilical cords of babies born in the maternity unit 
of Jessop Wing Sheffield Teaching Hospital (STH). The collection and use of 
these cords/HUVECs was regulated by the ethical committee and registered 
as ethical approval (STH15599, REC ref 10/H1308/25), see appendix (V) for 
more details. The cords were collected from mothers whom have consented 
and after following strict assessment measures. These measures ensure that 
cords were only collected from normal, full term deliveries (pre-term and 




infectious diseases (Hepatitis and HIV) were taken, positive tested mothers 
were excluded from the study.  
2.2.1.1.1 HUVECs isolation process: 
Fresh umbilical cords stored within individual containers in minimum 
essential media (MEM) (see appendix II for composition) at 4ᵒC and were 
ideally used within 24 hours of collection, for the isolation process. A total 
of 12 cords were used in the study.  
The isolation was carried out in accordance with the established protocol by 
(Jaffe et al., 1973). Cords without clamp markings and with a minimum 
length of 10cm minimum were used during all isolations. Cords not matching 
these criteria were discarded.  
Each cord was inspected for any damaged parts or any tears in its surface, 
and the outer layer was cleaned with Azo© wipes. Gentle massage was then 
applied to the cord towards one end, to expel any excess venous blood or 
blood clots. The vein was cannulated using a 14G cannula, and a tight bung 
was attached to the cannulated region to secure its place inside the vein. A 
long plastic needle sheath was first inserted into the vein, followed by a 
shorter needle, to allow the plastic part to be prominent. This also avoids 
the needle piercing through the vein wall. The needle was then clamped to 
secure it in place (Figure 2.1A). A 60ml syringe was attached to the needle 
inlet, and the vein was washed with 40 ml of pre-warmed serum free M199, 
by applying moderate pressure to remove traces of clots and blood. A 




was inflated with 10ml of 0.1% (w/v) collagenase solution (0.20 μm sterile 
filtered), prepared at room temperature in serum free M119 using 
collagenase from clostridium histolyticum (See Appendices I &II for all 
compositions). After observing moderate distention of the vein without any 
leaking, the cord was placed on a layer of Azo© wipes and left in the laminar 
flow hood at room temperature for exactly 12 minutes (Jaffe et al., 1973), 
allowing the detachment of venous endothelial cells by collagenase (Figure 
2.1B). 
The distal end of the cord was then placed in a 50ml falcon tube and was de-
clamped, allowing the contents for the cord (which contain the detached 
endothelial cells) to be collected in the tube, with a gentle massage applied 
to the cord to flush the cells. The tube was centrifuged at 300g for 5 minutes 
at 24°C, the supernatants carefully discarded, and the pellet re-suspended 
in 10 ml of pre-warmed complete growth media CGM, ensuring complete 
disposal of the pellet into the media.  
The cells were then transferred into a pre-coated 1% (w/v) gelatin T75 flask, 
and left to grow in the flow incubator at 37°C with 5% CO2 and 95% air 
overnight.  
The pre-coating of the flask was performed by adding 5 mL of 1% (w/v) 
gelatin to the flask and leaving it in the incubator at 37°C with 95% air and 
5% CO2 for at least 30 minutes, after which the gelatin was removed and the 




The next day, cells were observed under the microscope to make sure they 
were contamination free, and the flask was washed with PBS (pH 7.4) to 
remove any traces of blood and red blood cells. In addition to washing away 
non-adherent cells, media was replaced with fresh CGM; thereafter the 
media was changed every 2-3 days until the cells were observed under the 







(Figure 2.1) Isolation of HUVECs: (A) Fixation of the needle sheath followed 
by needle inside the umbilical vein. (B) Distended umbilical vein after loading 






In the first 24-36 hours after isolation, HUVECs look like small epithelioid 
clusters. However, after 48-72 hours, the clusters spread to the typical 
cobblestone monolayer appearance (Figure 2.2). 
 
(Figure 2.2) Cobblestone appearance of HUVECs under microscope 
following isolation from cords: This image has been taken using bright field 
microscopy and image was managed by the software LAS AF Lite by Leica©. 
Scale bar = 100 μm. 
2.2.1.1.2 Culture and sub culture of HUVECs 
HUVECs were passaged when 80-90% confluent, (approximately every 4-5 
days). HUVECs were always cultured in a 1% (w/v) gelatin coated T75 flask, 
and the CGM was changed once every 72 hours at a maximum. When the 
cells were ready to be passaged, the CGM media was discarded and the cells 
washed gently with 10 ml of PBS once. Pre-warmed Trypsin/EDTA 
(Ethylenediaminetetraacetic acid; EDTA, 0.2% v/v in PBS without 
Magnesium, Calcium or Phenol Red) was added to the flask (1 ml volume), 




Trypsin solution was applied to the cells as it dissolves the junctions between 
the cells, the trypsin exposure period was not exceeded by 3 minutes as to 
avoid the risk dissolving the cellular lipid bilayer. The flask was then gently 
tapped and checked under the microscope to confirm the detachment of 
cells. CGM (5 ml volume) was then added to the flask to neutralise the 
trypsin, and the contents of the flask were transferred to a 50 ml falcon tube, 
which was then centrifuged at 300g for 5 minutes at 24°C.  
The supernatant was gently discarded leaving a pellet at the bottom of the 
tube which was re-suspended into 24 ml of CGM, pre-warmed to 37°C. The 
cell solution was then transferred to two gelatin pre-coated T75 flasks (12 
ml each), and left to grow in the incubator.  
All HUVECs experiments were performed using cells at passage 2-3 and each 
stated n number represents HUVECs from a different donor. 
The volume of medium to surface area ratio was; 1ml per 5 cm2 (5 ml per a 
T25 flask or 15ml per a T75 flask), and 1 ml per well in a 12-well plate.  
2.2.1.1.3 HUVECs seeding density in a 12 well plate: 
HUVECs were seeded in a 12 well plate at 10,000 cells/cm2 and left to grow 
in the incubator for 48 hours after which they were viewed under the 
microscope for determination of confluence by eye.  
2.2.1.2 Human Coronary Artery Endothelial cells (HCAECs): 
Three vials of cryopreserved HCAECs from three different biological donors 




and were received in a dry ice filled container. The lot numbers for the three 
cell orders are 440Z021.1, 424Z011.1 and 411Z027. 
2.2.1.2.1 HCAECs Culture: 
Upon receipt of the cells and according to the supplier’s instructions, MV2 
supplemented media (composition of media in appendix II) was prepared 
and 9 ml of this prepared MV2 media was pre-warmed in a T75 flask to 37°C 
with 5% CO2 / 95% air for 30 minutes to be used for culturing the cells. The 
vial containing the cryopreserved cells was removed from the dry ice and a 
quarter twist to the cap was applied under the laminar flow hood to relieve 
the pressure, then it was re-sealed tightly. The vial was thawed quickly in a 
waterbath (30 seconds), thereafter the cells were transferred immediately 
from the vial into the pre-warmed T75 flask and returned to the incubator 
and left to grow. The media was changed and replaced with fresh MV2 
media 24 hours later, after which it was changed every 48 hours until the 
cells were 80-90% confluent.  
When the cells were confluent they were sub cultured (to passage 3) into 
four T25 flasks according to the protocol below. At this step the cells were 
either used to seed an experimental plate or stored frozen in liquid nitrogen 
until used. The cell density used in all experiments when cells were confluent 
was approximately 5,000 cells/cm2. 
2.2.1.2.2 HCAECs sub-culture: 
To maintain continuous healthy cell growth, the cells were passaged 1:3 
when 80-90% confluent. This was to avoid the cells from becoming over-




detach from the flask surface and die. Over-confluent cells also have a high 
possibility of suppressing the production of IL-1β (Jung et al., 2001), and 
therefore giving false data in the study. When the confluence level was 
reached, media was removed from the flask, and cells washed once with 
sterile PBS (pH 7.4). Afterwards, 3 ml of pre-warmed (37ᵒC) trypsin solution 
was added to the cells and the flask was left for 3 minutes in the incubator 
to aid detachment of cells. When the cells were viewed detaching under the 
microscope, the trypsin was diluted by adding 10 ml of CGM into the flask, 
and the contents were transferred into a 50 ml tube and centrifuged at 300g 
at 24ᵒC for 5 minutes. The supernatants were then discarded gently and the 
pellet was re-suspended in 1ml of CGM. 
The appropriate amount of CGM was then added to the 1 ml cell solution, 
to enable seeding into flasks to maintain growth, or experimental plates.  
The volume of culture medium to surface area ratio was; 1ml per 5 cm2 (5 
ml per a T25 flask or 15ml per a T75 flask), and 1 ml per well in a 12-well 
plate. 
All flasks were placed in the incubator and the media was changed with fresh 
CGM every 48 hours until cells became confluent. Endothelial cells at high 
passage numbers have been reported to have slower growth rates, loss of 
their surface markers and reduced stimulation response (King et al., 2003). 
Therefore, HCAECs at passages from 2 until passage 6 maximum were used 




2.2.1.3 Human Coronary Artery Smooth Muscle Cells (HCASMCs): 
Adult HCASMCs were bought from Sigma-Aldrich© and were supplied via 
Cell Applications INC.©. They arrived as a cryopreserved vial of half a million 
HCASMCs in their 2nd passage, frozen in basal smooth muscle cell media 10% 
v/v FBS and 10% v/v DMSO. This type of vascular smooth muscle cells (350-
05A) was previously used in studying signalling pathways which regulate 
differentiation of smooth muscle cells (Zhou et al., 2010) and the 
atherosclerotic leading pathways of the OxLDL induced inflammatory 
responses (Kiyan et al., 2014). 
2.2.1.3.1 HCASMCs culture: 
Cells were thawed as per the manufacturer’s instructions in 15ml of 
HCASMCs growth media (composition of media in appendix II) in a pre-
incubated T75 flask (the process of removing the cryopreserved vial from dry 
ice is identical to the steps in section 2.2.1.2.1). 
Similarly, to HCAECs, the media was changed and replaced with fresh 
HCASMCs growth media 24 hours later, after which it was changed every 48 
hours until the cells have become 80-90% confluent. 
When the cells became confluent they were sub cultured (to passage 3) into 
four T25 flasks according to the protocol below. At this step the cells were 
either used to seed into an experimental plate or stored frozen in liquid 
nitrogen until used.  
2.2.1.3.2 HCASMCs sub-culture: 
HCASMCs were sub-cultured following the same protocol as for HCAECs in 




48 hrs due to the faster growth of HCASMCs. HCASMCs were also washed 
with Hanks’ Balanced Salt Solution (composition in appendix II) instead of 
PBS.  
The medium to surface area ratio was also identical to that in HCAECs and 
HUVECS; 1ml per 5 cm2 (5 ml per a T25 flask or 15ml per a T75 flask), and 1 
ml per well in a 12-well plate. The cell density used in all experiments when 
cells were confluent was 10,000 cells/cm2. 
2.2.2 Cytokine stimulation of Vascular Cells 
Complete growth medium (CGM) (see appendix A.2.1.3) was used in all 
stimulation experiments and through all steps, except during treatment with 
cholesterol or NE, where the treatment was delivered in serum free media 
(SFM).  
To upregulate maximal endogenous proIL-1β production within endothelial 
cells (HUVECs and HCAECs) and HCASMCs, a combination of the cytokines 
IL-1α and TNF-α was used, both at working concentrations of 10 ng/ml, 
which has been previously reported to upregulate high levels of IL-1β 
production (Alfaidi et al., 2015).  
Cells at 80-90% confluency were trypsinised (as per protocol in section 
2.2.1.2.2) and centrifuged to collect a pellet of cells which was re-suspended 
in 1 ml of CGM, after which the cells were counted using a haemocytometer. 
HUVECs were seeded on a 1% (w/v) (gelatin) pre-coated 12-well plate at a 




the 12 well flat bottom plate in an identical approach between different 
repeats of experiments. No pre-treatment of the plate was required. 
After seeding the cells, the plate was incubated at 37°C with 5% CO2 for 48 
hours allowing cells to grow until they were 80-90% confluent. The cells were 
then washed once with PBS (pH 7.4) and the media replaced with 1 ml CGM 
containing both pro-inflammatory cytokines TNF-α and IL-1α at 
concentrations of 10 ng/ml each (further details of the pro-inflammatory 
cytokines used to upregulate and induce IL-1β synthesis and release are 
stated in appendix I). Cells were incubated with the pro-inflammatory 
cytokines for 48 hours, afterwhich the media was discarded from the plate 
and the cells were washed three times with either sterile PBS (pH 7.4) 
(endothelial cells) or Hanks’ Balanced Salt Solution (HCASMCs), to remove 
any debris, remaining IL-1β or any traces of serum from the CGM. This 
cytokine treatment ensures the cells are stimulated, free of any exogenous 
cytokine and activated to produce IL-1. 
2.2.3 Preparation of NE for use in cell culture  
NE cleaves proIL-1β in endothelial cells and causes significant secretion of 
mature IL-1β into the cell culture supernatants (Alfaidi et al., 2015). 
Therefore, NE was used as a maximum release control (positive control) for 
experiments in both endothelial cell types in my study.  
NE was purchased from Sigma-Aldrich© as lyophilised powder, 
reconstituted in 1ml of sterile deionised water, and stored in 10 μl aliquots 




plate as positive control.  NE incubation in HCAECs and HUVECs was carried 
out in SFM for a period of 6 hours. 
2.2.4 Preparation of cholesterol as endothelial and smooth muscle cell 
treatments 
2.2.4.1 Water-soluble cholesterol 
Water-soluble cholesterol was delivered to the cells via a complex of 
cholesterol and methyl-beta-cyclodextrin (MβCD), purchased from Sigma-
Aldrich©. The use of this cholesterol complex has been previously reported 
in several endothelial cell models in vitro, including HUVECs (Fang et al., 
2013), human pulmonary artery endothelial cells HPAECs (Yamamoto et al., 
2007), bovine artery endothelial cells BAECs (Byfield et al., 2004, Romanenko 
et al., 2002, Levitan et al., 2000) and mouse aortic smooth muscle cells 
(MASMs) (Rong et al., 2003). 
Each gram of this complex contains approximately 40 mg of cholesterol, with 
MβCD being the balance. The complex was reconstituted by adding 3 ml of 
sterile de-ionised water to make a stock solution of 10 mg/ml, which was 
mixed gently until completely dissolved. The stock was then divided into 200 
μl aliquots and stored at -20°C, to be used fresh in each experiment. 
Treatments of water-soluble cholesterol was carried out in SFM in all 
experiments. Cells were incubated with cholesterol for 6 hours at 37°C with 
5% CO2/ 95% air in both HUVECs and HCAECs experiments. Several 
concentrations were used throughout the study (50, 100, 250 and 500 
μg/ml). To test the effect of MβCD alone on the cells, endothelial cells were 




parallel to water-soluble cholesterol treatment. An example of a typical 
assay plate layout is shown below (Figure 2.3). 
 
(Figure 2.3) 12-Well plate layout used in HUVECs and HCAECs water-soluble 
cholesterol treatment experiments: The first three wells in column 1 (within 
blue box) represent endothelial cells (either HUVECs or HCAECs) treated 
with concentrations of 100, 250 and 500 μg/ml water-soluble cholesterol 
(conjugated with MβCD) for 6 hours, after being stimulated with cytokines 
TNF-α and IL-1α for 48 hours. The next 3 wells in column 2 are used as 
control for water-soluble cholesterol, as they are treated with same 
concentrations with MβCD alone. Three wells have been used as positive 
controls for IL-1β release, as they were incubated with 1 μg/ml of NE for 6 
hours following 48 hours of cytokine stimulation. A cytokine only well was 
set to test the effect of cytokine stimulation alone on IL-1β release. In 
addition, a treatment with 250 μg/ml of water-soluble cholesterol has been 
applied with non-cytokine stimulation to test the effects of the treatment 
alone on IL-1β levels. Finally, a non-cytokine stimulated, non-treated well 
has been used as an assay negative control. Each plate represents n=1 per 
treatment. 
2.2.4.2 Aggregated LDL 
Human plasma derived low density lipoprotein (LDL) was purchased from 
Sigma-Aldrich as a lyophilized powder. Aggregated LDL (AgLDL) was 
generated by full speed vortexing of 1 mg/ml LDL in PBS for 4 minutes at 




stored immediately in 500 μl aliquots at -20ᵒC until used fresh for 
experiments. Before each experiment, the AgLDL was vortexed for 10 
minutes at full speed until the contents were completely mixed. This 
vortexing process forms the correct ultrastructure of AgLDL similar to the 
structure of the veriscan modified LDL, which is one of the primary 
chondroitin sulphate proteoglycans of the arterial intima (Costales et al., 
2015).  
This method of preparing and using AgLDL has been used in human vascular 
smooth muscle cell (HVSM) in vitro, showing the activation of the receptor-
related protein 1 (LRP1), a critical receptor for aggregated LDL-induced foam 
cell formation from HVSMCs (Costales et al., 2015, Llorente-Cortés et al., 
2002). 
Similar to NE and water-soluble cholesterol treatments, AgLDL treatment 
was carried out for 6 hours in SFM, with different doses used (25, 50, 75, 
100, 125, 200 and 250 μg/ml). The experimental plate layout for both 





 (Figure 2.4) 12-Well plate layout used in HUVECs and HCAECs Aggregated 
LDL treatment experiments: The first six wells in columns 1&2 highlighted 
with blue represent endothelial cells (either HUVECs or HCAECs) treated 
with concentrations of 25, 50, 75, 100, 125 and 200 μg/ml of AgLDL for 6 
hours, after being stimulated with cytokines (TNF-α and IL-1α) for 48 hours. 
A well with 50 μl of sterile distilled water has been used as an AgLDL control. 
Two wells have been used as positive controls for IL- 1β release, as they were 
incubated with 1 μg/ml of NE for 6 hours following 48 hours of cytokine 
stimulation. A cytokine only well was set to test the effect of cytokine 
stimulation alone on IL-1β release. In addition, a treatment with 50 μg/ml of 
AgLDL has been applied to a well with non-cytokine stimulation to test the 
effects of the treatment alone on IL-1β levels. As an assay negative control 
a non-cytokine stimulated, non-treated well has been used. During this 
study one assay was repeated by using one positive control well instead of 
two and a well was treated with 250 μg/ml of AgLDL to further investigate 





2.2.4.3 Acetylated LDL 
Native Human Acetylated Low Density Lipoprotein (AcLDL) was purchased 
from Bio-Rad Laboratories Inc. as 2 mg of purified protein at concentration 
of 2 mg/ml. This form of LDL has been ultracentrifuged and purified to 
homogeneity and underwent the acetylation process with excess acetic 
anhydride.  This has been previously used in the process of specific cell type 
depletion when combined with a ribosome inactivating protein such as 
saporin (Roy et al., 2017), and been used as a targeted drug delivery 
mechanism reported to be taken up by cells via scavenger receptors 
(Limmon et al., 2008). Interestingly, AcLDL and oxidised LDL behave similarly 
as they are both degraded inside lysosomes (Liu et al., 2015, Brown et al., 
2000). AcLDL was used at different concentrations throughout my study (25, 
50, 75, 100, 125 and 200 μg/ml). 
2.2.4.4 Oxidized LDL 
Native oxidized Human Low Density Lipoprotein (OxLDL) was purchased 
from Bio-Rad Laboratories Inc. as 2 mg powder of purified protein from 
human plasma. Reconstitution was performed according to manufacturer’s 
instructions in 1 ml of sterile deionised water. Similar to Acetylated LDL 
(Section 2.2.4.3) this form has also undergone ultracentrifugation and 
purification to homogeneity. Oxidation was carried out using 20 µM cupric 
sulphate in PBS at 37°C for 24 hours, and was terminated with excess EDTA. 
The level of oxidation was measured by TBARS (Thiobarbituric acid reactive 
substances) and determined via a Malondialdehyde (MDA) standard. The 




oxidation levels of the batches I received were 24.6 nmoles/mg protein and 
38.9 nmoles/mg. In addition to its contribution in the overall cholesterol 
accumulation during the development of atherosclerosis, OxLDL molecules 
are favourably engulfed by macrophages, a process resulting in the 
macrophage-foam cell differentiation, an important step in the 
pathophysiology of an atheromatous plaque formation (Zhang et al., 2017). 
Due to their reported presence in atheromatous plaques and because of 
their vital role in the pathophysiology of atherosclerosis, it was important to 
investigate their potential to influence the activity of IL-1β.  OxLDL was used 
at different concentrations throughout my study (25, 50, 75 and 100μg/ml). 
2.2.4.5 Native Human Free LDL Cholesterol 
Human plasma derived low density lipoprotein was purchased from Sigma-
Aldrich as a lyophilized powder. Native LDL was generated at concentration 
of 1 mg/ml LDL in PBS and stored immediately in 500 μl aliquots at -20ᵒC 
until used fresh prior each experiment. Native LDL was used at different 
concentrations throughout my study (25, 50, 75 and 100μg/ml). 
2.2.5 Collection of Cell Lysates and Culture Supernatants 
After incubation with cholesterol, the culture supernatants of each well 
were collected and transferred to a set of ice-cold Eppendorf tubes. Cell 
debris was removed by centrifugation at 300g for 5 minutes, and the 
supernatant transferred to a new ice cold Eppendorf tube and immediately 
stored in -20ᵒC until analysed by ELISA. 
The cells in each well were then washed twice with 1 ml of ice cold PBS (or 




throughout. Cell lysates were collected via scraping the cells with a 
disposable cell scraper for each well, in 500μl ice-cold lysis buffer composed 
of 0.1% (v/v) Triton-X100 in PBS. Triton X was used as a detergent as it can 
gently detach the cells and has the ability to dissolve cellular membranes 
(Birdwell et al., 1978). To ensure complete lysis of cells, the lysate 
suspension was pipetted 4-5 times of the contents against the bottom of 
each well before transferring into an ice-cold Eppendorf tube. To prevent 
degradation of IL-1, lysates were stored immediately at -20ᵒC and analysed 
within 48 hours, or stored at -80ᵒC if immediate analysis wasn’t possible. 
2.2.6 IL-1β Quantification Using ELISA 
A quantitative sandwich enzyme linked immunosorbent assay (ELISA) kit 
(DLB50 by R&D Systems©, UK) was used to directly measure the levels of  
mature IL-1β (17 kDa). Investigating the effect of cholesterol on the release 
of IL-1β in the culture supernatants and the production of IL-1β within the 
cells lysates is a vital aim of the study, therefore both culture supernatants 
and cell lysates were analysed.  
The ELISA was performed following the manufacturer’s instructions. Briefly, 
a standard curve was generated from IL-1β standards at concentrations of 
3.9, 7.8, 15.6, 31.2, 62.5, 125, and 250 pg/ml in duplicate samples. Samples 
(test, standards and controls) were added to the ELISA plate, covered by a 
covering lid and incubated at room temperature for 2 hours. The plate was 
then washed three times with a supplied wash buffer. After the last wash 
the plate was inverted against a clean paper towel and blotted to ensure 




each well and the plate incubated for 1 hour at room temperature. The plate 
was then washed as before, and a supplied substrate solution (stabilized 
hydrogen peroxide plus stabilized chromogen tetramethylbenzidine) was 
added to each well. The plate was protected from light by foil covering and 
incubated for 20 minutes at room temperature. The reaction was then 
stopped using the supplied stop solution (2N sulphuric acid). To ensure 
thorough mixing of the stop solution, the plate was gently tapped and/or 
gently mixed using a 10 μl pipette tip. 
The plate was then read using a Varioskan© Flash microplate reader from 
Thermo Scientific©, at OD of 450nm. A standard curve was constructed 
using a four parameter logistic (4-PL) curve-fit using Skanit RE for Varioskan 
Flash 2.4.5 software. The average concentrations of IL-1β in pg/ml of all 
samples were than calculated using the four parameter logistic curve. 
The data were then analysed using the GraphPad prism for windows 
software, version 8.0. 
2.2.7 Lactate Dehydrogenase Cytotoxicity Assay  
A LDH cytotoxixity assay was performed to ensure that the quantified levels 
of IL-1β detected within cells and supernatants were due to stimulation by 
cholesterol and not secondary to cell death caused by toxicity. Lactate 
dehydrogenase (LDH) is an intracellular enzyme present in almost all cell 
types which acts as a mediator to the enzymatic oxidation of lactate to 
pyruvate (Sekine et al., 1994). It is released rapidly to the extracellular area 




measurement is an in vitro method that is commonly used as a cell death 
indicator (Abe and Matsuki, 2000).  
HUVECs and HCAECs (80-90% confluent), were seeded into 12 well 
experimental plates in CGM (see section 2.2.1 for protocol and seeding 
densities) and were incubated at 37°C with 5% CO2 for 48 hours. The media 
was then changed into CGM with the pro-inflammatory cytokine 
combination TNF-α and IL-1α (10 ng/ml, each) and incubated for a further 
48 hours. As negative control, two wells were incubated in CGM alone. The 
media was then changed into SFM and cholesterol or NE added. 
Cells were treated with either water-soluble cholesterol (100, 250 and 500 
μg/ml), MβCD (100, 250 and 500 μg/ml) as negative control, AgLDL (25, 50, 
75, 100, 125 and 200 μg/ml) or NE (1 μg/ml). As controls, some wells were 
incubated with media +/- cytokines. All incubations were for 6 hours at 37°C 
with 5% CO2.  
Cell cytotoxicity (viability) was measured using a LDH cytotoxicity assay 
(G1780 from Promega©, USA) performed fresh on supernatants collected 
immediately after incubation (with NE or cholesterol). 
Following manufacturer’s instructions, each sample was loaded into an 
assay plate and substrate solution was added. The plate was then covered 
by foil to protect from light, and incubated for 30 minutes at room 
temperature. To stop the reaction, 50μl of the supplied stop solution was 
added to all wells, and the plate was placed immediately in the chamber of 




at 490nm within 30 minutes. The percentage of LDH released into the 
supernatant was then calculated. 
2.2.8 Caspase-1 Activity Assay 
A Caspase-Glo® 1 Activity Assay was purchased from Promega® (Catalogue 
number G9951). This assay is specific for the use with a 96-well plate and 
does not require any form of sample preparation, allowing the assay to 
perform high throughput screening of the activity of caspase-1 and the 
inflammasome activation.  
Following the manufacturer’s instructions, cells were seeded into a 96-well 
plate (30,000 cells/100 μl) and equal volumes of the Caspase-Glo® 1 reagent 
were added to each well (1:2). The plate was left incubated at room 
temperature and covered with foil for one hour. Luminescence was then 
measured using the plate-reading luminometer.   
2.2.9 Inhibition of Caspase-1, NLRP3 and the P2X7 receptor 
To determine the mechanism of IL-1 release/cholesterol uptake in cells, 
inhibitors of Caspase-1, NLRP3 and the P2X7 receptor were used. All 
inhibitors were delivered in SFM for 1 hour prior to cholesterol treatment 
(following the protocol in section 2.2.4).  
For inhibition of Caspase-1 YVAD (50 μM (27 μg/ml)) was used. Studies 
showed that YVAD provides an irreversible cell-permeable and selective 
inhibition of caspase-1 (Garcia-Calvo et al., 1998, Zhang et al., 2014, Alfaidi 




MCC950 (10 μM (4.04 μg/ml)) was used as an inhibitor of the NLRP3 
inflammasome. MCC95O is a selective and potent inhibitor, which prevents 
the oligomerization of the NLRP3 inflammasome adaptor protein ASC 
(apoptosis-associated speck-like protein), blocking the release IL 1β induced 
by the inflammasome activators such as nigericin and ATP (Coll et al., 2015, 
Swanson et al., 2019, Guo et al., 2015).  
The chemical A438079 hydrochloride (2.5 μM (0.8565 μg/ml)), a competitive 
P2X7 receptor antagonist, was used to challenge the P2X7 receptor in my 
study. Studies have shown that this compound inhibits phagocytosis and 
mediates the NLRP3 inflammasome-dependent IL-1β secretion from 
neutrophils (Braganhol et al., 2015, Karmakar et al., 2016, Jiang et al., 2017). 
Further details regarding the inhibitors’ concentrations, compositions and 
sources are listed in appendix (I).  
2.2.10 Western Blotting Analysis of IL-1β Isoform 
2.2.10.1 Collection of culture supernatants and cell lysates for western 
blots 
Western blotting was performed on samples prepared following protocols 
described in sections (2.2.1 - 2.2.5). At the end of each experiment, 
supernatants were collected. The cells were then washed with ice cold PBS 
while the plates placed on ice. Each well was then treated with 100 μl of 
newly prepared ice cold RIPA buffer (see appendix for components) in 12-
well plates or 200 μl of buffer in 6-well plates. Cell lysates were collected 




Supernatants were collected and the pellet was discarded. Both 
supernatants and lysates were stored at -80 until analysed.  
2.2.10.2 Acetone precipitation and preparation of samples for 
electrophoresis 
In some experiments when assessing low levels of protein by western blot it 
was necessary to use alternative methods. Acetone precipitation was 
performed as per the protocol described by (Mambwe et al., 2019). Ice cold 
acetone (4 ml per ml of media collected) was added to samples and 
incubated at -20°C for one hour. The solution was then centrifuged at 1500 
rpm for 15 minutes. The supernatant was discarded and the pellet was air-
dried in a fume hood for 20 minutes. The pellets were then re-suspended in 
equal volumes of laemmlli buffer (100-150 μl) and boiled using a heat block 
at 95°C for 5 minutes.  
Following boiling, the samples were loaded into a NuPAGE™ 4-12% Bis-Tris 
Protein Gel (30 μl/well), and run at 200V for 30 minutes. The gel was then 
extracted from its plastic cassette to prepare it for blotting.  
2.2.10.3 Western Blotting using iBlot 2™ 
The extracted gel from section 2.2.10.2 was soaked in 20% v/v ethanol to 
activate it prior to blotting on the iBlot 2™ machine (See Appendix as per the 
manufacturer’s recommendation). The gel was placed gently against a 
nitrocellulose membrane provided in each cassette of the iBlot™ 2 
nitrocellulose transfer stacks. The cassette was enclosed following 





Following blotting, the cassette was discarded and the membrane placed in 
a tray with 10 ml of Odyssey® Blocking Buffer in TBS for one hour. After 
blocking the membrane was placed on a rotating tray and washed three 
times for 5 minutes with 0.01% v/v TBS-Tween (Tween20 from VWR 
chemicals see appendix A.2.4 for details and composition).  
The membrane was treated with the primary antibody of choice diluted in 
the blocking buffer and incubated overnight at 4°C (See appendix (I) for list 
of all primary antibodies used, their concentrations, sources and dilutions).  
The membrane was then washed three times for 5 minutes each in TBS-
Tween and incubated with the secondary antibody in room temperature for 
1 hour. The washing process was then repeated and the membrane placed 
on the Licor machine for measurements to be taken (See appendix (I) for list 
of all secondary antibodies used, their concentrations, sources and 
dilutions). 
2.2.11 Microscopic Imaging of LDL molecules 
2.2.11.1 Acetylated LDL and Plasma membrane labelling with CtB and 
WGA in HCAECs 
To determine uptake of cholesterol into cells,  HCAECs were stained for the 
presence of acetylated LDL (AcLDL) molecules as previously described (Singh 
et al., 2016). A directly conjugated LDL was used (AcLDL Alexa Fluor™ 488 
Conjugate, see appendix (I) for details).  
Three glass bottom dishes (35 mm dish with No. 1.5 coverslip with a glass 
diameter of 14 mm, supplied from MatTek Corporation©, United States) 




95% air/5% CO2 to enhance cell adherence to the glass surface. HCAECs were 
trypsinised and seeded (see section 2.2.1 for protocol and seeding density) 
into each dish. Dishes were then incubated for 48 hours. 
Cells were then cytokine stimulated (see section 2.2.2 for protocol) and then 
incubated with LDL (10 and 100 μg/ml) for 6 hours in serum free MV media 
(Appendix II). As control, one dish was incubated with media alone. 
After 5 hours of LDL treatment and for the last hour, all three dishes were 
treated with AcLDL Alexa Fluor™ 488 Conjugate (10 μg/ml). After the 6-hour 
incubation, cells were washed gently with PBS (pH 7.4) and the dishes were 
placed on ice. Cells were then labelled with Cholera Toxin Subunit B (CTB), 
Alexa Fluor™ 555 (CTB-555) conjugate (10 μg/ml) for 5 minutes on ice. CTB 
staining was used for labelling the plasma membrane and cell surface. 
The media was discarded and the cells were washed gently with PBS and 
fixed immediately with 4% w/v paraformaldehyde (PFA) and 0.5% v/v 
glutaraldehyde in PBS (pH 7.4) at 1 ml/dish for 45 minutes in room 
temperature, then washed with PBS. Glutaraldehyde was added to the 
fixation solution due to block diffusion of lipid-linked proteins (Perez et al., 
2017, Singh et al., 2016).  
Finally, cells were labelled with Wheat Germ Agglutinin (WGA), Alexa Fluor™ 
647 Conjugate (1 μg/ml in PBS) for 10 minutes in room temperature. The 
aim of WGA labelling was to allow visualisation of the compartments which 
contain LDL molecules inside the cells. Cells imaging was done using a Zeiss 




2.2.11.2 Imaging of LDL Uptake by HCAECs 
After treating HCAECs with LDL (Either OxLDL, AcLDL or Native LDL, see 
sections 2.2.4 & 2.2.5 for protocol), cells were washed with ice cold PBS 
three times and immediately fixed at room temperature with 10% Buffered 
Formalin solution (see appendix (II) section A.2.5 for composition). The 
fixation process with the formalin solution was carried under a ventilated 
fume hood for 15 minutes. The experimental plate was taken then to a bright 
field microscope and imaged. 
2.2.12 Statistical Analysis  
All statistical analyses were done using GraphPad prism for windows 
software, version 8.0.2. To check whether or not the data sets presented 
were normally or not normally distributed, Shapiro–Wilk’s test was used to 
confirm that my data were not normally distributed prior to running 
statistical analysis with Anova or student independent T-Test. Below is an 
example of data analysed by Shapiro-Wilk test using a normality and 
lognormality QQ plot (Figure 2.5). 
All experiments were repeated on three different biological donors at least, 
or three technical repeats as mentioned. One way Anova with corrections 
for multiple comparisons by Bonferroni post hoc test was used in all data 
containing more than two groups (with one variable being quantified levels 
of IL-1β by ELISA) and multiple experimental assay controls. In experiments 























(Figure 2.5) Normality and lognormality test for all data sets: QQ plot 
showing the linear distribution of data. In addition to the linear distribution 
and passing the normality test on GraphPad prism, Shapiro-Wilk test was 
also used to confirm that the data are normally distributed.  This test 
example was carried on the graph in Chapter 5 (Figure 5.4A), n=3.  
 
(Chapter 3) Optimisation of the Experimental 
Conditions for the Release of IL-1β, Including 





Inflammation is involved in all phases of coronary artery disease (Kleemann 
et al., 2008, Randolph, 2014). The role of active inflammation in 
atherosclerotic plaques increases vulnerability and can lead to plaque 
rupture (Sakaguchi et al., 2017, Shah, 2003), which is a significant clinical 
event with life threatening manifestations such as MI and stroke (Bentzon 
et al., 2014). 
As a consequence of inflammation, activation of the endothelium occurs 
(Gimbrone and García-Cardeña, 2016). The activated endothelium within a 
highly inflammatory environment of an atherosclerotic lesion causes 
endothelial cells and macrophages to produce high levels of pro-
inflammatory cytokines, such as IL-1β, which maintains the inflammatory 
process, through the induction of an adhesion cascade (Gomez et al., 2017, 
Ceneri et al., 2017). 
Cholesterol is present in atherosclerotic lesions from early stages, in the 
form of lipoprotein particles and lipid droplets containing free circulatory 
cholesterol. Due to oxidative, acidic and enzymatic modifications, some non-
inflammatory plasma lipoprotein molecules transform into crystallised 
particles, forming cholesterol crystals (Grebe and Latz, 2013, Abdul-Muneer 
et al., 2017).  It has recently been shown that both cholesterol in the form 
of crystals and free LDL molecules induce the release of IL-1β from 
macrophages and monocytes in vitro, but the role of cholesterol in 




remains to be elucidated (Estruch et al., 2015, Samstad et al., 2014, Duewell 
et al., 2010).  
This project focuses on investigating the role of cholesterol in inducing the 
release of IL-1β from the vascular endothelium. Specifically, the experiments 
presented in this chapter aim to identify the most effective form of 
cholesterol with respect to promoting IL-1β release from vascular cells, to 
be used in future experiments to elucidate the molecular mechanism of 
release (Chapter 5), and to optimise experimental conditions using HUVEC 
prior to using more clinically relevant, but also more expensive HCAECs 
(Chapter 4). In this chapter, two types of cholesterol were studied: water-
soluble cholesterol and aggregated LDL (AgLDL). 
3.2 Brief Materials and Methods 
All materials and methods used in the experimental approaches in this 
chapter are detailed in (Chapter 2), briefly: HUVECs were seeded at passages 
2-5 into 12 well plates and were allowed to grow until they were 80-90% 
confluent (approximately 48 hrs incubation). Cells were then stimulated by 
the cytokines IL-1α and TNF-α at a concentration of 10 ng/ml for each, for 
48 hrs. After thorough washing with PBS, cholesterol treatment (with either 
water-soluble cholesterol or AgLDL) was applied to the cells for 6 hrs in 
serum free media. Cells were harvested and samples stored until analysis. 
Supernatant media was also collected and analysed for cytotoxicity using a 
LDH toxicity assay. IL-1β ELISA was performed to measure the amounts of 
produced and released IL-1β in response to cholesterol treatment and pro-




taken to investigate the uptake of LDL molecules by vascular endothelial 
cells and the changes of cell morphology in response to stimulation and/or 
treatment.  
3.3 Results 
3.3.1 IL-1α and TNF-α in combination promote production, but only 
minimal release, of IL-1β in HUVECs. 
In this initial experiment, I investigated whether HUVECs could produce and 
release IL-1β without needing a second stimulus. As stimulation with a 
combination of IL-1α and TNF-α has previously been reported to upregulate 
intracellular levels of pro-IL-1β (Wilson et al., 2007, Alfaidi et al., 2015) to a 
detectable level, HUVECs were stimulated with a combination of these pro-
inflammatory cytokines prior to incubating with cholesterol or NE (as 
positive control). NE has previously been shown to induce IL-1β release from 
endothelial cells; hence, it is a suitable positive control for the assay. 
Observing cells under phase contrast and bright-field microscopy showed 
that the morphology of stimulated cells was changed. HUVECs appeared 
elongated in comparison to unstimulated cells, which had a cobblestone 







 (Figure 3.1) Morphologic change of HUVECs in response to cytokine 
stimulation: A and B are representative images of HUVECs seeded at 
passage 2 in a 6-well plate and allowed to grow until confluent at 37°C with 
95% air/5% CO2. In (A), the control cells were left in CGM and not stimulated. 
The cobblestone shape of HUVECs appears to be maintained. In (B) 
(stimulated cells with 10 ng/ml of IL-1α and TNF-α) the elongated 
appearance of cells suggests their successful priming. Images are 
representative and were recorded at 48 hours post incubation with the 
cytokines after fixing the cells with 2% w/v PFA. Images were taken using a 






Next, HUVECs from 3 different donors were seeded into experimental plates 
and stimulated with cytokines TNF-α and IL-1α as described in section 2.2.2. 
Cells in ‘plain’ CGM with no cytokine stimulation were used as controls. IL-
1β, measured by ELISA, showed 35-fold elevated levels of IL-1β in the lysates 
(125.4 ± 11.51 pg/ml) compared to unstimulated control cells (3.68 ± 0.65 
pg/ml) (Figure 3.2A), indicating the successful stimulation and upregulation 
of IL-1β intracellularly. 
In supernatants from these experiments, there was a consistent very low 
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 (Figure 3.2) TNF-α and IL-1α upregulate the production intracellularly (A) 
and release (B) of IL-1β in stimulated HUVECs. HUVECs from three different 
cords were seeded and stimulated with both TNFα and IL-1α for 48 hours at 
concentrations of 10 ng/ml each. (A) cell lysates and (B) cell culture 
supernatants. Values are presented as mean ± SEM, unpaired t-test was 





3.3.2 NE induces the release of IL-1β from HUVECs 
Next, to augment the release of IL-1β from HUVECs, I tested a known 
positive control, neutrophil elastase (NE) (Alfaidi et al., 2015). Three 
different biological donors of HUVECs were stimulated with the cytokine 
combination used in the previous section (section 3.3.1) and then either left 
stimulated with cytokines (incubated with CGM) as controls or treated  with 
NE for 6 hours, after thorough PBS washing. Culture supernatants and cell 
lysates were collected and assayed for IL-1β by ELISA. Treatment with NE did 
not alter IL-1β production in the lysates (130.1 ± 4.1 pg/ml) when compared 
with untreated controls (125.4 ± 11.51 pg/ml) (Figure 3.3A). However, 
released IL-1β detected in response to NE treatment of HUVECs was 
significantly increased, compared to cytokines stimulated alone, although 
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(Figure 3.3) HUVECs release IL-1β extracellularly following 6-hour 
incubation with NE: Quantification of IL-1β production in lysates (A), 
followed by release of IL-1β in supernatants (B). Values are presented as 
mean ± SEM, unpaired t-test was used for comparison between both 




3.3.3 Water-soluble cholesterol promotes the release of IL-1β in 
HUVECs 
Having established experimental conditions that will reliably induce IL-1β 
production and release in response to a second stimuli, I examined the 
effects of different forms of cholesterol upon IL-1β generation and release. 
Cultured HUVECs from three different donors were seeded into 12-well 
plates, stimulated with cytokines, and then treated with water-soluble 
cholesterol at different concentrations as shown in (Figure 2.3, methods). 
Cell culture lysates and supernatants were assayed for IL-1β using ELISA.  
Figures 3.4 and 3.5 show that water-soluble cholesterol led to a decrease in 
IL-1β inside cells compared to cells treated with only MβCD (the solubilising 
agent, control). Conversely, an increased release of IL-1β was detected in the 
supernatant of cholesterol-treated cells when compared with both the 
MβCD control and with the cytokine only treated control (Figure 3.5). 
Levels of IL-1β in cell lysates of cholesterol treated cells were an average of 
(28.1 ± 3.3), (27.4 ± 2.1) and (23.6 ± 3.7) pg/ml in samples with treatment 
concentrations of 100, 250 and 500 μg/ml respectively (Figure 3.4). IL-1β 
production in MβCD treated cells was highest following 250 μg/ml treatment 
(116.6 ± 10.5 pg/ml). Non-cytokine stimulated, water-soluble cholesterol 
treated cells had an almost undetectable level of IL-1β of 2.5 ± 0.5 pg/ml. It 
is clear, therefore, that cells need a pre-treatment with cytokines, in order 
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(Figure 3.4) Intracellular levels of IL-1β are lower in water-soluble 
cholesterol treated HUVECs: Cell lysates of water-soluble cholesterol 
treated cells and controls were analysed by ELISA for quantification of IL-1β 
production. Data are expressed as mean ± SEM, n=3 independent donors. 
Data are analysed by one-way ANOVA with correction for multiple 
comparisons by Bonferroni post hoc test, ****p<0.0001. 
 
For supernatants from these same experiments, increased release of IL-1β 
occured with water-soluble cholesterol compared to MβCD alone (Figure 
3.5). Average IL-1β release was (16.24 ± 2.3), (22.2 ± 2.3) and (20.4 ± 2.9) 
pg/ml for the doses 100, 250 and 500 μg/ml cholesterol, respectively.  
As a proportion of IL-1 inside HUVECs, approximately 10% was released in 
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(Figure 3.5) Water-soluble cholesterol promotes the release of IL-1β from 
HUVECs into culture supernatants: Release of IL-1β was induced from 
HUVECs treated with water-soluble cholesterol for 6 hours after cytokine 
stimulation. Data are obtained from cell culture supernatants collected from 
three sets of experiments using HUVECs each from a different donor (n=3). 
Data are expressed as mean ± SEM, analysis done by one-way ANOVA 
followed by Bonferroni post hoc test, **p<0.01 and ***p<0.001, 
****p<0.0001. 
3.3.4 Water-soluble cholesterol induces the release of lactate 
dehydrogenase in HUVECs in a dose dependent manner: 
To determine whether the IL-1β release seen following cholesterol 
treatment was due to stimulation of release by, or toxicity of, cholesterol, I 
measured levels of LDH in supernatants of stimulated cells. LDH release from 
cells indicates various forms of cell death (den Hartigh and Fink, 2018). 
High levels of LDH were released from HUVECs in response to incubation 




Incubation with the solubilising carrier, MβCD (negative control), had no 
adverse effects upon LDH release over and above the control (cytokines 
stimulated only). Specifically, the basal LDH release in CGM was 11%. This 
was increased 3 fold with cholesterol treatment (100 µg/ml, 250 µg/ml and 
500 µg/ml showed a LDH release of 32.9%, 42.9% and 43.2% respectively 
compared to the positive control).  
 
 
(Figure 3.6) Water-soluble cholesterol treated HUVECs exhibit induced LDH 
release: Culture supernatants of samples were used for analysis of LDH 
release by the LDH cytotoxicity assay. Levels of LDH were increased following 
incubation with water-soluble cholesterol, compared to control, n=3, data 





3.3.5 Aggregated LDL is not toxic to HUVECs and does not induce LDH 
release 
It has been widely known that there are multiple forms of cholesterol 
present in the vessel wall in the setting of atherosclerosis (Stocker and 
Keaney, 2004, Brown and Goldstein, 1983, Orekhov and Sobenin, 2018). As 
water-soluble cholesterol is not biologically present, I continued my 
investigation using AgLDL, a form that has been previously reported to be 
both present in atherosclerotic plaques of human cardiovascular patients 
and has been widely studied in in vitro models of atherosclerosis (Badimon 
and Vilahur, 2012, Marathe et al., 1998, Westhorpe et al., 2012). The aim of 
introducing AgLDL was to see if this form of modified LDL could also 
potentially induce the release of IL-1β from HUVECs.  
Given the previous data on cholesterol toxicity using water-soluble 
cholesterol (Figure 3.6), I first performed an AgLDL cytotoxicity assay (as 
described in section 2.2.7), to rule out the possibility that AgLDL was toxic to 
endothelial cells. The percentage of LDH release in AgLDL treated HUVECs 
was similar to that of the untreated controls (Figure 3.7), indicating that 
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(Figure 3.7) Cytotoxicity assay on HUVECs treated with AgLDL shows no 
cytotoxicity: An LDH cytotoxicity assay was used to analyse the culture 
supernatants of cells treated with AgLDL and controls. No significant 
difference between control and AgLDL treated samples with multiple 
concentrations (10-200 µg/ml) was seen. Three technical repeats from two 
different biological donors are presented data are expressed as mean ± SD. 
3.3.6 Investigating the Potential Roles of AgLDL Treatment on HUVECs 
Once the non-toxicity of AgLDL was confirmed (Section 3.3.5), the potential 
role on IL-1β signalling intracellularly and extracellularly was investigated. 
After incubation with AgLDL (section 2.2.4.2 for details), HUVECs culture 
supernatants and cell lysates were analysed for IL-1β using ELISA.  
3.3.6.1 AgLDL does not induce the production IL-1β in HUVECs  
AgLDL treated HUVECs showed only low levels of intracellular IL-1β 




IL-1β quantification of cell lysates showed IL-1β in the AgLDL treated samples 
was no different to the cytokine-only stimulated controls, with very low IL-1 
production in non-cytokine stimulated cells (Figure 3.8). ELISA quantification 
of lysates from AgLDL treated HUVEC show the quantified levels of IL-1β to 
be less than 40 pg/ml in each condition (29.2 ± 1.4, 39.4 ± 2.0, 39.4 ± 2.3, 
32.7 ± 0.9, 36.3 ± 5.4 and 37.2 ± 3.6 pg/ml, respectively), which is very low 
compared with previous water-soluble cholesterol data (section 3.3.4). The 
cytokine only treated samples and the NE treated samples generated 33.8 ± 
3.6 and 34.7 ± 3.5 pg/ml IL-1 respectively. Both the assay negative control 
and the non-cytokine stimulated control treated with 50 µg/ml had 
approximately 1.4 ± 0.6 pg/ml of IL-1β (which is below the detection limit of 
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(Figure 3.8) AgLDL has no effect on IL-1β production in HUVECs: HUVECs 
were treated with different concentrations of AgLDL (10-200 µg/ml) after 
cytokine stimulation. Cell lysates of AgLDL treated cells and controls were 
analysed by ELISA for intracellular quantification of IL-1β. Despite multiple 
concentrations used, AgLDL had no effect on inducing IL-1β production in 
stimulated or non stimulated HUVECs in comparison with controls. Data are 
expressed as mean ± SEM, three technical repeats from two different 
biological donors. 
3.3.6.2 AgLDL does not induce the release of IL-1β from HUVECs  
IL-1β in cell culture supernatants from samples treated with all different 
concentrations of AgLDL (except 10 µg/ml), was found to be lower or equal 
to the levels measured in the cytokine only treated samples (Figure 3.9).  


















        TNF & IL-1  +     -    +     -     +    +    +    +    +    +
      AgLDL (µg/ml)  - 50   -     - 10     25    50     75    100  200
               NE  +    -     -     -      -     -     -    -     -     -
 
(Figure 3.9) AgLDL has no effect on the release of IL-1β by HUVECs into 
culture supernatants: ELISA quantification of IL-1β for supernatants showed 
very low release of IL-1β from all AgLDL treated cells and controls.  Data are 
expressed as mean ± SEM, three technical repeats from two different 
biological donors. 
3.3.7 Summary of Results 
In this chapter, I demonstrate, the ability of HUVECs to release IL-1β in 
response to incubation with water-soluble cholesterol. Optimising this in 
vitro model was necessary before proceeding with more costly cells 
(HCAECs) and different forms of LDL. Water-soluble cholesterol has 
successfully shown its capability of being a second signal inducer of mature 
IL-1β from primed HUVECs, as measured by high sensitivity ELISA, unlike 
AgLDL. The data obtained from this chapter provide several lines of evidence 




- Pro-inflammatory cytokine stimulated (Primed) HUVECs, produce 
significant high levels of intracellular IL-1β. 
- HUVECs require priming, in order to release IL-1β in response to 
water-soluble cholesterol treatment. 
- Un-primed HUVECs, do not release IL-1β in response to water-
soluble cholesterol treatment. 
- The quantified release of IL-1β from primed HUVECs, in response to 
water-soluble cholesterol treatment, is higher than the release in 
response to NE (the positive control). 
- The water-soluble cholesterol-induced release of IL-1β is associated 
with LDH release suggesting cytotoxicity, however this has been 
investigated in the next two chapters. 
3.4 Discussion    
HUVECs were stimulated with the cytokine combination TNF-α and IL-1α, a 
regime that results in priming of endothelial cells and upregulation of the 
production of intracellular proIL-1β (Alfaidi et al., 2015, Wilson et al., 2007).  
This combination was chosen, as it induces the activation of Caspase-1 
(Furuoka et al., 2016), transcription upregulation of both the NLRP3 
inflammasome and proIL-1β (McGeough et al., 2017) and promotes 
endothelial cell adhesion molecules expression such as E-selectin (Wyble et 
al., 1997) and ICAM-1 (Thichanpiang et al., 2014). Many cytokines and 
mediators have been widely used for stimulating vascular smooth muscle 
cells, macrophages and endothelial cells (in particular INF-ɣ, TNF-α, IL-1α 




Mullen et al., 2010, Burzynski et al., 2015, Basatemur et al., 2019). However, 
the work by (Alfaidi et al., 2015) showed that this combination in particular, 
for the specified duration (IL-1α and TNF-α at a concentration of 10 ng/ml 
for each, for 48 hrs.) resulted in maximum proIL-1β production in primary 
vascular endothelial cells.  
Upregulation of proIL-1β inside cells is necessary in order to detect the 
release of mature IL-1β in response to a stimulus (Chan and Schroder, 2020, 
Andrei et al., 1999). Therefore, successful cytokine stimulation of HUVECs 
was crucial in all experiments. Incubation with NE was used as a positive 
control for IL-1β release, as this has previously been reported to significantly 
enhance release in cytokine stimulated endothelial cells (Alfaidi et al., 2015). 
Alfaidi, showed that NE cleaved and induced the release of bioactive IL-1β 
via a vesicular-mediated caspase-1-independent release process. 
My data show a morphological change by HUVECs in response to cytokine 
stimulation, indicating that the cells are successfully primed and this agrees 
with published reports that the morphological change of HUVECs from 
cobblestone appearance to elongated indicates that the cells are stimulated 
(Mason et al., 1997). Interestingly, this appearance is also seen in cells 
subjected to abnormal high shear stress (DeStefano et al., 2017). 
Additionally, ELISA analysis confirmed the presence of high levels of IL-1β 
within the lysate of HUVECs when stimulated with cytokines, which was not 
seen in lysates of unstimulated control cells. This is in agreement with a 




upregulates the production of proIL-1β and unstimulated HUVECs fail to 
produce constitutive levels of IL-1β (Wilson et al., 2007). Furthermore, the 
average levels of proIL-1β detected inside the cells was similar to the levels 
reported in the study by Wilson et al., 2007. This change of morphology 
together with the IL-1β ELISA data confirmed the successful stimulation of 
HUVECs.  
Although, in HUVECs, cytokine stimulation alone induced low release of IL-
1β into supernatants, this release was minimal because the cells were only 
primed and there was no second signal to induce the maximal release of IL-
1β. These findings are supported by the study of Rajamäki et al., (2010), 
which showed that IL1A and TNFA mRNAs were both highly and equally 
induced in primary macrophages that were stimulated with LPS alone or 
stimulated and treated with cholesterol crystals. However, the study also 
showed that cholesterol crystal treatment secondary to LPS priming 
markedly increased the expression of NLRP3, CASP1 and IL1B mRNAs, and 
only minimal expression  was seen in LPS only primed cells. Unsurprisingly, 
IL1A, TNFA, IL1B, NLRP3 and CASP1 mRNAs were not expressed in the non-
primed cholesterol crystals-treated macrophages in the same study. 
Although these data are from primary macrophages, this explains why in my 
data only limited amounts of IL-1β were secreted into culture supernatants 
of cytokine only primed cells, and therefore no robust release of IL-1β was 
detected due to the absence of a second signal that cleaves the proIL-1β into 




The potential role of water-soluble cholesterol as a secondary signal for 
inducing the release of proIL-1β in cytokine stimulated HUVECs was 
investigated, for the first time. Cholesterol is a primary structural 
component that maintains cellular membrane integrity and fluidity, 
therefore it is structured to be insoluble in blood and in aqueous medium 
(Roy et al., 2006). However, free cholesterol can be conjugated with a 
compound such as methyl-β-cyclodextrin to mimic solubility (Rong et al., 
2003). This water-soluble cholesterol compound was used previously in an 
atherosclerosis in vitro model of a lipid uptake study using mouse vascular 
SMCs (Xu et al., 2010). This study showed the water-soluble cholesterol 
treatment caused SMCs to undergo a complex mode of cell death and 
organelle damage, which activated SMCs autophagy of cholesterol as a 
survival process to prevent water-soluble cholesterol induced cell death. 
In my work, unstimulated HUVECs treated with water-soluble cholesterol 
alone was found not to have increased intracellular production of IL-1β, 
further indicating that cytokine stimulation is crucial in this experimental 
protocol. Stimulated HUVECs treated with water-soluble cholesterol showed 
decreased IL-1β inside cells in contrast to the ‘control’ MβCD (the solubilising 
agent). This suggested that water-soluble cholesterol did not enter the cell, 
or that water-soluble cholesterol inhibited the production of intracellular IL-
1β, that water-soluble cholesterol induces cell death and/or that the 




It has been previously shown that water-soluble cholesterol is taken up by 
SMCs (Xu et al., 2010), ruling this out as a possible reason. Furthermore, 
MβCD only treated cells showed high levels of intracellular IL-1β, indicating 
that MβCD does not inhibit IL-1β production. Interestingly, there was a 
statistically significant increased release of IL-1β by water-soluble 
cholesterol in HUVECs compared to MβCD only treated controls, which was 
higher than that from cells treated with NE (the positive control). Therefore, 
it seemed possible that water-soluble cholesterol treated cells have 
decreased IL-1β, due to the successful high release of IL-1β from the cells. 
My data, however, showed that water-soluble cholesterol, at the 
concentrations used in this project, might have potentially caused 
endothelial cell toxicity (which was further investigated in the next two 
chapters). This occurred despite the cells appearing to be physically intact 
by phase contrast microscopy. The percentage LDH that was released 
appeared to be correlated with the concentration of water-soluble 
cholesterol used. These data indicate that the IL-1β released into the culture 
supernatant is either because of the stimulation of active release in response 
to water-soluble cholesterol treatment, because of cell death induced by the 
water-soluble cholesterol. Cell toxicity is unlikely; as despite LDH release, the 
cells remain attached and appear healthy microscopically. LDH release is 
also associated with pyroptosis (Evavold et al., 2018), which is discussed in 
detail in chapter 5 and is a more likely explanation of the LDH release. These 
findings support a previous study that showed smooth muscle cell induced 




soluble cholesterol (Rong et al., 2003). However, in that study the incubation 
period was 72 hours, rather than 6-hours. Since the treatment of MβCD 
alone did not cause cell death, nor increased LDH, I conclude that it is the 
water-soluble cholesterol conjugated to MβCD at the concentrations 
studied that caused endothelial cell induced LDH release which was 
associated with the release of IL-1β.  
Since the overall aim of my project was to investigate the effects of 
cholesterol with its multiple forms on IL-1β induced release from the 
vascular endothelium, and after finding the data above, I proceeded to 
investigate a more clinically relevant form of cholesterol that is the major 
carrier of cholesterol in lesions (Kruth, 2001). One such form is aggregated 
LDL, which is believed to be formed in vivo (Persson et al., 2006) and has 
been found in early lesions and the subendothelial space (Frank and 
Fogelman, 1989, Tamminen et al., 1999) and found in plaques of ApoE 
knockout mice (Maor et al., 2000). In addition, other studies have shown 
that HVSMCs incubation with AgLDL in vitro can induce foam cell formation 
(Costales et al., 2015) a major pathological milestone in early atherosclerotic 
lesion formation (Clinton et al., 1992, Yahagi et al., 2016). Costales et al., 
(2015) also showed the internalisation and uptake of AgLDL molecules by 
HVSMCs after a 4 hour incubation (at concentration of 75 and 100 µg/ml) 
using AgLDL staining viewed by confocal laser microscopy. 
My data revealed no cytotoxicity of AgLDL on HUVECS at the concentrations 




aggregation of OxLDL reduced OxLDL cytotoxicity (Asmis et al., 2005). 
Surprisingly, however, AgLDL led to a low amount of IL-1β production in 
HUVECs and therefore was no appreciable and measurable release of 
mature IL-1β in these experiments. This was further investigated in HCAECs 
in the next chapter.  
3.4.1 Limitations and future work 
HUVEC s were used as an initial model of vascular endothelial cells, due to 
their cost effectiveness compared to HCAECs. Although HUVECs are venous 
endothelial cells, and the focus of my project is on arterial endothelial cells 
(HCAECs), which are prone to develop atherosclerotic lesions (Mestas and 
Ley, 2008) , HUVECs are still widely used in studies as an in vitro model of 
atherosclerosis. However, due to the project timeframe and the specific 
focus of this project on HCAECs, the work conducted on HUVECs was not 
continued.  
A next step to take the work from this chapter forward is to investigate the 
uptake of AgLDL by HUVECs. One such way is using oil red O staining of 
cholesterol (Kubo et al., 1997). Also investigating the effects of other 
modified LDLs (such as OxLDL and AcLDL) on the release of IL-1 and other 
pro-inflammatory cytokines. Recent studies highlighted the relationship 
between atherosclerosis development and venous thrombosis (Reich et al., 
2006, Prandoni et al., 2006). During atherosclerosis development in patients, 
both blood coagulation and platelets  are activated in addition to increased 
turnover of fibrin, which leads to developing thrombotic complications 




atherosclerosis contributes towards increasing the risk of venous 
thromboembolism (Arenas de Larriva et al., 2019).  
Investigating the mechanism of IL-1 release from HUVECs and comparing the 
mechanism of release, from venous, with that from arterial endothelial cells, 
will add to the understanding of atherosclerosis development and its 
association with cardiovascular diseases.  
3.5 Conclusions and Summary of Chapter 
In this chapter, I optimised an in vitro model of studying the IL-1β induced 
release from human vascular endothelial cells using HUVECs. This model will 
be used in more expensive and more biological relevant vascular endothelial 
cells in the next chapters (HCAECs). The data collected from the experiments 
conducted in this chapter showed the potential of modified cholesterol as a 
second stimulus to induce the release of IL-1β, secondary to pro-
inflammatory cytokine stimulation. The results also increased my attention 
towards a possible relationship between LDH release (while cells appear 
microscopically viable and intact) and the release of IL-1β from cells, which 





(Chapter 4) Modified LDL Cholesterol Induces IL-
1β Release from Primed Human Coronary 





Having established the optimal conditions for an in vitro model of 
cholesterol-induced IL-1β release from HUVECs, I extended my studies into 
a more biologically relevant endothelial cell type: human coronary artery 
endothelial cells (HCAECs). These cells are more representative of the 
microenvironment of atherosclerosis, making the findings more clinically 
relevant, an important factor in my study. 
Although it has been widely shown that macrophages take up some forms 
of modified LDL, in particular OxLDL (Ooi et al., 2017), there are multiple 
other forms of LDL reported to be present in atherosclerotic lesions, such as 
AgLDL (Tamminen et al., 1999), electronegative LDL (Sobal et al., 2000) and 
glycated LDL (Sobal et al., 2000).  
During the process of atherosclerosis development, and due to the 
combined effect of certain oxidants (ROS, free radicals, myeloperoxidase, 
lipoxygenase) as well as lipolytic (phospholipase A2, sphingomyelinase, 
phospholipase C), hydrolytic (esterase), and proteolytic enzymes (thrombin, 
tryptase, kinase, metalloproteinases), LDL molecules undergo modification 
processes. These modifications, which are either chemical, structural, or 
both, result in the generation of different types of modified LDL molecules, 
with OxLDL and AgLDL being the most commonly found, and the most widely 





Previous studies showed that macrophages take up molecules of acetylated 
LDL (AcLDL) in vitro, and this increases the expression of inflammatory 
molecules such as ICAM-1 and MMP9 in addition to causing apoptosis (Han 
et al., 2009, Virella et al., 1995), promoting release of IL-1β (Akeson et al., 
1991, Wakabayashi et al., 2018). 
The surfaces of vascular cell walls (smooth muscle cells, endothelial cells and 
macrophages) have several scavenger receptors such as CD36, LOX-1 and 
TLRs, which all promote the internalisation of OxLDL and mediate its cellular 
effects (Di Pietro et al., 2016, Kiyan et al., 2014). OxLDL also plays a major 
role in inducing the release of IL-1β from macrophages by activating the 
NLRP3 inflammasome (Liu et al., 2014), secondary to its uptake, which is 
mainly by the scavenger receptor CD36 (Kuda et al., 2013, Stewart et al., 
2005). 
These studies suggest AcLDL and OxLDL may be potential stimulants of 
cytokine release in endothelial cells. OxLDL has already been found in human 
coronary atherosclerotic plaques (Hasanally et al., 2017, Nishi et al., 2002). 
AcLDL, however, although widely used as a modified LDL and a lipid model, 
is not biologically available and has not been reported in vivo (Steinberg, 
2009).  
Recent studies have also raised attention towards the importance of native 
(unmodified) LDL in the early stages of inflammation, endothelial 
dysfunction and atherosclerotic lesion formation by interacting with ROS 




2014). ROS upregulates LOX-1 with or without the presence of Native LDL, 
although the extent of upregulation of LOX-1 is increased when ROS 
interacts with Native LDL, resulting in OxLDL formation. In view of this, and 
to investigate the role of unmodified LDL and to further understand the 
effect on endothelial cells between modified vs un-modified LDL, I studied 
free native human LDL in my study.  
In this chapter, therefore, HCAECs were stimulated with pro-inflammatory 
cytokines and water-soluble cholesterol was used as a potential release 
stimulus. Then, the effect of AgLDL, AcLDL, OxLDL and unmodified native 
human low-density lipoprotein (Native LDL) were tested for their ability to 
potentiate release of IL-1β from endothelial cells. 
The first part of my project hypothesis was to identify whether or not 
vascular endothelial cells take up cholesterol. Since the endothelium is the 
innermost layer of the vascular wall, there is a high potential for the inflamed 
and damaged endothelial cell layer to engulf modified LDL molecules, or act 
as a gateway for their entry during the pathological development of an 
atherosclerotic lesion. Published studies have shown microscopic images 
illustrating macrophage uptake of LDL (Roy et al., 2019, Haberland et al., 
2001). However, very few studies have examined endothelial cellular uptake 
of modified LDL. Therefore, I examined the change of morphology and 
behaviour of HCAECs in response to incubation with modified and 




The second part of my hypothesis was to investigate if endothelial cells 
would release IL-1β secondary to the uptake of LDL, and whether or not IL-
1β release is dependent on LDL entering the vascular endothelial cells, 
providing a second signal to activate proteins able to cleave and release 
mature IL-1β from the cells. 
After setting a solid experimental infrastructure for my project with the 
optimisation of the in vitro model (Chapter 3), this chapter illustrates the 
experimental work that I conducted to address the first two parts of my 
hypothesis.  
4.2 Materials and Methods 
Detailed materials and methods used in this chapter are explained in 
(Chapter 2). Concentrations, sources and lot numbers of all reagents used, 
can be found in Appendices (I) and (II).  Briefly, HCAECs were cultured as per 
protocol (section 2.2.1.2). Modified and non-modified cholesterol 
treatments were applied to the cells (section 2.2.4). HCAECs culture samples 
were used for quantification of IL-1β by ELISA (section 2.2.6), LDH toxicity 
assay (section 2.2.7) and western blotting (section 2.2.10). HCAECs were 






4.3.1 IL-1α and TNF-α in combination promote production and release 
of IL-1β in HCAECs.  
HCAECs were seeded and stimulated with TNF-α and IL-1α, as described in 
(section 2.2.2). Similar to HUVECs, bright field microscopic imaging of 
stimulated HCAECs show a changed morphology from round cells to long 
string-shaped cells (Figure 4.1B compared with Figure 4.1A). This indicated 
that the cells were successfully stimulated, which was later confirmed by 
ELISA.  
 
(Figure 4.1) Morphology changes of HCAECs in response to stimulation 
with the pro-inflammatory cytokines TNF-α and IL-α: A and B represent 
HCAECs seeded at passage 3 in a 12-well plate. HCAECs stimulated with the 
combination of pro-inflammatory cytokines shown in image B appear 
elongated and stretched, in comparison to the non-stimulated HCAECs 
shown in A. Images A and B taken using a bright field phase contrast Leica© 





For the cell culture lysates and supernatants, quantification of IL-1β by ELISA 
showed high levels of IL-1β production in the cytokine-stimulated cell lysates 
compared with non-stimulated control cell lysates, as expected (Figure 4.2). 
There was an approximate 47-fold increase in IL-1β production from 
stimulated cells (163.2 ± 23.33 pg/ml) compared with cell lysates of non-
stimulated controls (3.51 ± 1.62 pg/ml).  
IL-1β was also significantly increased in the supernatants of the cytokine-
stimulated cells (37.27 ± 1.01 pg/ml) when compared with supernatant 
samples of non-stimulated controls (6.21 ± 0.55 pg/ml). However, although 
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(Figure 4.2) TNF-α and IL-1α upregulate the intracellular production (A) and 
release (B) of IL-1β significantly in stimulated HCAECS: HCAECs from three 
different donors were seeded and stimulated with both TNF-α and IL-1α for 
48 hours at concentrations of 10 ng/ml each. (A) Represents cell lysates 
while (B) represents cell culture supernatants. Values are presented as mean 
± SEM, unpaired t test was used for comparison between both samples, 
**p<0.01, n=3. 
 
4.3.2 NE induces the release of IL-1β from HCAECs 
NE was reported to induce the release of  high amounts (exceeding 




and this, therefore, was a potential positive control for my work. To test this, 
HCAECs from three different biological donors were stimulated with pro-
inflammatory cytokines (10 ng/ml of TNF-α and IL-1α as per protocol in 
(section 2.2.2)). After washing, cells were then treated with NE at 
concentration of 1 µg/ml for 6 hours. 
NE treatment enhanced the release of IL-1β in cytokine-stimulated HCAECs 
(Figure 4.3), although there was some release of IL-1β after cytokine-
stimulation alone. Comparing HUVECs to HCAECs, the absolute levels of 
released IL-1β were higher in HCAECs (49.45± 2.9 pg/ml) (Figure 4.3) 
compared with HUVECs (section 3.3.2) from previous chapter. Following NE 
treatment, IL-1β release was 3-fold higher in HCAECs than HUVECs. 
As a percentage of the total IL-1β inside the cells, under the conditions 
tested, HCAECs released 14.91%, which is 40% higher than the percentage 
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(Figure 4.3) Stimulated HCAECs release IL-1β extracellularly following a 6-
hour incubation with NE: (A) IL-1β in lysates shows levels are unchanged 
within the cell. (B) IL-1β in supernatants shows NE increased release of IL-
1β. Values are presented as mean ± SEM, unpaired T test was used for 
comparison between both samples, **p<0.01 in supernatants, n=3. 
 
In terms of IL-1β production, there was a difference in the overall amount of 
IL-1β produced inside HCAECs, compared to HUVECs, under identical 
conditions (130.1 ± 4.1 pg/ml in HUVECs compared with 331.6 ± 22.04 pg/ml 
in HCAECs) (Figure 3.3A versus Figure 4.3A).  
4.3.3 Water-soluble cholesterol induces the release of LDH from 
stimulated HCAECs 
In an earlier section (section 3.3.4), water-soluble cholesterol led to LDH 
release in HUVECs, therefore, this “cytotoxicity” assay was performed first 
to determine if the cells released LDH. Unsurprisingly, for HCAECs, the basal 
release of LDH was similar to HUVECs. However, HCAECs treated with 100 
µg/ml, 250 µg/ml and 500 µg/ml exhibited LDH release 20.5%, 27.9% and 




the concentration of water-soluble cholesterol (Figure 4.4). The conjugation 
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(Figure 4.4) LDH assay on HCAECs treated with water-soluble cholesterol 
shows induced LDH release: The percentage of LDH released is shown in 
relation to the maximum LDH release control of the assay (100%). HCAEC 
treated with water-soluble cholesterol show increased LDH release 
compared to control. Values are presented as means of three technical 




4.3.4 AgLDL does not induce LDH release from HCAECs 
AgLDL was also tested for its ability to cause potential cell death. HCAECs in 
CGM, without any treatment, showed 17% LDH release after 6 hours, which 
is similar to that of the different doses of AgLDL treatments (10,25, 50, 75, 
100 and 200 µg/ml) showing 13.6%, 16.6%, 13.9%, 15.8%, 13.6% and 14.3% 
respectively. Thus, AgLDL does not have an LDH inducing effect on HCAECs. 
NE treated cells showed 19% LDH release after 6-hour incubation. The non-
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 (Figure 4.5) LDH assay on HCAECs with AgLDL shows no release: The 
percentage of LDH released in relation to the maximum LDH release control 
of the assay (100%) does not differ between samples. Triplicate samples of 





4.3.5 AgLDL does not induce the release of IL-1β from HCAECs 
AgLDL occurs in vivo, in the vessel wall as well as in the blood (Singh et al., 
2019, Tamminen et al., 1999) and may theoretically provide a physical 
stimulus for IL-1β release. Cytokine release was therefore measured after 
exposure of HCAECs to AgLDL. HCAEC lysate samples from cells treated with 
AgLDL at concentrations of 10, 25, 50, 75, 100 and 200 µg/ml produced IL-
1β quantified at concentrations of 379.6, 374.8, 330.4, 323.3, 253.5 and 
373.8 pg/ml, respectively within cells (Figure 4.6). NE treated samples 
(positive controls) and cytokine only treated control produced 331.6 ± 22 
and 333.8 ± 15.1 pg/ml IL-1β inside cells. Together and alongside the 
controls, these data show AgLDL is not inducing IL-1β production inside 
HCAECs (Figure 4.6).  
Although there were high levels of intracellular IL-1β consistent between 
cytokine-stimulated samples, there was low release in culture supernatants. 
ELISA quantification of IL-1β in culture supernatants (Figure 4.7) showed 
release of IL-1β in AgLDL treated samples to be comparable to the cytokine 
only treated control, but less than the NE treated positive control of the 
assay (Figure 4.7). IL-1β release into culture supernatants of samples treated 
with AgLDL (at concentrations of 10, 25, 50, 75, 100 and 200 µg/ml) were an 
average of (11.5 ± 2.2, 12.3 ± 2.6, 9.8 ± 1.8, 9.6 ± 1.9, 11.97 ± 2.5 and 8.4 ± 
0.8 pg/ml) respectively (Figure 4.7). NE treated cells (positive control) 
released 17.3 ± 2.1 pg/ml and 9.3 ± 1.2 pg/ml in cytokine only stimulated 
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(Figure 4.6) AgLDL treatment and intracellular production of IL-1β in 
HCAEC: No difference in intracellular IL-1β  levels is seen between samples. 
n=3, data are expressed as mean ± SEM, Data are analysed by ordinary one-
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(Figure 4.7) AgLDL does not appear to induce release of IL-1β from HCAEC 
into culture supernatants: n=3, data are expressed as mean ± SEM, Data are 





4.3.6 AcLDL molecules reside within cellular perinuclear and 
cytoplasmic compartments that maintain surface connectivity in 
HCAECs with limited access to the extracellular space. 
To investigate whether LDL was entering the cells, I used imaging to 
investigate uptake of AcLDL by HCAECs. A pre-labelled acetylated LDL 
(AcLDL) was used for those studies (as per protocol in section 2.2.11.1). 
Results obtained from confocal fluorescent microscopy, showed minimal 
uptake of AcLDL molecules inside HCAECs after 6 hours, mostly in the 






(Figure 4.8) AcLDL resides intracellularly around the nucleus in HCAECs 
after a 6-hour incubation: In this condensed Z stack image, LDL 
molecules appear to be residing in perinuclear area and in the cytoplasm 
of HCAECs both A and B. AcLDL Alexa Fluor™ 488 Conjugate shown in 
green, Alexa Fluor™ 555 (CTB-555) conjugate staining was used for 
labelling the plasma membrane and cell surface, shown in blue. Finally, 
cells were labelled with Wheat Germ Agglutinin (WGA), Alexa Fluor™ 647 





(Figure 4.9) Montage of individual slices from a z stack confocal imaging of 
a Human coronary artery endothelial cell showing AcLDL molecules 
residing around the nucleus after incubation with AcLDL: The numbers in 






4.3.7 Investigating the Potential Roles of AcLDL Treatment on IL-1β 
activity in HCAECs 
4.3.7.1 HCAECs incubation with AcLDL does not induce cell death  
After determining uptake of AcLDL molecules by HCAECs, the effect of AcLDL 
incubation with HCAECs and production and release of IL-1β was tested. 
First, toxic effects of AcLDL on the cells or any possibility of induced cell 
death was excluded. Experiments using HCAECs incubated for 6 hours with 
different concentrations of AcLDL, were analysed for cytotoxicity by using 
the LDH cytotoxicity assay described in section (2.2.7).  
LDH assay data showed variations and no pattern of LDH release in 
proportion to AcLDL concentration (Figure 4.10), indicating the non-toxicity 
of AcLDL, especially at high concentrations. The highest release of LDH was 
recorded in cells treated with 50 µg/ml of AcLDL, which had 267% more LDH 
release compared to cytokine only stimulated control.  
Bright-field microscopy images were taken at the end of the 6th hour of 
incubation with 50 µg/ml of AcLDL and were compared with both cytokine 
only stimulated and non-treated non-stimulated HCAECs as controls (Figure 
4.11). These showed that cells were thriving and attached to the 
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(Figure 4.10) AcLDL incubation with HCAECs induces LDH release at low 
concentrations: Triplicate samples of HCAECs culture supernatants treated 
with AcLDL in different concentrations (10, 25, 50, 100, 200 µg/ml) and 
assayed for LDH (following the protocol in section 2.2.7). Results showed the 
release of LDH in variable manner in relation to the concentration of AcLDL. 
LDH release was high in low concentrations (10-50 µg/ml) and low release 
was measured at high concentrations of AcLDL. Data are represented as 







(Figure 4.11) AcLDL incubation with HCAECs is not inducing cell death: 
Cytokine stimulated (10 ng/ml of TNF-α and IL-1α for 48 hours) and AcLDL 
treated (50 µg/ml of AcLDL for 6 hours) HCAECs (A), appear to have larger 
size with dilated cytoplasm compared to cytokine only treated cells (C). 
Untreated, unstimulated HACECs (B) maintain their round shape. Images 
were taken by bright-field phase contrast Leica© microscope x75 lens, scale 
bar 75 µm. Treatment with AcLDL and or cytokine stimulation did not affect 







4.3.7.2 AcLDL does not induce the production of intracellular IL-1β in 
stimulated HCAECs 
AcLDL was non-toxic to HCAECs by LDH assay and by microscopic evaluation 
(section 4.3.7.1), and its ability to promote IL-1β release from HCAECs was 
investigated next. 
HCAECs isolated from three different donors (n=3) were cultured (sections 
2.2.1 - 2.2.2) and incubated with AcLDL using a range of concentrations (50, 
100, 200 µg/ml) delivered in serum free MV2 media (see appendix for media 
composition) for 6 hours. After the incubation period, the levels of produced 
IL-1β were quantified by ELISA (section 2.2.6). As expected, AcLDL treatment 
had no direct effect on increasing the production of IL-1β intracellularly 
when compared with cytokine stimulated only and NE treated controls. 















        TNF & IL-1 +     -       +     +      +     +
      AcLDL (µg/ml) -      -       - 50       100   200
               NE +      -       -     -       -      -
 
(Figure 4.12) AcLDL treatment does not induce production of IL-1β inside 
HCAECs: n=3 independent donors, data are expressed as mean ± SEM, Data 





4.3.7.3 AcLDL induces IL-1β release from stimulated HCAECs 
Next, IL-1β release was studied. HCAECs were stimulated by TNF-α and IL-1α 
for 48 hours (section 2.2.2) followed by a 6-hour incubation with AcLDL. The 
results of IL-1β quantification in culture supernatants showed significant 
increase in IL-1β release compared to cytokine only stimulated and NE 
treated controls (Figure 4.13). Separate experiments using high (50-200 
µg/ml) and low (10-20 µg/ml) concentrations of AcLDL revealed  the peak of 
this induction of IL-1β release was at the 50 µg/ml concentration of AcLDL 
(Figures 4.13 and 4.14). 
(Figure 4.13) AcLDL induces the release of IL-1β from HCAECs: ELISA 
showing high levels of IL-1β released in culture supernatants of cells treated 
with AcLDL. Cells treated with 50 µg/ml AcLDL appear to have the highest 
released IL-1β levels. Samples were compared to cytokine only treated cells 
as a control, n=3 independent donors, data are expressed as mean ± SEM, 
analysed by one-way ANOVA followed by Bonferroni post hoc test, 
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To investigate this I repeated the same experiment with lower 














        TNF & IL-1 +       +     +      -       +     +
      AcLDL (µg/ml) - 50     -      - 10 20
               NE +       -      -      -        -      -
  
(Figure 4.14) AcLDL induces IL-1β release from HCAECs at low 
concentrations and is concentration dependent: Low concentrations of 
AcLDL (10 and 20 µg/ml) results in induced release of IL-1β from stimulated 
HCAECs. Data are presented as mean ± SEM, n=3. 
 
4.3.7.4 HCAECs only release LDH during AcLDL incubation  
On comparing results of LDH release (section 4.3.7.1) with IL-1β release 
(section 4.3.7.3) I noticed the LDH release increased in cells that also had 
higher IL-1β release.  As I showed that AcLDL is not toxic to the cells, I wanted 
to investigate if it damaged the HCAECs, and whether or not the cells 
eventually die or continue to survive after the AcLDL is removed. For this 




µg/ml AcLDL for 6 hours (section 2.2.4), and then the media was replaced 
with complete growth media for 12 hours. Cells were then analysed for LDH 
release (using the cytotoxicity assay described in section 2.2.7).  
Results showed no difference in LDH release between all samples after 12 
hours of incubation in complete growth media post AcLDL treatment (Figure 
4.15). Both AcLDL treated and non-treated cells released levels of LDH within 
the same range (Figure 4.15). Thus, the AcLDL treatment of 6 hours before 
changing the media had no permanent damaging effect on cells nor did it 
















        TNF & IL-1 +   +     -    +    +   +
      AcLDL (µg/ml) - 50    - 10 20   50
 
(Figure 4.15) HCAECs treated with AcLDL release similar LDH levels 
compared to non-treated controls after 12 hours post treatment: HCACEs 
treated with different concentrations of AcLDL (10, 20 and 50 µg/ml) for 6 
hours followed by washing with PBS and incubation in complete growth 
media for 12 hours. Results show the almost identical levels of LDH release 
between all samples (AcLDL treated and non AcLDL treated) regardless of 




4.3.8 Investigating the role of OxLDL treatment on HCAECs 
4.3.8.1 OxLDL molecules are taken up by stimulated HCAECs 
To determine whether OxLDL is taken up by HCAECs, I incubated cytokine- 
stimulated and non-stimulated HCAECs with OxLDL (50 µg/ml) and imaged 
the cells at 6 and 24 hours post incubation using bright-field microscopy 
(section 2.2.11.2).  
Results showed the presence of OxLDL within the cytoplasm of cytokine-
stimulated HCAECs (Figure 4.16) with the majority being in the perinuclear 
site (similar to AcLDL uptake seen in section 4.3.6). The build-up of OxLDL 
appears to take a needle shape similar to cholesterol crystals seen in 
macrophages (Rajamaki et al., 2010).  
To determine whether non-cytokine-stimulated cells would eventually take 
up OxLDL following longer incubation, cells were exposed to OxLDL for 24 
hours (Figure 4.17). Prolonged treatment did not result in uptake of OxLDL 
in unstimulated cells, but did increase the amount of visible OxLDL build-up 






(Figure 4.16) OxLDL is seen in the perinuclear region of OxLDL treated 
HCAECs: (A,B,C and D) Four different cell samples of HCAECs stimulated with 
pro-inflammatory cytokines IL-1α and TNF-α (10 ng/ml for 48 hours), then 
treated with OxLDL (50 µg/ml for 6 hours). The intracellular build-up of 
OxLDL can be seen taking a crystallised shape highlighted in red.  Cytokine 
stimulated non OxLDL-treated cells (F) have an elongated appearance 
consistent with previously shown images. Non-cytokine stimulated, OxLDL 
treated cells in (E) are rounded in shape and do not take up OxLDL. Images 
were taken by bright-field phase contrast Leica© microscope, scale bar 25 





(Figure 4.17) Build-up of OxLDL in the perinuclear region of HCAECs 
following a 24-hour OxLDL incubation: (A,B,C and D) Four different cell 
samples of HCAECs stimulated with pro-inflammatory cytokines IL-1α and 
TNF-α (10 ng/ml for 48 hours), then treated with OxLDL (50 µg/ml for 24 
hours). OxLDL treated cells show an increased intracellular build-up of OxLDL 
compared to 6 hours (Figure 4.16). Cytokine only stimulated cells (E) appear 
mainly elongated. Non-cytokine stimulated, OxLDL treated HCAECs show no 
uptake of OxLDL. Images were taken by bright-field phase contrast Leica© 
microscope, scale bar 25 µm. Higher resolution and larger size images can 




4.3.8.2 OxLDL incubation does not induce production of cellular IL-1β in 
HCAECs  
As AcLDL is not fully biologically relevant and referred to as a “model lipid”. 
I then investigated whether OxLDL has the same effect on HCAECs. Three 
different biological donors of HCAECs were stimulated (section 2.2.2) and 
treated with OxLDL (section 2.2.4.4) for 6 hours. As expected, IL-1β levels did 
not show a significant change in the amount of produced IL-1β inside the 
cells, indicating that OxLDL does not induce the production of IL-1β by 
stimulated HCAECs. This was consistent with results seen with AcLDL in the 
previous section. OxLDL also did not have an effect on IL-1β production in 















TNF & IL-1               -            +          +         +         +          -
OxLDL (µg/ml)         -            -          10       20       50       50
 
(Figure 4.18) OxLDL does not induce IL-1β production in HCAECs: ELISA 
analysis showing OxLDL (10,20 and 50 µg/ml) treatment for 6 hours did not 
affect production of IL-1β inside cytokine stimulated or non-stimulated 
HCAECs. n=3 independent donors, data are expressed as mean ± SEM, 





4.3.8.3 OxLDL Induces the Release of IL-1β from HCAECs  
The culture supernatant of the cells treated in (section 4.3.8.2) were 
analysed by ELISA to determine levels of IL-1β release. Results showed a 
significant increase in released IL-1β from cells treated with 50 µg/ml (Figure 
4.19). The released levels of IL-1β were 2.4 fold that of cytokine only 
controls. Cells treated with 10 and 20 µg/ml of OxLDL did not release IL-1β  
above levels detected in cytokine only stimulated controls or in 















TNF & IL-1               -            +          +         +         +          -
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(Figure 4.19) OxLDL induces the release from HCAECs in a concentration 
dependent manner: HCAECs released high amounts of IL-1β after treatment 
with 50 µg/ml compared to cytokine only stimulated controls. n=3 
independent donors, data are expressed as mean ± SEM, analysed by one-





4.3.8.4 The OxLDL induced release of IL-1β from HCAECs is accompanied 
by LDH release 
To ensure that cells were not harmed by OxLDL treatment, bright-field 
microscopic imaging of the OxLDL treated cells was performed to determine 
whether the cells were intact and thriving.  
The cells remained viable and attached to the experimental plate after 
thorough washing with PBS. However, cells incubated with OxLDL (50 
µg/ml), looked larger in size compared with both the untreated cells and the 
cytokine-stimulated controls (Figure 4.20). The OxLDL treated cells also 
appear to have engulfed particles of OxLDL as a result of the 6-hour 
incubation (as they appear larger in size compared to control cells in figure 
4.20). A few cells also appeared with an abnormal morphology and had a 
thinner cytoplasm compared to healthy control cells. These changes to the 
treated cells were further investigated in the current and final chapters.  
To further determine this effect of OxLDL, LDH release was investigated as 
per protocol (Section 2.2.7). Cells were treated with 50 µg/ml OxLDL, for 6 
hours to cause IL-1β release prior to LDH assessment. There was a 55.3% 
increase in LDH release in OxLDL treated cells compared to cytokine only 






(Figure 4.20) OxLDL treated HCAECs appear to have a fatty dilated 
cytoplasm suggesting OxLDL uptake: Proinflammatory cytokine stimulated 
(10 ng/ml of TNF-α and IL-1α for 48 hours) HCAECs were treated with OxLDL 
(50 µg/ml) for 6 hours (A), while (B) were left without OxLDL as stimulation 
only controls. Treated cells had a fatty cytoplasm appearance and were 
significantly larger in size than untreated controls. Some cells appear 
abnormal and have a thin cytoplasm maybe suggesting that those cells 

















        TNF & IL-1   +         +
     OxLDL (µg/ml) -              50
 
(Figure 4.21) OxLDL at the IL-1β inducing concentration promote the 
release of LDH: HCAECs incubated with OxLDL (50 µg/ml) released 55.3% 
more LDH than cytokine-stimulated controls. Samples from three different 
biological donors n=3, data expressed as mean ± SD. Red bar represents the 
maximum LDH released from positive control. Positive control value was as 
100% release. Vehicle only negative control (contains media only) displayed 




4.3.9 Investigating the effects of Native human LDL treatment on 
HCAECs 
To determine whether LDL has to be modified (for example oxidised) before 
it  can exert an effect on HCAECs, I investigated the effects of native LDL 
treatment on cytokine-stimulated HCAECs. HCAECs were treated with three 
different concentrations of native LDL (10, 25 and 50 µg/ml) for 6 hours, 
prior to analysis. Culture supernatants showed that native LDL has no effect 














TNF-α & IL-1α    +          -         +         +         +
 Native LDL -          -        10       25       50
 
 (Figure 4.22) Native LDL does not induce the release of IL-1β from 
stimulated HCAECs: HCAECs were stimulated with proinflammatory 
cytokines IL-1α and TNF-α (10 ng/ml for 48 hours), then treated with native 
LDL (10, 25 and 50 µg/ml for 6 hours). No difference in IL-1β release was 
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     Native LDL (µg/ml) -              50
 
(Figure 4.23) Native LDL treatment does not induce the release of LDH from 
HCAECs: HCAECs were stimulated with pro-inflammatory cytokines IL-1α 
and TNF-α (10 ng/ml for 48 hours), then treated with native LDL (50 µg/ml 
for 6 hours). No significant release of LDH was seen in either group. Red bar 
represents the maximum LDH released from positive control. Positive 
control value was as 100% release. Vehicle only negative control (contains 




Representative bright-field microscopy of these cells showed that the 
cytokine only stimulated cells appeared almost identical to cells treated with 
native LDL secondary to cytokine stimulation, with no evidence of LDL 
uptake compared to OxLDL treated cells (Figure 4.24).   
 
(Figure 4.24) HCAECs do not engulf native LDL after 6 hours of treatment: 
HCAECs without stimulation or treatment (A) and HCAECs stimulated with 
Pro-inflammatory cytokines IL-1α and TNF-α (10 ng/ml for 48 hours) (B) as 
controls. Stimulated HCAECs treated with native LDL (50 µg/ml for 6 hours) 





4.3.10 Summary of Results 
The response of HCAECs to the pro-inflammatory cytokine combination in 
producing intracellular IL-1β was greater than that seen in HUVECs. Primed 
HCAECs also released high levels of IL-1β in response to NE, in agreement 
with findings from (Alfaidi et al., 2015). The key findings of this chapter in 
the context of the cholesterol induced IL-1β release from HCAECs are: 
- HCAECs release IL-1β when incubated with modified LDLs (OxLDL and 
AcLDL) only when the cells are cytokine stimulated (primed). 
-  AgLDL does not induce IL-1β release from primed HCAECs.  
-  AcLDL is taken up by cells and induces the release of IL-1β from primed 
HCAECs.   
- OxLDL is taken up by cells and induces the release of IL-1β from primed 
HCAECs.  
- HCAECs release IL-1β in response to uptake of modified LDLs. 
- The release of IL-1β from HCAECs is associated with release of LDH.  
4.4 Discussion 
This chapter investigates the effect of LDLs on HCAECs, a relevant cell type 
for the investigation of atherosclerosis. In a similar pattern to HUVECs, 
HCAECs are successfully activated by cytokines, as confirmed by the change 
in morphology and stimulated to release IL-1β, in agreement with previous 
studies (Alfaidi et al., 2015). Although lysates in both cytokine-stimulated 
HCAECs and HUVECs contain high levels of IL-1β, HCAECs produced more 




responsive to cytokine-stimulation than HUVECs. This also agrees with 
published work showing that coronary artery ECs are substantially different 
to HUVECs in terms of the cytokines and interleukins they produce 
(Krishnaswamy et al., 1999, Dewberry et al., 2000, Francis et al., 1999).  
Due to water-soluble cholesterol being not biologically relevant, I tested the 
effects of AgLDL treatment on HCAECs. However, AgLDL failed to release IL-
1β into the culture supernatant of HCAECs similar to that seen in HUVECs. 
This may be because the aggregates of LDL are so large that they cannot 
enter the cells. Indeed, some investigators have suggested that cholesterol 
retention in AgLDL results mainly from surface attachment of AgLDL and that 
it does not enter cellular compartments (Zhao et al., 2004). Zhao et al., 
showed uptake of AgLDL by macrophages, but only minimal surface 
retention and incomplete internalisation in HCAECs. This non-entry would 
explain the lack of IL-1β release seen in my AgLDL experiments and indicates 
that the release of IL-1β from HCAECs in response to LDL is contingent on 
the mechanism of cellular LDL uptake. 
Experiments conducted using AcLDL, the model lipid ligand, added more 
evidence supporting the LDL uptake theory of IL-1β release. Low doses of 
AcLDL induced high amounts of IL-1β release compared to high doses (100 
and 200 µg/ml), with the highest quantified levels of IL-1β release seen in 
samples treated with AcLDL at concentration of 50 µg/ml, although all 
concentrations used successfully released high levels of IL-1β compared to 




is that HCAECs take up small molecules of AcLDL, and therefore release IL-
1β proportionally in response to the uptake. However, high concentrations 
may be harder take up by endothelial cells, since AcLDL can aggregate at high 
concentrations (Okaji et al., 2004, Zhang et al., 1997, Ruuth et al., 2018).  
Confocal imaging with fluorescently labelled AcLDL showed the cellular 
uptake of AcLDL by HCAECs, especially in the perinuclear region of the cells. 
This uptake, however, was only seen in cells treated with 50 µg/ml, which 
was the maximum IL-1β releasing concentration from treated cells. Higher 
concentrations of AcLDL were not taken up by cells. This adds further 
support to why lower concentrations of AcLDL (10,20 and 50 µg/ml) caused 
higher IL-1β  release compared to higher concentrations which were not 
taken up by HCAECs. To clarify that these results were not caused by the 
thorough washing and chemical treatment used in the imaging protocol 
resulting in partial cell loss and creating a high risk of LDL denaturation, I 
conducted bright-field microscopy imaging following a direct formalin fixing 
protocol. This altered protocol also showed uptake of AcLDL at 
concentration of 50 µg/ml. 
Although AcLDL is a common form of modified LDLs that has been widely 
used in LDL uptake studies of vascular cells and macrophages (Doran et al., 
2008, D'Elios et al., 2017), it was considered not to be a biologically relevant 
candidate for my study. AcLDL is a laboratory-prepared artificial tool for 
modified LDL studies and has never been reported to be found in vivo 




Conversely, several studies showed the presence of OxLDL in multiple 
phases of atherosclerosis development in human atherosclerotic lesions and 
within macrophages and foam cells, confirmed by electron microscopy, 
radionuclide microscopy and fluorescent tagging of OxLDL (Steinberg, 1997, 
Ross, 1999a, Parthasarathy et al., 2000, Davies et al., 2006, Stacy, 2019, Nishi 
et al., 2002). Furthermore, OxLDL has been used in multiple atherosclerotic 
modelling studies in vitro as well as on human and in vivo studies of 
macrophages and vascular cells (Ahsan et al., 2015, Asmis et al., 2005, Brown 
et al., 2000, Hasanally et al., 2017, Kiyan et al., 2014, Stewart et al., 2005, 
Thum and Borlak, 2008). These studies have shown many roles that OxLDL 
plays during the process of atherosclerosis development and lesion 
formation, from endothelial injury to recruiting monocytes and 
macrophages and inducing platelet aggregation, and also show that OxLDL 
plays a role in inducing growth factors, increase the macrophage LDL uptake, 
increase the production of ROS and the creation of OxLDL autoantibodies, 
which all contribute towards increasing inflammation, thrombosis and 
plaque disruption. Furthermore, OxLDL induces metabolic dysfunction, 
oxidative stress and oxidative DNA damage (Thum and Borlak, 2008, Mondal 
et al., 2013).  
During atherosclerotic lesion formation, LDL molecules that infiltrate to the 
subendothelial space undergo further oxidation and modification, 
transforming the infiltrated LDL molecules into OxLDL (Davignon and Ganz, 
2004, de Nigris et al., 2003, Steinberg, 2009, Stewart et al., 2005). This has a 




rupture is correlated with high levels of OxLDL in both plaque and plasma 
(Nishi et al., 2002), which increases the risks of developing acute coronary 
syndromes and stroke (Packer, 2000, Rioufol et al., 2002). 
Thus, OxLDL was a great candidate for my study. Indeed, OxLDL induced high 
levels of IL-1β release from stimulated HCAECs in my experiments. This is in 
agreement with studies that report that OxLDL activates the NLRP3 
inflammasome, inducing release of IL-1β from other cells such as THP-1 
macrophages (Liu et al., 2014). There is no published work, that I am aware 
of, on activated HCAECs that showed the OxLDL induced release of IL-1β. 
OxLDL, at the concentration of 50 µg/ml, induced the maximum release of 
IL-1β from HCAECs, matching release with the highest studied concentration 
of AcLDL (the model ligand), and confirming that the effect is concentration 
dependent. OxLDL had also the highest IL-1β inducing effect of all the 
different modified LDLs studied. AcLDL, at 50 µg/ml, induced a recorded 
average of 155.38 pg/ml of IL-1β in supernatants, while OxLDL at the same 
concentration induced an average of 185.6 pg/ml, suggesting that OxLDL has 
a more inflammatory role than AcLDL.  
 Studies have shown the uptake of OxLDL by macrophages was accompanied 
with increased expression of both the LOX-1 and CD36 scavenger receptors, 
a significant event in the process of foam cell formation (Xie et al., 2018, Rios 
et al., 2012, Cerletti et al., 2010). However, the uptake of OxLDL and the 
association between the uptake and the release of IL-1β has never been 




OxLDL molecules within the cytoplasm of stimulated HCAECs. Non-
stimulated HCAECs did not uptake OxLDL particles which adds further 
validation to the theory of LDL infiltration only after dysfunctional and 
inflamed endothelium, and that normal healthy (uninjured) endothelium 
does not allow infiltration (or uptake) of LDL molecules at high and low 
concentrations. These findings highlight the ability of HCAECs to internalise 
and uptake OxLDL, and the potential of OxLDL molecules for clustering inside 
the cell and potentially creating OxLDL crystal-like particles. This uptake 
consequently provides a secondary danger signal that cleaves ProIL-1β into 
a mature IL-1β, which was detected in culture supernatants of these cells. 
This project aims to understand the effect of LDL on the release of IL-1β from 
HCAECs. Thus, it was important to study and monitor the LDH release in 
response to treatment with the different LDLs. Although no cell death was 
seen following treatment with all modified and non-modifed LDLs used in 
my study, I found LDH release associated with cells that have released IL-1β. 
HCAEC samples that did not release a significant amount of IL-1β did not 
release a significant amount of LDH either. In OxLDL treated HCAECs the 
increase in LDH release is less than that seen in AcLDL treated HCAECs with 
the same concentration, which had a 2.7 fold increased release of LDH 
compared to cytokine only stimulated control (section 4.7.1). This suggests 
that LDH release is associated with the mechanism of release and not the 
amount of IL-1β released, which will be further investigated in the next 
chapter. However, the idea of cell death and the release of IL-1 is not new. 




and cannot exit the cell. It had been thought that IL-1 is passively released 
from dead cells, but recently new mechanisms have been proposed 
including pyroptosis (discussed in chapter 5). 
Finally, native LDL did not release a significant amount of IL-1β from treated 
HCAECs. Microscopically, it was clear that the reason for this was that 
inflamed and non-inflamed HCAECs did not take up native LDL. This is in 
agreement with a recent study that reported that OxLDL but not native LDL 
induced vascular inflammation (Daub et al., 2010). In this study, only OxLDL 
but not native LDL, induced foam cell formation in human CD34+ progenitor 
cells and induced ICAM-1 expression in the differentiated endothelial cells. 
Furthermore in the same study, activated platelets (20 μM adenosine 
diphosphate (ADP)), treated with OxLDL (10 μg/ml for 4 hours) showed 
uptake and internalisation of OxLDL by fluorescent microscopy, and this 
internalisation caused endothelial activation and inhibited endothelium 
regeneration. However, this was not seen after incubation with native LDL.  
In my data, HCAECs treated with Native LDL experienced very low release of 
LDH. This further emphasises the role of LDH release from endothelial cells 
that was seen accompanied with all the modified cholesterol-induced IL-1β 
release mechanisms. 
4.4.1 Limitations and future work 
Although AcLDL molecules were seen inside the cells (section 4.3.6), in the 
perinuclear region by fluorescent microscopy, the protocol used (section 




different chemicals in order to fix the cells and stain the AcLDL. In addition, 
there was also a suggestion that the cells appeared senescent. Vascular 
endothelial cells and HCAECs in particular are known to become senescent 
in response to ageing as well as during inflammation and inflammatory 
markers expression (Olivieri et al., 2013). Therefore, uptake of AcLDL and 
OxLDL imaging was done by a formalin fixing protocol (section 2.2.11.2), 
which required less cell exposure to chemicals, and imaged by Brightfield 
microscopy. Although Brightfield microscopy was less specific than 
fluorescent tagging of OxLDL and AcLDL, the OxLDL internalisation was clear.  
The accumulation of OxLDL particles/droplets was a very interesting finding 
in my work, however, a specified evaluation method was needed to further 
identify the chemical and physical properties of these internalised particles, 
and to investigate whether they were crystalized intracellularly. Many 
studies were able to image cholesterol crystals using electron microscopy 
(Abela and Aziz, 2006), polarized microscopy (Baumer et al., 2019) and 
optical coherence tomography (Katayama et al., 2020, Toutouzas et al., 
2016, Koide et al., 2017) thus, this may be a future research direction.  
4.5 Conclusions and Summary of Chapter 
OxLDL is a key player in the pathophysiology of atherosclerosis and is present 
during all stages of atherosclerotic lesion formation. In this chapter, I have 
shown for the first time, that OxLDL induces the release of IL-1β from 
stimulated HCAECs. This release is secondary to HCAECs’ uptake of OxLDL. 
OxLDL builds up in the perinuclear area in HCAECs and forms OxLDL crystal-




incubation until 24 hours. OxLDL induces the release of LDH but does not 
cause typical cell death within 6 hours of treatment. Native LDL on its own 





(Chapter 5) Unravelling the Mechanism Leading 
to IL-1β Release from Primed and OxLDL 








My project, and in particular this chapter, was based on the well-established 
understanding in macrophages that the NLRP3 inflammasome needs two 
signals to activate (Karasawa and Takahashi, 2017a) and, without this 
activation, IL-1β cannot be secreted (Rajamaki et al., 2010). 
The first signal, referred to as the “priming signal”, initiates via the NF-κB 
signalling pathway, which detects several TLRs, PAMPs and DAMPs (such as 
OxLDL (Duewell et al., 2010)) that trigger the activation of NF-κB, leading to 
the intracellular regulation of proIL-1β. At this stage, proIL-1β is produced, 
but remains within the cell until a second signal, known as the 
“oligomerization signal”, is established (Dinarello and van der Meer, 2013). 
This signal comprises the oligomerization of the NLRP3 inflammasome 
activation components, phosphorylation of ASC and Caspase-1, which allow 
the external secretion of IL-1β from the cell (Mezzasoma et al., 2016).  
Recent studies have identified multiple other upstream pathways that lead 
to NLRP3 inflammasome activation, such as the potassium ion efflux which 
is induced by the P2X7 receptor, acting as an agonist to the NLRP3 
inflammasome (Tschopp and Schroder, 2010). Moreover, the release of 
cathepsin B is essential for cholesterol crystal induced activation of the 
NLRP3 inflammasome and release of IL-1β via lysosomal destabilisation in 
macrophages (Schroder et al., 2010, Niemi et al., 2011).  
To determine whether the mechanism of OxLDL induced IL-1β release from 




Caspase-1/NLRP3 inflammasome dependent pathway, as hypothesised, I 
used inhibitors of Caspase-1 (Ac-YVAD-cmk) and the NLRP3 inflammasome 
(MCC950). Since the P2X7 receptor is highly involved in the early stages of 
the molecular pathway of IL-1β secretion (Section 1.5), I also conducted 
experiments using a P2X7 receptor inhibitor (A-438079-Hydrochloride). 
Lysosomal destabilisation is proposed as the most effective upstream 
pathway leading to activation of the NLRP3 inflammasome (Section 1.5), and 
release of active cathepsin B is a hallmark of lysosomal destabilisation, 
therefore studying the expression of cathepsin B was also included in my 
investigation.  
Pyroptosis has recently been shown to be associated with Caspase-1/NLRP3 
activation leading to IL-1β release from macrophages (Evavold et al., 2018, 
Kayagaki et al., 2015). These studies have identified a pyroptosis formed 
membrane pore as the gateway of IL-1β exit from the cell, and identified 
active GSDMD (cleaved GSDMD by active caspase-1) as the pyroptosis 
effector protein. Therefore, I also investigated GSDMD protein expression in 
HCAECs to further understand the mechanism of OxLDL-induced IL-1β 
release from these cells.  
5.2 Materials & Methods 
Detailed materials and methods used in this chapter are explained in 
(Chapter 2). Briefly, HCAECs were cultured as per protocol (section 2.2.1.2). 
Cells were treated with inhibitors of either Caspase-1, the NLRP3 
inflammasome, or the P2X7 receptor inhibitor as described in (section 2.2.9). 




cells as described in (section 2.2.4). The produced and secreted levels of IL-
1β were quantified by ELISA (section 2.2.6). Lysates and supernatants were 
also analysed for Caspase-1 activity (section 2.2.8).  
The cells were imaged after incubation with OxLDL in the presence of each 
inhibitor by bright-field and phase contrast microscopy as described (section 
2.2.11). Cell lysates and culture supernatants were also analysed by western 
blotting (section 2.2.10) to investigate expression of IL-1β, cathepsin B and 
GSDMD. 
5.3 Results 
5.3.1 OxLDL induces the release of IL-1β from HCAECs via a Caspase-
1/NLRP3 dependent pathway 
Having shown that OxLDL was an effective second stimulus to release IL-1β 
from cytokine-stimulated HCAECs and given the biological relevance of 
OxLDL (Section 4.3.8), I used OxLDL (50 µg/ml for 6 hours) as the main 
second stimulus in investigating all inhibitor effects for modulating the 
release of  IL-1β. 
5.3.1.1 Caspase-1 inhibition does not inhibit intracellular production of 
IL-1β, but significantly reduces OxLDL induced IL-1β release 
Cytokine stimulated HCAECs (section 2.2.2) treated with OxLDL both with 
and without the presence of the potent caspase-1 inhibitor YVAD, showed 
no significant difference between intracellular production levels of IL-1β 
inside the cells (Figure 5.1A). However, the supernatants showed a 
significant reduction in IL-1β release (approximately 2.5 fold) from the cells, 
(Figure 5.1B), suggesting that the release of IL-1β from HCAECs is via a 




Given that the level of IL-1β release from OxLDL and YVAD treated, 
stimulated cells, was not different to cytokine only stimulated cells (Figure 



































































(Figure 5.1) YVAD inhibits OxLDL induced IL-1β release from HCAECs with 
no effect on production: HCAECs stimulated with pro-inflammatory 
cytokines IL-1α and TNF-α (10 ng/ml for 48 hours) and treated with OxLDL 
(50 µg/ml for 6 hours) with and without the presence of YVAD (50 μM) 
showed no  significant difference between production in cell lysates (A), 
while in supernatants (B) significant inhibition of IL-1β release was observed. 
n=3 independent donors, data are expressed as mean ± SEM, analysed by 




5.3.1.2 Inhibition of Caspase-1 causes ProIL-1β leakage from primed 
HCAECs following OxLDL treatment 
Western blot analysis of cell lysates (Figure 5.2A) and culture supernatants 
(Figure 5.2B), showed proIL-1β is expressed in all lysates. However, only the 
supernatants of primed cells (stimulated with pro-inflammatory cytokines 
IL-1α and TNF-α (10 ng/ml each) for 48 hours), that have undergone OxLDL 
treatment (50 µg/ml for 6 hours) following Caspase-1 inhibition shows the 
presence of proIL-1β (Figure 5.2). This surprising result suggests that proIL-
1β is somehow being released from cells, even when OxLDL is present, if 
processing to mature IL-1β is inhibited (due to presence of YVAD). 
 
(Figure 5.2) Caspase-1-inhibited, OxLDL-treated, primed HCAECs leak 
ProIL-1β into culture supernatant: HCAECs stimulated with pro-
inflammatory cytokines IL-1α and TNF-α (10 ng/ml for 48 hours) and treated 
with OxLDL (50 µg/ml for 6 hours) with and without the presence of YVAD 
(50 μM)  showed ProIL-1β  expressed in all cell lysates (A), but ProIL-1β was 
only detected in the supernatant (B), of the YVAD and OxLDL-treated, 
primed HCAECs. The western blots were repeated 4 times. This figure is a 
representative blot. Β-actin was used as a house keeping protein to ensure 





5.3.1.3 Inhibition of the NLRP3 Inflammasome, inhibits IL-1β release 
Having confirmed that inhibition of Caspase-1 reduces the release of mature 
IL-1β into supernatants from OxLDL treated HCAECs, and to further 
investigate whether the Caspase-1/NLRP3 activation pathway of OxLDL 
induced release of IL-1β, the NLRP3 inflammasome activation inhibitor 
MCC950 was used in the next set of experiments. Inhibiting the NLRP3 
inflammasome in OxLDL treated, cytokine stimulated HCAECs, does not 
affect IL-1β production (Figure 5.3A), but results in complete inhibition of 
the OxLDL induced IL-1β release from stimulated HCAECs (Figure 5.3B). The 
level of release is lower than that measured in cytokine only stimulated cells, 
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(Figure 5.3) MCC950 inhibits OxLDL induced IL-1β release from HCAECs 
with no significant effect on production: HCAECs stimulated with pro-
inflammatory cytokines IL-1α and TNF-α (10 ng/ml for 48 hours) and treated 
with OxLDL (50 µg/ml for 6 hours) with and without the presence of MCC950 
(10 μM)  showed no  significant difference in IL-1β production in cell lysates 
(A), while complete inhibition of IL-1β release was observed in supernatants 
(B). n=3 independent donors, data are expressed as mean ± SEM, analysed 





5.3.1.4 Caspase-1 is activated in HCAECs by OxLDL  
Having shown that the mechanism of OxLDL induced IL-1β release from 
HCAECs is via Caspase-1/NLRP3 (Sections 5.3.1.1 - 5.3.1.3); I investigated the 
role of OxLDL on HCAECs in relation to caspase-1 activation, to further 
validate my findings. This approach is important as it indicates the dynamic 
nature of the system, and is therefore preferable to the western blot 
technique. Application of a caspase-1 bioluminescent substrate (Caspase-
Glo 1, see section 2.2.8 for details) showed that OxLDL induced the activity 
of intracellular caspase-1, increasing it by approximately 75% in cytokine-
stimulated cells and more than 100% in OxLDL treated cells only, compared 
to caspase-1 inhibited cells. As expected, inhibition of the NLRP3 
inflammasome resulted in the lowest Caspase-1 activity (Figure 5.4A). 
Released Caspase-1 activity (in the supernatant) followed the same trend of 
produced caspase-1, except that the lowest released caspase-1 activity was 
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TNF-α & IL-1α +          +          +          -
OxLDL 50µg/ml +          +          +         +
       YVAD -          +          -          -
    MCC950 -          -           +         -
(B)
 
(Figure 5.4) OxLDL increases Caspase-1 activity in HCAECs: HCAECs 
stimulated with pro-inflammatory cytokines IL-1α and TNF-α (10 ng/ml for 
48 hours) and treated with OxLDL (50 µg/ml for 6 hours) showed nearly 75% 
increase in capsase-1 activity intracellularly as shown in lysates (A), and in 
released active caspase-1 in supernatants (B). OxLDL without cytokine 
stimulation induced the highest Caspase-1 activity, with nearly two folds in 
both released and produced active caspase-1. n=3 independent donors, data 
are expressed as fold-change (FC) normalised to the assay negative control 




5.3.2 The P2X7 receptor facilitates OxLDL uptake 
Next, the P2X7 receptor was investigated, because it was known to 
modulate an important upstream pathway that leads to the NLRP3 
inflammasome activation in monocytes (Sections 1.5 and 5.1). The 
competitive P2X7 receptor antagonist A438079 hydrochloride (P2X7Ri) was 
used as per protocol (section 2.2.9).  
5.3.2.1 Inhibition of the P2X7 receptor inhibits the OxLDL induced 
release of IL-1β 
P2X7 inhibition resulted in partial but non-significant inhibition of IL-1β 
production inside the cells, as measured in lysates (Figure 5.5A). However, 
complete inhibition of IL-1β release was observed in cell culture 
supernatants following P2X7 receptor inhibition (Figure 5.5B).  
Thus, P2X7 receptor appears to be involved in the mechanism of OxLDL 
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TNF & IL-1         -           +          +         +
OxLDL               -           -           +         +
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(Figure 5.5) Inhibition of the P2X7 receptor prevents OxLDL induced release 
of IL-1β from HCAECs: HCAECs stimulated with pro-inflammatory cytokines 
IL-1α and TNF-α (10 ng/ml for 48 hours) and treated with OxLDL (50 µg/ml 
for 6 hours) showed a slight non significant reduction of intracellular IL-1β in 
lysates (A). Released IL-1β  in supernatants (B), showed an approximate 
reduction of 92% following P2X7 receptor inhibition. n=3 independent 
donors, data are expressed as mean ± SEM, analysed by one-way ANOVA 





5.3.2.2 Inhibition of the P2X7 receptor, but not Caspase-1 or NLRP3 
inhibits the intracellular expression of proIL-1β and reduces inactive 
caspase-1 expression, following OxLDL treatment in primed HCAECs 
 
Having shown that inhibition of caspase-1, NLRP3 and P2X7 receptor led to 
inhibition of IL-1β release into HCAECs supernatants after priming and OxLDL 
treatment, I wished to study the protein expression of IL-1β and procaspase-
1 inside and potentially outside cells. The latter proved very difficult and, 
after many months of trying to detect IL-1β outside cells, I concluded that 
this was not possible due to a lack of antibody sensitivity. I performed a serial 
dilution experiment (See figure 7.1 in Appendix IIII) and determined that the 
lowest amount of active IL-1β detectable in my system was 1.25 μg/ml. My 
supernatant samples contained significantly less than this lower limit and, 
even with 10-fold concentration of cell supernatants, I was not able to detect 
any bands in my samples. Therefore, I concentrated on the analysis of lysates 
during my studies.   
HCAECs express proIL-1β (31kD) and proCaspase-1 (50kD) intracellularly 
after stimulation with the pro-inflammatory cytokine combination IL-1α and 
TNF-α (10 ng/ml for 48 hours) (Section 2.2.2). By Western blot, I was not able 
to detect any bands representing other forms of IL-1β, including 17kD. The 
data show that P2X7 receptor inhibition reduced the expression of 
proCaspase-1 and proIL-1β in primed HCAECs only following OxLDL 
treatment (Figure 5.6). Expression of both pro forms of these proteins was 





(Figure 5.6) Inhibition of the P2X7 receptor reduces the expression of 
inactive Caspase-1 and proIL-1β from HCAECs: Western Blotting analysis of 
cell lysates of primed HCAECs (stimulated with pro-inflammatory cytokines 
IL-1α and TNF-α (10 ng/ml for 48 hours)) and treated with OxLDL (50 µg/ml 
for 6 hours) in the presence of inhibitors of either Caspase-1, NLRP3 or the 
P27X receptor inhibitor. Reduced expression of both pro forms is seen, 
secondary to P2X7 receptor inhibition and OxLDL treatment.  Β-Tubulin was 
used as a house keeping protein to ensure equal loading of samples. 
5.3.2.3 HCAECs Uptake of OxLDL is regulated via the P2X7 receptor 
The Western blot data in the previous section, especially when using the 
P2X7Ri, suggested a possible connection between OxLDL and the P2X7 
receptor, since only when these were present in the cells and milieu was the 
production of proIL-1β and proCaspase-1 reduced. Since activation of the 
P2X7 receptor leads to opening of a dye permeable pore involved in cellular 
trafficking (Qu and Dubyak, 2009, Karasawa et al., 2017). I hypothesised that 
the P2X7 receptor could also be involved in lipid uptake by HCAECs, similar 




Bright-field microscopy showed that P2X7 receptor inhibition prevents the 
uptake of OxLDL by HCAECs (Figure 5.7B) compared to OxLDL treated, 
cytokine stimulated cells, where OxLDL is clearly seen inside the cells (Figure 
5.7A). Inhibiting the NLRP3 inflammasome by MCC950, did not prevent the 
OxLDL uptake and crystal-like structure formation, figures (5.7C and 5.7D). 
These data highlight the novel, early role of the P2X7 receptor in regulating 
entry of OxLDL into HCAECs which thereafter leads to Caspase-1/NLRP3 
pathway activation. It also, potentially, explains why P2X7Ri leads to a 
reduction in released IL-1β if the entry of OxLDL as a second priming step for 
HCAECs is prevented.  
(More detailed large images and high-resolution images for this experiment 






    
(Figure 5.7) Inhibition of the P2X7 receptor prevents the OxLDL uptake by 
HCAECs: HCAECs stimulated with pro-inflammatory cytokines IL-1α and TNF-α (10 
ng/ml for 48 hours) and treated with OxLDL (50 µg/ml for 6 hours) without any 
inhibitor, shows OxLDL droplets within the cells. Positive control cells without any 
inhibitor treatment showing OxLDL droplets inside cells (A), P2X7 receptor 
inhibited cells with no OxLDL droplets visible (B), Caspase-1 inhibited cells 
showing OxLDL droplets/particles visible (C). Image (D) is the cytokine only 
stimulated control. OxLDL droplets/particles are highlighted in red circles. Images 
were taken by bright-field phase contrast Leica© microscope, scale bar 25 µm. 
Images have been cropped and modified to fit for this comparison figure. More 
images of this experiment, higher resolution and original size uncropped images 







5.3.3 The OxLDL release of IL-1β from HCAEC is via a lysosomal 
destabilisation-pyroptosis pore-formation pathway 
As previously described (section 1.5), the NLRP3 inflammasome can be 
activated by several mechanisms of which lysosomal destabilisation appears 
to be prominent (Lima et al., 2013, Niemi et al., 2011, Karasawa and 
Takahashi, 2017a). 
To investigate whether the HCAECs-OxLDL activation of the NLRP3 
inflammasome is also associated with release of mature activated (25-26 
kDa) cathepsin B (section 1.5, introduction), lysates and supernatants were 
analysed by western blotting and a cathepsin B antibody was used to 
investigate expression of cathepsin B isoforms.  
5.3.3.1 Heavy chain cathepsin B is expressed in Cytokine stimulated 
HCAECs and released into culture supernatants, only following OxLDL 
treatment.  
HCAECs (stimulated with IL-1α and TNF-α 10 ng/ml for 48 hours, only) did 
not express the heavy chain (25-26 kDa) or procathepsin B (43 kDa) in either 
the lysate (figure 5.8A) or supernatant (figure 5.8B). In contrast, primed and 
OxLDL treated HCAECs (50 µg/ml for 6 hours), had high expression of the 
heavy chain cathepsin B isoform inside the cells, regardless of Caspase-1 or 
NLRP3 inflammasome inhibition, with lower expression of procathepsin B. 
Heavy chain cathepsin B was detected in OxLDL treated primed HCAECs with 
reduced expression after inhibition of Caspase-1 or NLRP3 inflammasome. 
NE which has a different mechanism of inflammasome activation which is 
caspase-1 independent (Alfaidi et al., 2015), did not induce cathepsin B 






 (Figure 5.8) OxLDL induces cathepsin B activation and secretion in primed 
HCAECs: Representative western blot of cell lysates (A) shows heavy chain 
cathepsin B (25-26 kDa), expressed in OxLDL treated (50 µg/ml for 6 hours), 
cytokine stimulated HCAECs (IL-1α and TNF-α 10 ng/ml for 48 hours), 
regardless of Caspase-1 or NLRP3 inhibition. Cytokine only stimulated lysates 
did not express either pro and mature forms. Secretion of activated 
cathepsin B in cell supernatants (B), was only found in OxLDL treated primed 
cells, with minimal expression after inhibition of Caspase-1 and NLRP3 
inflammasome. Western blot was repeated 3 times. α-Tubulin was used as 
a house keeping protein to ensure equal loading of lysate samples (shown). 
Culture supernatants were equally loaded, further details and full blots can 





5.3.3.2 OxLDL induced release of IL-1β is associated with GSDMD 
activation and cleavage, triggering pyroptosis. 
The actual mechanism of release/exit of IL-1β from HCAECs was still elusive, 
but recent papers (Evavold et al., 2018, Kayagaki et al., 2015) suggested that 
pyroptosis, a highly inflammatory cell state which may precede cell death, 
uses intracellularly generated pores produced by a pore effector protein 
called gasdermin D (Shi et al., 2015). I hypothesised that IL-1β may exit twice 
primed HCAECs using gasdermin generated pores.  
Western blot analysis for GSDMD isoforms in HCAECs, showed that primed 
HCAECs (stimulated with pro-inflammatory cytokines IL-1α and TNF-α at 
concentration of 10 ng/ml for 48 hours) express the full-length GSDMD (FL-
GSDMD) protein (Figure 5.9). OxLDL treated (50 µg/ml for 6 hours), primed 
HCAECs show low expression of the cleaved C-terminal (22kDa) fragment. 
Both N-terminal and C-terminal fragments were not expressed after 
Caspase-1 or P2X7 receptor inhibition. 
These results suggest that OxLDL-induced release of IL-1β from primed 
HCAECs is via programmed pyroptosis of these cells, and that OxLDL initiates 
programmed pyroptosis to facilitate release of IL-1β, but only after uptake 






(Figure 5.9) OxLDL induces GSDMD activation and cleavage in primed 
HCAECs: Western blot analysis of cell lysates shows FL-GSDMD (50 kDa), 
expressed in primed HCAECs (cytokine stimulated HCAECs with IL-1α and 
TNF-α at concentrations of 10 ng/ml for 48 hours). Cleaved GSDMD was only 
expressed in OxLDL treated (50 µg/ml for 6 hours), cytokine stimulated 
HCAECs. Caspase-1 or P2X7 receptor inhibited cells, only expressed the FL-
GSDMD. Western blot was repeated 3 times. 
5.3.4 Summary of Results  
In this chapter, I was able to show, for the first time, that cytokine stimulated 
HCAECs treated with OxLDL, release IL-1β via a caspase-1/NLRP3 
inflammasome activation pathway. The uptake of OxLDL occurs via a P2X7 
receptor regulated mechanism. The release of IL-1β is via a destabilisation 
of lysosomes leading to a pyroptosis, GSDMD regulated pore-forming 
mechanism.  Key findings from this chapter to support this are: 





2- Inhibition of the NLRP3 inflammasome prevents the processing of proIL-
1β  and significantly prevents release of IL-1β from the primed HCAECs.  
3- OxLDL treatment, without priming, induces caspase-1 activity in HCAECs.  
4- Inhibition of the P2X7 receptor inhibits OxLDL induced release from 
primed HCAECs, and inhibits cellular uptake of OxLDL. 
5- Heavy chain cathepsin B and C terminal GSDMD (weak expression) are 
only expressed following the two-step priming and OxLDL treatment in 
HCAECs. 
5.4 Discussion 
The aim of this chapter was to understand the mechanism of OxLDL-induced 
release of IL-1β from HCAECs. Data presented support the hypothesis that a 
caspase-1/NLRP3 inflammasome activation pathway is involved in IL-1β 
release, and that this mechanism of release is similar to that studied in 
macrophages.  
There is a well-established understanding that the protease caspase-1 is 
activated by the NLRP3 inflammasome, this activation cleaves proIL-1β 
intracellularly to a mature active IL-1β and controls the secretion of this 
active form extracellularly from the cell, via a highly inflammatory 
programmed cell death known as pyroptosis (Schneider et al., 2017).  
Ac-YVAD-cmk (YVAD), was chosen in my study based on previous work that 
showed it is a strong peptide-based inhibitor of caspase-1, and considered 
an efficient reducer of IL-1β cleavage, as shown in macrophages and HCAECs 




experiments, there was a significant reduction of the OxLDL-induced release 
of IL-1β from HCAECs into cell supernatants after caspase-1 inhibition by 
YVAD, this appeared to be inactive proIL-1β as assessed by western blot. I 
was unable to detect active IL-1β by western blot due to sensitivity issues, 
as well as the possibility that no active IL-1β was in fact present. This finding 
(section 5.3.1.2) is in agreement with previous work showing that YVAD 
inhibition results in secretion of uncleaved IL-1β from nigericin-treated, 
primed macrophages (Schneider et al., 2017). These data, alongside mine 
confirm that the mechanism of release of IL-1β from macrophages and 
vascular endothelial cells are similar.  
To further identify the mechanistic pathway, I used MCC950 as an NLRP3 
inflammasome inhibitor, chosen because it is a potent and selective inhibitor 
of the NLRP3 inflammasome that does not inhibit NLRP1 or NLRC4 (Coll et 
al., 2015). In addition to being highly selective, it has been shown to block 
the release of active IL-1β by inhibiting the effect of several strong activators 
of the NLRP3 inflammasome such as nigericin and ATP in macrophages, by 
preventing the oligomerisation of ASC (Guo et al., 2015). 
In my work, MCC950 significantly blocked the release of IL-1β from OxLDL 
treated HCAECs, which confirms that the IL-1β release mechanism is via a 
Caspase-1/NLRP3 activation pathway. Furthermore, there was no release of 
proIL-1β detected as a result of the NLRP3 inflammasome inhibition, unlike 
YVAD-induced caspase-1 inhibition. This is likely due to the role of MCC950 




2019, Guo et al., 2015), which prevented caspase-1 activation; while in 
caspase-1 inhibited cells, OxLDL may have partially activated the 
inflammasome, resulting in minimal release. This could have been tested 
using an ASC oligomerization assay (Mambwe et al., 2019), although I 
studied caspase-1 activation as a more robust assay. These data direct 
attention towards MCC950 and NLRP3 inflammasome inhibitors as 
important targets for inflammation control.  
Although I expected to observe that OxLDL increased the activity of caspase-
1 in primed HCAECs, it was also interesting that OxLDL significantly induced 
caspase-1 activity in unstimulated HCAECs. Furthermore, the levels of 
caspase-1 activity in non-primed cells were higher than that of primed cells, 
and this was consistent in analysis of caspase-1 activity in both supernatants 
and lysates.  
Since the caspase assay used measures the activity of caspase-1 and other 
cross-reacting caspases including Caspase-11 and Caspase-8 (as mentioned 
in the product sheet), it is likely that this increase in unprimed cells is due to 
multiple inflammatory effects that OxLDL elicit on HCAECs, which may result 
in promoting the activity of multiple caspases (Xu et al., 2019, Yu et al., 2019, 
Schroeter et al., 2001). Other studies have reported that priming cells 
(macrophages, HUVECs and HCAECs) with the  same proinflammatory 
cytokine combination (IL-1α and TNF-α) used in my study results in strong 




Shayakhmetov, 2016, Alfaidi et al., 2015, Wilson et al., 2007). These findings 
also add further evidence to the inflammatory properties of OxLDL.  
After demonstrating that OxLDL treatment induced release of IL-1β from 
HCAECs via a caspase-1/NLRP3 mechanism, I continued investigating the 
likely upstream and downstream pathways.  
In terms of upstream pathways, the plasma membrane receptor (known as 
P2R) most involved in immunity and inflammation is the P2X7 receptor, 
which is expressed by most adaptive and innate immune (Di Virgilio et al., 
2017) and endothelial cells (Subauste, 2019, Platania et al., 2019). The P2X7 
receptor is an ATP-gated plasma membrane ion channel that, upon 
stimulation, generates a pore (Giuliani et al., 2017). 
Since the P2X7 receptor is a major agonist of the NLRP3 inflammasome 
(Tschopp and Schroder, 2010) studied in context to OxLDL and foam cell 
formation in macrophages (Schroder et al., 2010, Niemi et al., 2011), 
studying its effects on ameliorating the release of IL-1β from HCAECs was 
novel and likely important. The P2X7 receptor inhibitor used was A-438079-
hydrochloride, reported to be a strong P2X7 receptor antagonist by blocking 
the potassium ion efflux from cells, resulting in inhibition of the NLRP3 
inflammasome and inhibiting the secretion of IL-1β in cells such as murine 
and human neutrophils (Karmakar et al., 2016). Indeed, blocking the P2X7 
receptor in primed HCAECs resulted in inhibition of IL-1β secretion, but it 
was also interesting to note reduced intracellular levels of both  procaspase-




pathway showing that potassium ion efflux is one of the main initiators of 
the NLRP3 inflammasome, and that loss of activation of the NLRP3 
inflammasome results in the absence of intracellular processing of both 
procaspase-1 and proIL-1β. This also suggests, for the first time, that the 
P2X7 receptor is a very important early target of activation of inflammatory 
responses in HCAECs.  
It was interesting to investigate the morphological changes of HCAECs in 
response to these inhibitors. Although no significant changes in cell 
appearance and extent of OxLDL intracellular crystal/particle formation 
were noted as a result of Casapse-1 and NLRP3 inflammasome inhibition, it 
was very clear indeed that inhibition of the P2X7 receptor resulted in a 
complete absence of intracellular OxLDL. This suggests that the P2X7 
receptor is crucial for OxLDL uptake and that it is possibly involved early on 
as a regulator in the process of OxLDL uptake and induced release of IL-1β in 
HCAECs. This finding agrees with a recent study conducted on podocytes, 
showing that blocking the P2X7 receptor (with the same inhibitor used in my 
project) results in inhibition of OxLDL uptake and, therefore, stops OxLDL-
induced apoptosis of podocytes (Zhu et al., 2019). The study also stated that 
absence of uptake led to inhibition of IL-1β secretion, primarily due to the 
inhibitor’s role in blocking potassium ion efflux which resulted in inactivation 
of the NLRP3 inflammasome (Zhu et al., 2019). Another study by (Dewi et 
al., 2012) showed that P2X7 receptor inhibitor (AZ11645373) reduced OxLDL 
induced secretion of IL-8 and MCP-1 as well as preserving morphology 




regulation of the uptake of OxLDL in HCAECs was shown for the first time in 
my project.  
Another major feature of inflammasome regulation is lysosomal 
destabilisation, accompanied by release of mature heavy chain cathepsin B 
from cells and considered the single most effective upstream regulator for 
the NLRP3 inflammasome activation. This has been extensively reported in 
cholesterol crystal induced NLRP3 inflammasome activation pathway in 
macrophages (Lima et al., 2013, Niemi et al., 2011, Karasawa and Takahashi, 
2017a, Schroder et al., 2010), and therefore, I analysed cathepsin B isoforms. 
Cathepsin B heavy chain was observed in OxLDL-treated, primed HCAECs 
only, regardless of Caspase-1 or NLRP3 inflammasome inhibition. This is in 
agreement with previous studies conducted on macrophages, which showed 
that cholesterol crystals activate the NLRP3 inflammasome by lysosomal 
destabilisation and subsequent cathepsin B activation and release (Moore et 
al., 2013, Oury, 2014, Rajamaki et al., 2010). This also indicates that 
lysosomal destabilisation takes place after uptake of OxLDL, which then 
leads to inflammasome activation. Hence, this explains why mature 
cathepsin B was seen regardless of caspase-1 or NLRP3 inflammasome 
inhibition in this current study, since I have shown that inhibition of either 
did not inhibit uptake or OxLDL crystal-like particle formation. These findings 
also suggest that OxLDL intracellular particles, which were reported in my 
study, behave similarly to cholesterol crystals. As discussed in (section 4.4.1), 
to further prove the nature of the OxLDL particles I imaged, I would need to 




tomography, or stochastic optical reconstruction microscopy (STORM) such 
as that developed by (Varsano et al., 2018). 
To determine whether cathepsin B was activated and expressed in HCAECs 
following OxLDL treatment only (Caspase-1 dependent), or via any 
secondary stimulus (that could elicit IL-1β and isn’t caspase-1 dependent), 
NE was used as a stimulus, because it is known to induce the release of IL-
1β from primed HCAECs via a caspase-1 independent pathway (Alfaidi et al., 
2015). NE treated HCAECs did not induce activation of mature cathepsin B, 
suggesting that this cathepsin B activation is due to the inflammatory 
properties of OxLDL and its downstream roles. 
OxLDL activates the NLRP3 inflammsome, in a similar mechanism to its 
function in macrophages (introduction, sections 1.4 and 1.5), and leads to 
cathepsin B activation and secretion, via lysosomal destabilisation. 
The next stage was to consider how IL-1β exited the cell and under which 
cellular process. Recent studies on macrophages have suggested pyroptosis 
(section 1.5.3), a process which is associated with increased expression and 
release of caspase-1-activated GSDMD protein. This area of study is not well 
understood and caspase-1 has been shown to be involved in both GSDMD 
dependent and independent pyroptosis pathways (Shi et al., 2015, Kayagaki 
et al., 2015, Tsuchiya et al., 2019).  
In my study, although it was very clear that primed HCAECs expressed the 
full-length GSDMD protein regardless of Caspase-1 or P2X7 receptor 




inhibited cells, indicating that a pyroptotic activity was triggered. Despite 
multiple repetition of the western blotting analysis, the bands observed in 
this study were faint. The reason behind this is likely because of the 6-hour 
treatment period used in my project, as other studies used longer treatment 
durations (minimum of 16 hours of OxLDL treatment) to show GSDMD C 
terminal band (Evavold et al., 2018, Zhaolin et al., 2019). However, this 
duration of time in serum free media would have led to significant HCAECs 
death by apoptosis which could potentially confound the results (King et al., 
2003).  
The low expression level was also consistent with the relatively low levels of 
LDH released from HCAECs after a 6-hour treatment with OxLDL. 
Furthermore, given that HCAECs are primary human cells, the expression 
levels of proteins such as GSDMD and IL-1β are lower than that reported in 
many studies that used cell lines.  
In addition to GSDMD expression, LDH release from cells is also considered 
an important factor associated with pyroptosis and studies have shown that 
LDH release occurs during pyroptosis (Bergsbaken et al., 2009, Evavold et al., 
2018). My study showed LDH release was associated with OxLDL release in 
HCAECs (Section 4.3.8.4) without cell loss or cell death. It is also important 
to point that this release of LDH was in direct proportion to the release of IL-
1β from HCAECs, and that the optimised concentration of 50 µg/ml which 
with the highest inducing release of IL-1β, was also the highest inducing 




The gasdermin data, together with LDH release as a result of OxLDL 
treatment, support the hypothesis that OxLDL induces the release of IL-1β 
via a pyroptotic mechanism. Activation of GSDMD results in membrane pore 
formation, and this activation and cleavage of GSDMD is enough to create 
membrane pores, which act as secretion windows for inflammatory 
molecules (de Rivero Vaccari et al., 2014, Bergsbaken et al., 2009, Schneider 
et al., 2017, Evavold et al., 2018). Thus, IL-1β is released from HCAECs in 
response to cytokine stimulation and OxLDL, via an endothelial cell 
membrane pore formation mechanism. The pores appear to be temporary 
in this experimental setting since wide scale cell death/loss does not occur.   
5.5 Conclusions and Summary of Chapter 
In this chapter, I showed that the release of IL-1β from HCAECs, in response to 
OxLDL secondary to priming with cytokines, is via a Caspase-1/NLRP3 
dependent mechanism, supporting the main project hypothesis.  
I also showed that OxLDL induces the activity of caspase-1, with or without 
the presence of priming cytokines.  
I have postulated a mechanism (figure 5.10). Briefly, the P2X7 receptor plays 
a key role in the initiation of the Caspase-1/NLRP3 cascade by regulating the 
uptake of OxLDL by primed HCAECs. This triggers lysosomal destabilisation, 
which activates the NLRP3 inflammasome and caspase-1, which cleaves 
proIL-1β into mature IL-1β and cleaves GSDMD into a mature C-terminal 




which allow IL-1β to exit the cell along with other inflammatory proteins and 
cytokines by initiating pyroptosis (Figure 5.10). 
 
(Figure 5.10) Unravelling the mechanism of OxLDL induced release of IL-1β 
release from primed HCAECs: When vascular endothelial cells are inflamed, 
the innate immune system is activated which triggers the intracellular 
synthesis of proIL-1β and the first signal of the inflammasome activation via 
the NF-kB pathway. This leaves an inactive IL-1β and an inactive 
inflammasome, until a second danger/inflammatory signal is received by the 
cell. OxLDL, the second signal, enters to the cell via the P2X7 receptor, which 
triggers cascades of inflammasome activation pathways primarily lysosomal 
destabilisation and activation of cathepsin B, which thereafter activates the 
inflammasome via oligomerization of ASC. This results in the release of 
active caspase-1, which cleaves proIL-1β into bioactive mature IL-1β and 
cleaves GSDMD into mature C-terminal GSDMD, which triggers a pyroptotic 
cell response and creates membrane pores. The created membrane pore 
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6.1 Overview of final discussion and relevance of the study 
There is a well-established understanding that atherosclerosis is a disorder 
that begins with structural changes to the arterial wall, leading to life 
threatening cardiovascular events, and that this process is driven by two 
important factors: inflammation and lipid accumulation (Glanz et al., 2020). 
This understanding was established after decades of studies providing 
evidence that inflammation is associated with atherosclerosis development, 
and is equally important to hyperlipidaemia in this process (Section 1.3).  
In 2005, robust evidence showed the direct relationship between hsCRP 
levels and ACS disease progression and cardiovascular complications (Ridker 
et al., 2005). Ridker also showed that statins have a favourable effect on 
prognosis in CVD and ACS patients by lowering inflammation, independent 
of lowering LDL (Ridker et al., 2008, Ridker et al., 2005).  
These studies were conducted in parallel with multiple clinical trials, all of 
which aimed to investigate to what extent inhibition of inflammation can be 
promising in prevention of atherosclerosis development. These  include: the 
CANTOS trial (NCT01900600), which used a monoclonal L-1β antibody 
(canakinumab) and the CIRT (Cardiovascular inflammation reduction trial) 
(NCT01594333) which targeted inflammation using Low dose methotrexate. 
However, after an average follow up of 27 months, the CIRT trial was 
stopped, as methotrexate did not significantly reduce adverse CVD events, 
mainly due to the absence of its effect on lowering L-1β, IL-6 and hsCRP 




In addition, (Sabatine et al., 2017) showed that LDL reduction using 
Evolocumab (a PCSK9 inhibitor), alone, without the administration of an 
anti-inflammatory agent, led to a 12.6% reduction in the risk of adverse 
cardiovascular events (MI, cardiovascular death, stroke, coronary 
revascularisation or hospitalisation due to unstable angina). This study also 
showed that the risk reduction increased to nearly 19% after the first year 
of administrating the treatment. Interestingly, the CANTOS trial showed that 
the anti-inflammatory treatment (in particular IL-1β inhibition), using 
canakinumab, without a LDL lowering agent, led to 15-17% reduction in the 
same end points (Ridker et al., 2017).  
Surprisingly, the range of risk reduction of both approaches in CVD 
endpoints is similar, and raise attention towards the association between 
LDL and inflammation in atherosclerosis development, without focusing on 
one of them as a single target to ameliorate atherosclerosis. The data 
suggest that both are equally important targets. My understanding is that 
there is a strong positive interaction between LDL and inflammation, and the 
combined effect drives the pathophysiological development of plaques and 
CVDs thereafter. This is in agreement with the study conducted by (Bohula 
et al., 2015), which was among the first trials to use the combined LDL-
lowering plus inflammation-lowering approach. The main objective of this 
trial (which is also known as the IMPROVE-IT Trial NCT00202878), was to 
evaluate the clinical outcome of using an LDL lowering agent as well as a 
pleotropic inflammatory lowering agent at the same time. Bohula et al., 




absorption) combined, results in strong LDL and inflammation reduction, 
and that this combined effect is more efficient in reaching target hsCRP and 
LDL-C levels, and, therefore, results in better outcomes for the patients with 
significantly fewer CVD complications and events (Bohula et al., 2015). In 
particular, achieving both target levels of hsCRP and LDL-C with both 
simvastatin and ezetimibe combined reduced the relative risk of the primary 
endpoints by 29%, compared to achieving neither target by either of the 
drugs alone. This study highlighted the importance of the dual target 
approach for future drugs and atheroprotective agents, and has inspired 
many studies, including my project.  
Two years after the IMPROVE-IT study, the CANTOS trial was published. This 
reignited interest in IL-1β in particular, and in the mechanism of its release 
from vascular cells. Specifically, CANTOS showed that there was a 31% 
reduction in CVD mortality and all-cause mortality among the trial 
participants, as a result of the robust inhibition of inflammatory response, 
by inhibiting IL-1β. There was also a 35-40% reduction in serum hsCRP and 
IL-6, with no change in LDL-C (Ridker, 2018).  
Thus, there remains a need to develop a therapeutic/preventative system 
that targets both inflammation and cholesterol, and can potentially limit the 
residual inflammation and residual cholesterol risk and become more 
efficient than the recently proposed agents. The complexity of IL-1β release 
is well known. However, there are unanswered questions regarding what 




could be targetable in future. This thesis has highlighted, for the first time, 
that OxLDL leads to the release of mature bioactive IL-1β, from the vascular 
endothelium, via a caspase-1/NLRP3 inflammasome, GSDMD-D-pyroptosis 
pathway, triggered by P2X7 mediated uptake of OxLDL (Figure 5.10). Thus, 
the research presented highlights the potential importance of inhibitors for 
the NLRP3 inflammasome, the P2X7 receptor and GSDMD, as potential 
atheroprotective targets, reducing inflammation and cholesterol entry to 
cells to ameliorate atherosclerosis development.  
6.2 Summary of the study, limitations and future perspective 
LDL is present in the arterial wall in different forms, such as OxLDL, and the 
highly inflammatory environment of atherosclerotic lesions with the 
presence of oxidising agents and free radicals alters the structure of these 
molecules and changes their forms (Valko et al., 2007, Stocker and Keaney, 
2004, Steinberg, 1997). Therefore, studying the effect of different types of 
modified cholesterols on the propensity of the vascular endothelium to 
become inflamed adds to the overall understanding of atherosclerosis and 
early detection of pathological changes. Despite this, in vitro models of 
atherosclerosis, in context to IL-1β release and expression, have been 
primarily focused on macrophages and HVSMCs, with less focus on 
endothelial cells.  
The endothelium is the inner most layer of the artery, and, therefore, it is 
the layer that is in continuous contact with the blood stream. Thus, studying 
the endothelium is important if we want to understand the early changes to 




also plays a key role in atherosclerosis, the changes that occur to the 
expression of IL-1β in human vascular endothelial cells in response to 
different types of LDL molecules is the core of my study.  
In all experiments, cytokine-stimulated versus non-cytokine stimulated cells, 
in the presence or absence of LDL (as controls), were investigated. This was 
crucial to tease out the mechanisms involved in release of IL-1β when 
exposed to LDL. Non-stimulated cells showed that modified LDLs (such as 
OxLDL or AcLDL) are not sufficient to cause release of this inflammatory 
cytokine, in an inactive endothelium. Only when an endothelial cell has been 
exposed to inflammatory stimuli, is IL-1β released, and this release is 
dependent on a second stimulus: in this case, modified LDL.  
I began my study using HUVECs, then  followed that by HCAECs, using 
multiple forms of LDL (water-soluble cholesterol, OxLDL, AcLDL, AgLDL and 
Native LDL) with treatment time of 6 hours. This time was chosen as it has 
previously been shown to be the optimum time for IL-1β  release, following 
two-step stimulation (Alfaidi et al., 2015). Furthermore, it has been shown 
that the 6-hour treatment with OxLDL, in particular, was sufficient for THP-
1 macrophages to take up OxLDL and to elicit inflammatory effects 
(Munteanu et al., 2006). My studies showed that HCAECs can engulf and 
allow infiltration of modified LDL (not unmodified native LDL), and this was 
only if the cells were inflamed (primed or stimulated by inflammatory 
stimulus). Similarly, HCAECs only released IL-1β following these two-step 




IL-1β release from primed HCAECs. However, AgLDL and native LDL did not 
cause release, probably because neither of these types of LDL were taken up 
by the cells. AgLDL is thought to be too large for the cells to engulf, and 
native LDL lacks the modification needed to cause uptake.  
After optimising the in vitro model to elicit the maximum release of IL-1β: 
using IL-1α and TNF-α stimulated HCAECs treated with OxLDL, I used these 
conditions alone to investigate the mechanisms involved.  
Primed HCAECs released significant amounts of IL-1β after incubation with 
OxLDL. This was concentration dependent and was recorded to release the 
maximum levels of IL-1β at a concentration of 50 µg/ml. Stimulated HCAECs 
do not release IL-1β without this second stimulus of OxLDL. Similarly, 
unstimulated (un-primed) HCAECs do not release IL-1β. This confirms the 
two-step process that is crucial for the mechanism of IL-1β release in a 
priming step to produce proIL-1β followed by a second signal to initiate the 
cleavage of and release of mature IL-1β.  
I have shown that primed HCAECs engulf OxLDL via the P2X7 receptor, 
creating OxLDL crystal like particles inside the cell. Inhibition of the P2X7 
receptor inhibits the uptake of OxLDL and the release of IL-1β.  
I have also shown that OxLDL induces the release of IL-1β from HCAECs via a 
caspase-1/NLRP3 pathway, and that this mechanism is contingent on the 
OxLDL uptake by HCAECs. Furthermore, OxLDL increases caspase-1 activity 
in HCAECs, indicating its highly inflammatory properties. The uptake of 




and release of active cathepsin B. The activated NLRP3 inflammasome 
releases active caspase-1, which cleaves proIL-1β into mature IL-1β and 
cleaves GSDMD into active GSDMD creating membrane pores that allow the 
exit of mature IL-1β.  
Understanding the inflammatory pathways that lead to developing life 
affecting diseases (such as atherosclerosis) helps significantly in discovering 
new techniques and methods to prevent these diseases by altering or 
completely inhibiting such pathways. In particular, data from this study 
suggests the importance of inhibitors (such as the NLRP3 inflammasome 
inhibitors and P2X7 receptor inhibitors) in ameliorating the inflammatory 
responses, which lead to development of atherosclerosis, and therefore 
preventing IHDs and ACS. 
This study has several limitations that could be addressed in future 
investigations. Most imaging protocols require the cells to be fixed with 
chemicals and/or wax, which could potentially dissolve the cholesterol 
inside tissue. Frozen sections are generally used to image crystals in cells, 
which can lead to potential errors caused by ice-crystal formation when 
freezing tissue. However, this study focussed on cells alone, rather than 
tissue, and cells were imaged following formalin fixation alone, which does 
not affect crystal formation. 
The focus of the study was to observe the changes that occur in release and 
production as well as the expression of IL-1β, and this study concentrated 




prolonged treatments could add more to the understanding of the 
mechanisms of IL-1β release from HCAECs. 
At the time of this study, human GSDMD inhibitors were not well established 
and therefore GSDMD expression was visualised using western blotting. 
Although weak active GSDMD was detected, I was unable to confirm the role 
of GSDMD by use of an inhibitor. The current available inhibitors such as 
Necrosulfonamide (NSA) (Rathkey et al., 2018, Sun et al., 2012), Bay 11-7082 
(McKenzie et al., 2020) and disulfiram (Li et al., 2019), are not GSDMD 
specific (McKenzie et al., 2020), and inhibit caspase or NF-κB, which also 
inhibit GSDMD cleavage, as part of their downstream pathways.  
HCAECs released levels of IL-1β that fall below the detection limit of western 
blotting see (Appendix A.4). Therefore, I was unable to confirm that only 
active IL-1β was being detected in the ELISA relied on during the study. 
However, information from the supplier stated that the detection of proIL-
1β, although possible, is rare.  
To continue this project, given time, the effects of longer and shorter periods 
of OxLDL treatment on HCAECs, would be investigated to confirm the time 
scale involved in OxLDL action. Investigating the effects of human GSDMD 
inhibitors once well established and available commercially would also be an 
interesting avenue. In addition to HCAECs, investigating the effects of OxLDL 
on HVSMCs, and comparing the effects with HCAECs, could add more 




Another promising direction to take this project could also be to investigate 
whether the release of IL-1β from endothelial cells is luminal or abluminal, 
using methods such as transwell plates. This would potentially answer the 
question of which direction endothelial cells release IL-1β: to the luminal 
side, or abluminally towards SMC? Knowing this would add more 
understanding to the release mechanism and approaches to inhibit IL-1β 
release. 
In context of the mechanistic study, adding more pathway specific inhibitors 
such as ASC, cathepsin B and scavenger receptor inhibitors such as CD36, 
could also more clearly define the pathway and show other possible ways of 





6.3 Concluding remarks 
Due to the complexity of cardiovascular disease development, the 
amelioration of atherosclerosis by one therapeutic agent has proven, so far, 
to be difficult. The current available agents and medications are costly, and 
there is uncertainty about the side effects of long term use associated with 
them. Atherosclerosis is usually asymptomatic, and the medications and 
management are usually started when it becomes symptomatic. Thus, there 
is still a need to develop a preventative agent, rather than a therapeutic, to 
stop and potentially reverse atherosclerosis lesion formation in the early 
development phases, rather than the late phases.  
My study highlights potential targets that could potentially be developed as 
future preventive and therapeutic agents. The oxidation of LDL within blood 
vessels is a major event triggered by a complex inflammatory pathway 
involving the high expression of multiple inflammatory cytokines. I speculate 
that, in addition to the approach of lowering LDL-C and inflammation, 
specific inhibition of the NLRP3 inflammasome and P2X7 receptors could 
add further specificity to target residual inflammation and residual LDL-C 
risk, and, therefore, limit, and potentially reverse, atherosclerosis lesion 
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A.2 Appendix (II) Solutions 
A.2.1 Composition of solutions used in HUVECs tissue culture 
(A.2.1.1) Minimum Essential Media (MEM) 
MEM contains 500mL of EMEM (1x), 5mL of amphotecrin B, 5mL Penicillin-
Streptomycin (10,000IU/ml), 10mL of 1M HEPES and 6ml of 7.5% sodium 
bicarbonate (0.20μm filtered). 
(A.2.1.2) Serum Free Media (SFM): 
SFM was prepared by adding 50mL M119 medium (10x), 5mL L-gultamine 
(100x) and 5mL Penicillin-Streptomycin (10,000IU/ml), to 450mL of sterile 
deionised water. As a colour detector, an amount of 10ml 7.5% sodium 
bicarbonate was added, to make up 500 ml of SFM. 
(A.2.1.3) Complete growth media (CGM): 
CGM contains SFM supplemented with 10% FBS (Foetal Bovine Serum), 10% 
NBCS (New-born Calf Serum), ECGS (Endothelial Cells Growth Factor) 
(10μg/mL) and heparin (90μg/mL). 
(A.2.1.4) Gelatin: 
10g of gelatin was dissolved in 500mL of sterile deionised water to make a 
stock solution of 2% (w/v) gelatin which was stored at 4°C after autoclaving. 
Stock solution was then diluted in sterile deionised water to make a working 
solution of 1%. 
(A.2.1.5) Trypsin/EDTA: 





A.2.2 Composition of solutions used in HCAECs tissue culture 
(A.2.2.1) Complete Endothelial Cell Growth Medium MV2  
MV2 medium contains 500 ml of endothelial cells basal medium added with 
supplements at final concentrations as follows: Foetal Calf Serum 0.05 ml / 
ml, Human Recombinant Epidermal Growth Factor 5 ng/ml, Human 
Recombinant Basic Fibroblast Growth Factor 10 ng / ml, Insulin-like Growth 
Factor (Long R3 IGF) 20 ng/ml, Human Recombinant Vascular Endothelial 
Growth Factor 165 0.5 ng/ml, Ascorbic Acid 1 μg/ml and Hydrocortisone 0.2 
μg/ml. 
(A.2.2.2) Serum Free MV Medium  
MV medium contains 500 ml of endothelial cells basal medium added with 
supplements at final concentrations as follows: Human Recombinant 
Epidermal Growth Factor 5 ng/ml, Human Recombinant Vascular Endothelial 
Growth Factor 165 0.5 ng/ml, and Hydrocortisone 0.2 μg/ml. 
(A.2.2.3) Trypsin/EDTA: 
 1X in PBS without Magnesium, Calcium and without Phenol Red. 
A.2.3 Composition of solutions used in HCASMCs tissue culture 
(A.2.3.1) Complete Growth Media 311-500 
Contains Molybdic Acid 4H2O (Ammonium), Copper (II) Sulfate / Cupric(II) 
Sulfate, Ferrous Sulfate, Manganese (II) Sulfate, Nickel Chloride, Sodium 
Selenite, Zinc Sulfate, Ammonium Metavanadate with added smooth muscle 
cell growth factors, supplements and components to promote optimal 
culture and growth of HCASMCs. 
(A.2.3.2) Serum Free HCASMCs Media 310-500 
Contains contents of Complete Growth Media (A.2.3.1) in previous section, 




(A.2.3.3) Hanks’ Balanced Salt Solution H6648 
Maintains osmotic balance and pH while providing vital inorganic ions and 
water to HCASMCs, contains sodium bicarbonate. Doesn’t contain phenol 
red, magnesium sulfate and calcium chloride. 
(A.2.3.4) Trypsin/EDTA 
 1X in PBS without Magnesium, Calcium and without Phenol Red. 
A.2.4 Composition of solutions and materials used in Western Blotting 
and Pre-Western Blotting sample preparation 
(A.2.4.1) Radioimmunoprecipitation assay buffer (RIPA buffer) 
RIPA buffer was prepared freshly at time of use by adding 150Mm of Sodium 
Chloride (NaCl) to 1% Triton X-100, Sodium Deoxycholate 0.50%, SDS 0.10%, 
50mM of Tris pH 8.0 and 1Mm of protease inhibitor AEBSF. RIPA buffer was 
used as a lysis buffer to collect cell lysates for analysis by Western Blotting.  
(A.2.4.2) 4–15% Mini-PROTEAN® TGX™ Precast Protein Gels 
4–15% precast western blotting polyacrylamide gels, with the following 
measurements 8.6 × 6.7 cm (W × L) for a volume of 15 µl per well. Bought 
from BIO-RAD #4561086. 
(A.2.4.3) Laemmli Sample Buffer 
Laemmli Sample Buffer is used for preparing the samples before loading 
them to the SDS PAGE. Bought from BIO-RAD #1610737. 
(A.2.4.4) TBS-Tween  
TBS-Tween was used for washing the nitrocellulose membrane and was 





A.2.5 Composition of other solutions used in the study 
(A.2.5.1) Cell Fixating 10% Buffered Formalin Solution 
Composed of Na H2 PO4 , Concentrated Formaldehyde and sterile deionised 
water. 
A.3 Appendix (III) High-resolution images from thesis figures. 
A.3.1 High-resolution images from (Figure 4.16): 
Images were taken by bright-field phase contrast Leica© microscope scale 


















A.3.2 High-resolution images from (Figure 4.17):  
Images were taken by bright-field phase contrast Leica© microscope scale 















A.3.3 High-resolution images from (Figure 5.7):  
Images were taken by bright-field phase contrast Leica© microscope scale 
bar 25 µm. (Images 1-10 OxLDL treated (50 µg/ml for 6 hours), Cytokine 








































A.4 Appendix (IIII) IL-1β Antibody serial dilution  
To further validate ELISA results and to show that primed HCAECs are 
releasing IL-1β in response to OxLDL treatment. An experiment was 
conducted to show the detection levels of the IL-1β antibody used (figure 
7.1). results showed that the levels of secreted IL-1β fall below the detection 
limit of the antibody used ((ab33774) from Abcam antibodies), and 
therefore cannot be measured. However the detection limit of the ELISA is 
3.9 pg/ml and quantification using ELISA was relied on through my study.  
 
 
(Figure 7.1) Investigating the detection limit of IL-1β antibody : Western 
blot analysis of  serial dilution performed on recombinant human mature IL-
1β. This experiment was done to identify the detection limit of the IL-1β 
antibody (ab33774). Detectable concentrations: (1) 10 μg/ml (200,000 pg/20 
μl), (2) 5 μg/ml (100,000 pg/20 μl), (3) 2.5 μg/ml (50,000 pg/20 μl), (4) 1.25 
μg/ml (25,000 pg/20 μl). While undetectable concentrations were samples 
(5-6); (5) 0.625 μg/ml (12,500 pg/20 μl), (6) 0.3125 μg/ml (6,250 pg/20 μl), 
(7) 0.15625 μg/ml (3,125 pg/20 μl), (8) 0.0781 μg/ml (1562.5 pg/20 μl) and 
(9) 0.039 μg/ml (781.25 pg/20 μl). Concentrations in μg/ml and in pg/20 μl 





A.5 Appendix (V) NHS permission for the use of umbilical cords for 





A.6 Appendix VI full blots of western blot figures presented in 
chapter 5. 
Western Blotting in my project was challenging considering the 
experimental setting and the nature of the cells and its low protein levels, as 
addressed in this thesis and as shown by the previous demonstration in 
Appendix (IIII). Original (unedited) blots of all western blot representative 
figures in chapter 5 are shown in this appendix to add further clarification to 
the bands shown in each figure. 
A.6.1 Full Blot of (Figure 5.2) 
 
The bands used in the representative blot in (figure 5.2) are highlighted in 
red boxes. In this blot, all samples are HCAECs stimulated with the cytokine 
combination of TNFα and IL-1α (10 ng/ml each, for 48 hours) in different 
treatment conditions as follows: 
1- + OxLDL + YVAD  
2- + OxLDL + YVAD  
3- + OxLDL  
4- + AcLDL +YVAD 
5- + YVAD  











A.6.3 Full blots used in the presentation of (figure 5.8) 
 
 
Samples are for HCAECs in the following conditions: 
+Cytokine +OxLDL +YVAD (Lysate 1, Supernatant 6) 
+Cytokine +OxLDL +MCC950 (Lysate 2, Supernatant 7) 
+Cytokine +OxLDL (Lysate 3, Supernatant 8) 
+Cytokine (Lysate 4, Supernatant 9) 
+Cytokine +NE (Lysate 5, Supernatant 10) 
